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Introduction
The main task of the immune system is to eliminate life threatening enti-
ties (pathogens and tumors) while the normal tissues should be protected. To 
achieve this, the cells comprising the immune system developed several stra-
tegies to discriminate between self and non-self. A mechanism exploited by 
dendritic cells (DC) is based on the expression of Pattern Recognition Receptors 
(PRRs) [1,2]. A single PRR type has a preference for a given set of molecular 
patterns and when this preference is met, binding of this molecular pattern to 
a PRR will occur. Molecular patterns that bind to PRRs can be derived from 
either pathogens, from aberrant cells or normal cells. PRRs such as C-type 
lectin receptors (CLRs) and Toll like receptors (TLRs) (reviewed in [3]) bind to so 
called pathogen-associated molecular patterns (PAMPs), which include lipids, 
proteins and carbohydrates [1]. More specifically, CLRs recognize carbohydrate 
moieties present on pathogens, thereby playing an important role together with 
other PRR signals in the immune defense against pathogens [4,5]. In addition, 
CLRs recognize specific carbohydrates on apoptotic and malignant cells due to 
their altered glycosylation and can thus contribute to the clearance of abnor-
mal cells [6,7]. Finally, CLRs are also involved in mediating cellular interactions 
between hematopoietic cells and plasma glycoprotein turnover [4]. CLRs bind 
carbohydrates via their carbohydrate recognition domains (CRDs) in a calcium 
(Ca2+)-dependent manner [8]. CRDs can be broadly divided into mannose- or ga-
lactose specific CRDs. The carbohydrate specificity is determined by the amino 
acid sequence comprising the CRD and on the ability and flexibility of the CRD 
to bind to a three-dimensional carbohydrate structure [4,9,10]. On the surface 
of microbes, these carbohydrate structures are typically found in dense arrays 
while on host cells the same or related carbohydrates are expressed in different 
configurations [11]. The mannose-binding lectin (MBL, also known as mannose 
binding protein), a soluble CLR circulating in the blood that upon binding to 
pathogen-derived carbohydrates initiate the complement cascade [12], specifi-
cally recognizes the characteristic orientation of sugars on pathogens whereas 
the glycan orientation on endogenous cells precludes tight multivalent inter-
actions [4]. Nevertheless, other CLRs are more flexible in binding similar, but 
differently orientated, sugars exposed on pathogens and endogenous cells and 
are therefore able to recognize foreign as well as endogenous ligands [13,14]. 
For instance, dendritic cell-specific intercellular adhesion molecule-3 (ICAM-3) 
grabbing non-integrin (DC-SIGN, CD209), a CLR expressed by DC and certain 
macrophages, binds a broad range of ligands that include pathogen-derived 
ligands like human immunodeficiency virus-1 (HIV-1) [15], Candida albicans 
[16], and Mycobacterium tuberculosis [17], but also endogenous ligands like 
ICAM-2 [18] and ICAM–3 [19]. The ability of several CLRs to interact with 
both foreign as well as endogenous ligands indicates that a CLR alone is not 
sufficient to instruct the immune system to discriminate between self and non-
self. TLRs are regarded to fulfill this role in providing the danger signal [20] 
since they recognize pathogen-derived ligands with an exquisite specificity. 
However, an increasing number of endogenous ligands for TLRs have been 
reported so far (reviewed in [21]). The discrimination between self and non-self 
is therefore not dependent on only one type of PRR, but rather on the interplay 
with multiple receptors which together will shape the immune response. More-
over, the immune system has several safety check points incorporated if one 
component fails to discriminate between self and non-self. For instance, after 
processing of trapped CLR ligands, these are presented in the context of major 
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histocompatibility complex (MHC) class II molecules to T cells for inspection. 
Moreover, regulatory T cells control immune reactions against self [22]. In this 
review, we will discuss the resulting responses upon binding pathogen-derived 
and endogenous ligands with regard to the CLRs expressed on DC. Moreover, 
general aspects of CLRs are discussed concerning their carbohydrate specificity, 
the relevance of combining multiple CRDs, the ability of several CLRs to signal 
or to interfere with other signaling pathways, and the interactions with other 
immune receptor families.
C-type lectins on DC
DC originate from the bone marrow and migrate to peripheral tissues where 
they become sessile as immature DC. These immature DC mainly function as 
endocytic cells and sample the environment for invading antigens by using its 
CLRs [23,24]. Upon inflammation, TLRs expressed on the DC will be triggered by 
specific PAMPs, leading to the maturation of the DC [25]. During this maturation 
step, a DC will acquire capacities to induce an adaptive immune response and 
lose its strong capacity to internalize pathogens. As a result, mature DC mainly 
function as antigen-presenting cells and are located in lymphoid organs to pre-
sent specific antigens to naïve T cells [23]. In the absence of inflammation, no 
TLR signals are present and consequently the DC remain in their immature state 
and may play a role in tolerizing mechanisms such as maintenance of tissue 
homeostasis and the induction of regulatory T cells [26]. 
A wide variety of CLRs has been detected on DC that recognize carbohydrate 
structures on pathogens as well as on endogenous proteins. In general, most 
CLRs will function as PRRs by binding to and internalizing pathogens into 
lysosomal compartments for degradation to enhance antigen processing and 
presentation by the DC [27,28]. Since immature DC are strong phagocytes, they 
express a large diversity of CLRs. In general, CLR expression decreases upon 
maturation and this correlates with a decreased ability of mature DC to take 
up antigens [27]. Two major subsets of DC are described in humans. The mye-
loid subset includes interstitial DC and Langerhans cells that are strategically 
located in peripheral tissues at the site of entry of most pathogens. The other 
subset consists of the plasmacytoid DC that are located in lymphoid organs 
[29]. Immature interstitial DC express a considerable variety of CLRs including 
DC-SIGN, mannose receptor (MR) and DEC-205, whereas plasmacytoid DC and 
Langerhans cells express a limited number of CLRs like blood DC antigen-2 
(BDCA-2) or Langerin respectively (reviewed in [27] and [30]). 
Since CLRs are able to interact with carbohydrate structures on pathogens and 
on endogenous proteins, this indicates additional functions for CLRs next to 
their role in pathogen recognition. These functions include the establishment of 
homeostasis upon binding glycosylated endogenous ligands and the involve-
ment in several cellular processes such as adhesion and migration [27]. Indeed, 
several CLRs such as DC-SIGN and MR have been implicated in mediating 
these functions upon binding endogenous proteins [13,27]. The MR is a CLR 
that contains eight CRDs and binds carbohydrates that have mannose, fucose 
or N-acetyl glucosamine as terminal sugar [31]. It is expressed on DC and 
macrophages, but also on lymphatic endothelium [32]. This CLR interacts with 
many pathogens such as C. albicans and HIV-1. This receptor was originally 
identified because it was able to recognize endogenous glycoproteins such 
as lysosomal hydrolases. MR mediates the clearance of these harmful agents, 
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thereby playing an important role in maintaining homeostasis [13]. Besides the 
clearance of endogenous ligands, MR expressed on lymphatic endothelium can 
also act as a cell adhesion molecule by binding to L-selectin on lymphocytes 
[32]. DC-SIGN is a CLR with only one CRD and, as described above, binds an 
extensive variety of viral, bacterial and parasitic ligands. Similar to the MR, 
DC-SIGN can act as an antigen-uptake receptor as well as an adhesion recep-
tor by mediating DC-T cell and DC-endothelial cell interactions by binding to 
ICAM-3 and ICAM-2, respectively [18,19]. Recently, it was described that DC-
SIGN mediates the interaction between DC and neutrophils through binding to 
Lewis X expressed by the β2-integrin MAC-1 of the neutrophil. The interaction 
between the two cell types induces the maturation of the DC and the immune 
response is skewed towards a T helper type 1 response [33]. This latter effect is a 
specific type of T cell response and responsible for cell-mediated/inflammatory 
immunity [34]. As potential clearance receptor, DC-SIGN is implicated in the 
binding of carcinoembryonic antigen (CEA) expressed on carcinoembryonic 
colorectal cancer tumor cells [7]. 
Structure of C-type lectins
Types of C-type lectins
Members of the CLR family contain one or more CRDs for binding to carbohy-
drate structures [30]. CLRs exist either as transmembrane proteins or as soluble 
proteins (Fig. 1A). Collectins such as MBL and the lung surfactant proteins A 
and D are examples of soluble CLRs and are important for the clearance of 
microorganisms (reviewed in [35]). Transmembrane CLRs can be divided into 
type I and II CLRs depending on the orientation of the amino terminus. Type I 
CLRs such as MR and DEC-205 contain several CRDs or CRD-like domains, and 
have an extracellular N-terminus. Type II CLRs comprising DC-SIGN, Langerin, 
dendritic cell immunoreceptor (DCIR), C-type lectin receptor 1 (CLEC-1), den-
dritic cell lectin (DLEC), BDCA-2, Dectin-1, and Dectin-2 have only one CRD 
and their N-terminus is intracellularly located [30]. For the type II CLRs, two 
main clusters can be identified in the human genome. One cluster is located at 
chromosome 19p13 and includes DC-SIGN, L-SIGN (liver/lymph node SIGN) 
and lymph node sinusoidal endothelial cell C-type lectin adjacent to CD23 and 
CD69 [36-38]. The second cluster maps at chromosome 12p13 and contains 
DCIR, CLEC-1, CLEC-2, Dectin-1, and DLEC, close to CD6, activation-induced 
C-type lectin (AICL), CD161, CD94 and the NKG2 family [39-42]. The localiza-
tion into clusters suggests that the different functional CLRs descend from one 
ancestor gene during evolution to meet the need for more functional different 
CLRs [43]. 
Carbohydrate recognition domain (CRD) 
CLRs contain the prototype C-type lectin fold, consisting of two anti-parallel β 
strands and two α helices. This common fold contains irregular loop structures 
from which two are involved in monosaccharide binding [44]. Ca2+ is required 
in establishing the interaction of carbohydrates to the CRD and therefore these 
type of lectins are classified as C-type lectins. Carbohydrates interact with a 
primary ligand binding site in the CRD by coordinating bonds with the Ca2+ 
ion and further hydrogen bonding with amino acid side chains that also bind 
to the conserved Ca2+ [45]. The characteristic CRD can be subdivided into two 
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broad groups; those binding mannose-type carbohydrates and those binding 
galactose-type carbohydrates. The mannose-type CRD group contains the trip-
let amino acid sequence EPN, whereas the galactose-type CRD group contains 
the triplet QPD [46]. Each CRD recognizes a particular panel of carbohydrates 
that is, besides a specific sequence in the CRD domain, determined by the 
ability and flexibility of the CRD domain to bind multivalently to differently 
oriented sugars [9,10]. For example, DC-SIGN and its homologue L-SIGN bind 
mannose in a different manner compared to MBL. The CRD of MBL recog-
nizes a single terminal mannose residue, and strong binding is only obtained 
when three CRDs are combined into a trimeric complex (Fig. 1A) [9]. The dis-
tance between individual CRDs within MBL oligomers is approximately 4.5-5.3 
nm. Therefore, it has been proposed that a MBL can only recognize mannose 
densely packed on large mannosylated areas of pathogens and not the short 
distance (2-3 nm) between mannose residues present on endogenous proteins 
Structure And orIentAtIon oF c-type lectInS. CLRs either exist as soluble or as 
transmembrane type I or type II lectins [30]. MR as well as DEC-205 (not shown in the Figure) 
are type I CLRs and contain multiple CRDs. MR contains eight CRDs of which CRD4 is most re-
sponsible for monosaccharide binding. However, multiple CRDs (4-8) are required for binding 
to multivalent ligands [68]. Another type I CLR is E-selectin which is an endothelial surface 
adhesion receptor for leukocytes. On these cells, E-selectin is located in lipid rafts and this 
localization is important for signaling during leukocyte-endothelial cell interactions [72]. The 
expression and function of E-selectin and other selectins on DC is still under investigation. 
DC-SIGN, Dectin-1 and DCIR belong to the type II CLR family and contain only one CRD. DC-
SIGN forms a tetramer to increase its avidity for its ligands [9]. Moreover, DC-SIGN is located 
in microdomains (±200 nm in diameter) on the surface of DC which enhances the binding of 
virus-sized particles [70]. It is not known whether Dectin-1 and DCIR can form oligomers to 
increase their affinity for their ligands. Dectin-1 contains the activatory signaling motif ITAM 
in its cytoplasmic domain whereas DCIR contains the inhibitory signaling motif ITIM [41,77]. 
Collectins such as MBL and lung surfactant protein A and D are soluble CLRs and play an im-
portant role in innate immunity. They oligomerize to increase their affinity for carbohydrate 
ligands exposed on the surface of microbial pathogens [12].
Figure 1A
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[4,9]. In contrast, by forming tetramers, DC-SIGN and L-SIGN (Fig. 1A) can 
recognize mannose on pathogens as well as on endogenous proteins because 
they recognize other spatial arrangements [9]. Snyder et al. [47] developed a 
tetramer model by homology modelling and calculated that the surface area 
encompassed by the tetrameric CRD of DC-SIGN is approximately 16 nm2 per 
CRD molecule. Ligands for DC-SIGN and L-SIGN must possess a surface gly-
cosylation level exceeding one glycan molecule per 16 nm2 of its surface area 
to allow multiple interactions with one tetramer. Several pathogen-derived as 
well as endogenous proteins contain this glycosylation level and are therefore 
ligands for DC-SIGN and L-SIGN [47]. 
Glycan arrays consist of an extensive panel of immobilized polysaccharides, gly-
coproteins, oligosaccharides and monosaccharides. Nowadays, these assays are 
frequently used as a new approach to investigate in more detail the carbohydrate 
preferences of several CLRs [48-50]. However, one has to be cautious with the 
analysis of these data because spatial arrangement plays a prominent role in 
binding. As an example of such studies, the binding specificity of DC-SIGN and 
L-SIGN was compared with a glycan array in which biotinylated oligosaccha-
rides were immobilized in streptavidin-coated wells [51]. Fluorescently la-
beled extracellular domains of DC-SIGN and L-SIGN were probed to this array. 
Remarkable significant differences were observed for these two CLRs despite their 
77% homology in amino acid sequence. The authors discovered that L-SIGN 
only binds mannose-containing glycans, while DC-SIGN is also able to bind 
fucose-containing glycans such as Lewis X [51]. Differences in the carbohydrate 
binding profile of DC-SIGN and L-SIGN were also demonstrated by van Liempt 
et al. [52], although they found that L-SIGN is able to bind to the fucose ligands 
Lewis A, B, and Y. In contrast to the afore-mentioned glycan array, van Liempt 
et al. used different Lewis antigens coupled to biotinylated polyacrylamide and 
tested the capacity of K-562 cells expressing DC-SIGN or L-SIGN for binding 
to these agents [52]. Probably, due to a rather low affinity for fucose ligands, 
binding is only established when L-SIGN is present in multiple copies on the 
surface of a cell. Both groups point to the amino acid Valine 351 present in the 
CRD of DC-SIGN that might explain the difference in fucose specificity [51,52]. 
Valine 351 in DC-SIGN creates a hydrophobic pocket that strongly interacts with 
the Fuc1,3/4-GlcNAc moiety of Lewis antigens. In L-SIGN, at the correspond-
ing position of Valine 351 in DC-SIGN a Serine 363 is present and creates a 
hydrophilic pocket that excludes binding to Lewis X [52]. Since CRDs recognize 
subtle differences in the arrangement and branching of carbohydrates, a minor 
modification can already result in the loss of binding. For example, sialylation 
of Lewis X and ICAM-2 abrogates the binding to DC-SIGN [51,53]. Platelets with 
heavily sialylated ICAM-2 cannot bind to DC-SIGN, whereas endothelial cells 
with unsialylated ICAM-2 do bind DC-SIGN [53]. Thus, sialylation modulates 
the binding specificity of DC-SIGN. In addition, these subtle differences prevent 
the interference of DC-SIGN with other CLRs like the selectins that have a high 
specificity for sialyl Lewis X [51]. Nevertheless, some CLRs share an overlapping 
array of ligands and contribute to redundancy. 
Cytoplasmic domain of CLRs
A general characteristic of most CLRs is that they endocytose foreign ligands 
that subsequently are targeted to lysosomal compartments. Peptide fragments 
that result from lysosomal degradation end up in MHC class II molecules at the 
cell surface and are in turn inspected by T cells for self/non-self discrimina-
tion. Endocytosis by CLRs that have bound ligand is mediated by conserved 
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motifs in the cytoplasmic tails of these lectins such as the di-leucine motif and 
tyrosin-based sequences (Fig. 1B) [54]. DC-SIGN contains both motifs, but it 
appears that for this lectin only the di-leucine motif is required for internaliza-
tion upon ligand binding since mutation of this di-leucine motif abrogated 
internalization [55]. The MR expresses only the tyrosin-based sequences [56]. 
Remarkably, MR recycles via early endosomes back to the cell surface enabling 
endocytosis of large quantities of glycoconjugates [57]. The tri-acidic cluster, 
expressed by DEC-205 and DC-SIGN, is a putative motif involved in routing 
internalized glycoconjugates to lysosomal and MHC-II-positive late endosomes 
indicating that these CLRs enable loading of peptides on MHC class II mo-
lecules [55,58]. Overall, it appears that cytoplasmic sequences determine the 
specific intracellular routing of each CLR. CLRs that express several different 
motifs like DC-SIGN seem to have specialized routing pathways that might 
depend on the nature of the bound pathogens [54]. 
Besides expression of internalization sequences in their cytoplasmic tails, some 
CLRs also contain signaling motifs like the immunoreceptor tyrosine-based 
activation motif (ITAM) or the immunoreceptor tyrosine-based inhibition motif 
(ITIM) (Fig. 1B). The β-glucan receptor Dectin-1 contains an ITAM motif and 
cooperates with TLR-2 in eliciting inflammatory responses against zymosan 
[59]. Upon triggering this Dectin-1/TRL-2 pathway, the cytokines TNF-α and 
IL-12 are produced. Recently, it was discovered that Dectin-1 can also signal 
SIGnAlInG And InternAlIzAtIon motIFS Are preSent In the cytoplASmIc tAIlS 
oF clrS. The cytoplasmic tails of CLRs contain several conserved motifs that may direct their 
intracellular targeting. Endocytosis is mediated by either di-leucine motifs (LL) and/or tyro-
sine-based sequences with the consensus motif FXXXXY or YXXØ (depicted in bold and bold 
underlined respectively; in which X designates any amino acid and Ø designates any amino 
acid with a bulky hydrophobic side chain). The motif YXXØ, a recognition site for adapter pro-
teins that might mediate intracellular targeting [78], and a dileucine motif involved in target-
ing to the endosomal/lysosomal pathway [79] are found in the cytoplasmic tail of DC-SIGN. In 
particular, the dileucine motif has been shown to support internalization of DC-SIGN-ligand 
complexes in transfected cells [55]. This is in contrast to the MR and DEC-205, which are 
constitutively endocytosed through their tyrosine-based (FXXXXY) motifs [58]. Moreover, the 
cytoplasmic domain of DC-SIGN contains an acidic triad (EEE; in grey box) that in DEC-205 
has been reported to target the CLR to organelles for antigen processing and peptide loading 
onto MHC class II molecules [58]. In addition, Dectin-1 and DCIR have an ITAM (depicted in 
bold in grey box) and an ITIM motif (depicted in bold cursive), respectively, which have been 
shown to induce specific signaling cascades [60,62].
Figure 1B
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via an additional pathway independent of TLR-2 [60]. In this pathway, the 
protein tyrosine kinase Syk is recruited to Dectin-1 in response to yeast, and 
this subsequently results in the production of IL-2 and IL-10. DC deficient 
for Syk are not able to produce these two cytokines, but are still able to pro-
duce IL-12 which indicates that Dectin-1/Syk and Dectin-1/TLR-2 pathways 
can operate independently [60]. Other CLRs that contain a complete or partial 
ITAM sequence are DC-SIGN, macrophage galactose-type C-type lectin (MGL), 
CLEC-1, and CLEC–2, but it is not clear yet whether these CLRs use a pathway 
similar to Dectin-1 [54]. DC-SIGN has been described to interfere with TLR-4 
signaling upon M. tuberculosis binding, indicating the existence of a different 
or additional pathway [61]. 
DCIR contains an ITIM sequence and this sequence is able to inhibit B-cell 
receptor mediated Ca2+ mobilization and tyrosine phosphorylation [62]. How-
ever, the exact role of this motif in modulating DC function is still unknown. 
In addition to ITAM and ITIM sequences, most CLRs, like DC-SIGN and MR, 
contain multiple serine and threonine residues that are potential phosphoryla-
tion sites [54]. MR is indeed reported to be involved in signaling transduction 
events. For example, one study reported that the anti-human MR monoclonal 
antibody 19.2 inhibits the LPS-induced IL-12 production by DC by interfering 
with TLR signaling [63]. Another monoclonal antibody against MR induces 
phenotypic and functional maturation of immature DC that have the ability 
to dampen inflammation and to inhibit the generation of Th1-polarized im-
mune responses [64]. Moreover, MR is implicated in the activation of NF-κB in 
response to Pneumocystis carinii [65]. The CLR BDCA-2 does not contain any 
signaling motif, however is able to induce Ca2+ mobilization [66]. It is conceiv-
able that CLRs lacking signaling motifs might dynamically associate with other 
signaling proteins for example during microbial infection. 
Multimerization 
Recognition of carbohydrates by CLRs is highly dependent on the density of 
the carbohydrates present on the cell surface as well as on the degree of mul-
timerization of the CRDs [67]. Multimerization of CRDs can occur within one 
single molecule like in MR (Fig. 1A). MR contains several CRDs in its extracel-
lular portion with only weak affinity for single carbohydrates. At least three of 
these CRDs must cooperate to achieve a high-affinity binding to multivalent 
glycoconjugates [68]. Multimerization of CRDs can also be achieved by oligo-
merization of several CLRs which is for instance observed for DC-SIGN [47]. 
DC-SIGN and L-SIGN both form tetramers when expressed at the cell surface 
as well as in a recombinant soluble form (Fig. 1A) [9,10]. The neck domain is 
responsible for this tetramer formation [9]. The portion of the neck domain 
adjacent to the CRD is sufficient to mediate formation of dimers, while regions 
near the N-terminus are required for stabilization of tetramers [10]. In general, 
multimerization of CRDs results in an increased binding potential for carbo-
hydrates. This is exemplified by the finding that a monomeric DC-SIGN CRD 
is still able to bind the HIV-1 envelope glycoprotein gp120, but the avidity 
increases substantially when a tetrameric CRD is used [69]. Receptor oligo-
merization not only increases the avidity for oligosaccharides, but may also 
help to cluster cytoplasmic internalization motifs leading to a more efficient 
signaling platform for internalization [69]. It is very likely that the way of 
expression of CLRs on the cell surface will determine the degree of multimeri-
sation. For instance, DC show a clustered distribution of DC-SIGN in so-called 
microdomains which are important for binding and internalization of virus 
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particles. A significant portion of these clustered DC-SIGN molecules resides in 
lipid rafts on DC [70]. Lipid rafts are microenvironments with elevated choles-
terol and glycosphingolipid content with the property to include and exclude 
proteins to variable extents [71]. The localization of DC-SIGN in lipid rafts 
may create a platform that favors pathogen binding and bringing signaling 
molecules into contact with DC-SIGN that are recruited in the same rafts as 
well [67]. This localization into lipid rafts might be a common mechanism for 
more CLRs since E-selectin expressed on endothelial cells colocalizes with lipid 
rafts as well (Fig. 1A). This localization seems to be important for signaling 
during leukocyte-endothelial cell interactions since E-selectin must associate 
and activate phospholipase Cγ, which will only take place when E-selectin is 
present in these lipid rafts [72]. Moreover, TLR-2 and TLR-4, which have been 
implicated to be involved in the actions of Dectin-1 and DC-SIGN respectively, 
were recently discovered to locate in lipid rafts as well [73,74]. After bacterial 
infection, TLR-2 is enriched in caveolin-1-associated lipid rafts at the surface 
of airway epithelial cells and is in this way involved in the initiation of the host 
response to potential bacterial infections [73]. Triantafilou et al. shows that 
TLR-4 is located in lipid rafts together with CD14 and other bacterial recogni-
tion immune receptors upon LPS stimulation [74]. They propose that different 
combinational associations of receptors within activation clusters determine 
the specific responses to a variety of bacterial stimuli [74,75]. The observation 
that certain CLRs and TLRs reside in lipid rafts together with the actual findings 
of interactions between two PRRs, like SIGN-related 1 (SIGNR-1) physically 
interacting with TLR-4-MD-2 [76] could possibly mean that these receptors 
reside in the same lipid rafts.
Glycoconjugates; binding partners of CLRs 
General characteristics of glycoconjugates
Most organisms glycosylate an extensive part of their cell-surface and se-
creted proteins. In humans, about 80% of these proteins contain oligosac-
charides (glycans). This high frequency of glycosylated proteins indicates a 
crucial function for protein glycosylation. In fact, it plays a role in stability 
of glycoproteins, protection against proteolytic cleavage, adhesion, antigenic 
variation and protective immunity [80,81]. 
Usually, glycans are found in nature as glycoconjugates which can be glyco-
proteins or glycolipids and greatly exceed the diversity of proteins and nucle-
ic acids [82]. This diversity is the result of the different disaccharide linkages, 
anomerization of glycosidic linkages (α,β), branching of glycan chains, and 
modification of hydroxyl groups of sugars by various groups (phosphate-, 
sulphate-, amino-) in the glycan molecule [50]. In spite of the enormous 
variability, glycans can be divided in three major classes depending on how 
they are linked to proteins or lipids: N-linked glycans, O-linked glycans, and 
glycosylphosphatidylinositol (GPI) anchors [82]. 
N-linked glycans are the most abundant group in nature and consists of a 
pentasaccharide core structure that can be extended by up to five ‘anten-
nae’ or branches. The oligosaccharide side chain is attached to the protein 
via an asparagine amino acid that is part of the Asn-X-Ser/Thr consensus 
sequence [80-82]. This consensus sequence is conserved between eukaryotes 
and prokaryotes [80]. Once the glycans are covalently attached to proteins, 
these are further modified in eukaryotes only. These modifications include 
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removal of several mannose residues and addition of sugar groups in the ER 
and the Golgi complex. As a result, eukaryotic N-linked oligosaccharides can 
be divided into high-mannose, complex, and hybrid type. Lower eukaryotes 
like yeast predominantly contain high-mannose structures, such as the DC-
SIGN ligand mannan present on C. albicans, while higher eukaryotes like 
men have evolved their glycosylation machinery to produce more complex 
glycans [16,83,84]. In humans, N-linked structures are present on the vast 
majority of glycoproteins such as on the ICAM subfamily of adhesion mo-
lecules like the DC-SIGN ligands ICAM-2 and ICAM–3 [85]. Viral proteins 
often contain N-linked glycans like the envelope glycoprotein E2 from Hepa-
titis C virus (HCV) and the glycoprotein gp120 from HIV-1 [86-88]. Viruses 
use the host machinery to synthesize their glycoconjugates, and this results 
in glycoproteins that resemble the host glycoproteins, providing a manner for 
the virus to evade the immune system of the host [81,89]. Bacteria can also 
escape the human immune system by producing glycoconjugates that are 
closely related like the Lewis blood group antigens as found on for example 
Helicobacter pylori [84,90]. 
In contrast to the N-linked glycans, O-linked oligosaccharides are less fre-
quently found on eukaryotic glycoproteins and do not contain a common 
core structure [81]. In these type of sugars, the carbohydrate residue is co-
valently attached to the amino acid side chains via the hydroxyl group of 
serine or threonine [82]. The process of O-linked glycosylation occurs on 
fully folded proteins in the Golgi complex in eukaryotes [80,81]. In bacteria, 
the O-glycosylation process takes place in the cytoplasm or at the interface 
between cytoplasm and surface appendages such as pili and flagella [80]. 
Many bacterial glycoconjugates have O-linkages while archaea contain pre-
dominantly N-linked glycans [91,92]. In humans, O-glycans are detected in 
mucins and collagens [82,89]. 
The third group of glycans, the GPI anchors attach proteins or glycoproteins 
to eukaryotic cell membranes. GPI anchors are naturally occurring glyco-
lipids and share the same basic core structure with a linear tetrasaccharide 
attached to the 6-O-position of inositol [81,82]. The basic carbohydrate struc-
ture of GPI anchors in yeast and protozoan parasites is similar to those in 
mammals [84,90]. The existence of prokaryote GPI anchors is still a matter 
of debate [93]. 
CLRs may specifically recognize one of these three groups of glycans, but the 
recognition of more than one group is also possible like MR in interacting with 
N-linked mannose structures present on HIV-1 as well as with O-linked mucins 
from normal and tumor cells [94-96]. 
Central to the different glycosylation processes described above are the gly-
cosyltransferases. These enzymes catalyze the stepwise synthesis of both 
N- and O-linked oligosaccharides and can be grouped into many families like 
sialyl-, galactosyl-, and fucosyl-transferases, depending upon the type of sugar 
it transfers to the oligosaccharide chain [91]. The expression of human glyco-
syltransferases can be tissue specific which results in cells that present a unique 
set of oligosaccharides like the human blood group antigens Lewis A, B, X and 
Y [50]. Besides tissue-specific expression of glycosyltransferases, the differen-
tiation status of the cell and the presence of cytokines can induce expression 
of certain glycosyltransferases resulting in the appearance of special glycans 
[50,97-99]. Tumor cells frequently express altered glycosylation patterns which 
include both the under- and over-expression of naturally-occurring glycans, 
as well as neoexpression of glycans normally restricted to embryonic tissues. 
These changes are normally the result of differences in the expression levels of 
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glycosyltransferases in the Golgi compartment of tumor cells [100]. The differ-
ence in glycosylation pattern of malignant tissue compared to healthy tissue 
results in a differential binding of lectins (Fig. 2) [101]. 
Microbes also express a unique set of glycans due to the presence of specific 
glycosyltransferases. This expression can be very dynamic to manage antigenic-
diversity and immune evasion like in H. pylori (Fig. 2) and Campylobacter 
jejuni. In H. pylori, the dynamic expression of glycans is established by frame-
clrS recoGnIze cArBohydrAte StructureS expreSSed on mIcroBIAl And en-
doGenouS cellS SuBject to cell-SpecIFIc or modIFIed GlycoSylAtIon. Several 
CLRs recognize endogenous cell-type specific glycosylation (1 vs. 2) such as DC-SIGN in in-
teracting with neutrophils via Lewis X. This carbohydrate moiety is specifically expressed 
by Mac-1 on these type of cells [33]. Moreover, DC-SIGN recognizes ICAM-2 expressed on 
endothelial cells, but not the heavily sialylated ICAM-2 expressed by platelets [53]. Aberrant 
cells (3) such as dying and tumor cells frequently have an altered glycosylation compared to 
their original state. MBL has been reported to bind several malignant as well as apoptotic and 
necrotic cells (reviewed in [6]). In addition, DC-SIGN binds to breast and colorectal cancer 
cells and DEC-205 recognizes apoptotic thymocytes [7,102]. The interactions between CLRs 
and aberrant cells may result in clearance of these cells or may provide a way for tumor cells 
to escape immunity. 
CLRs recognize specific strains of pathogens (4 vs. 5) due to their specific glycosylation. For 
instance, DC-SIGN binds to M. tuberculosis through the mannosylated mycobacterium cell 
wall lipoarabinomannan whereas M. smegmatis is not recognized because this structure is 
not mannose-capped [17]. Moreover, DC-SIGN specifically recognizes the Lewis+ variant of 
the human gastric pathogen H. pylori via the Lewis antigens expressed on LPS present on the 
bacterial surface. These Lewis antigens are dynamically expressed on H. pylori due to on and 
off switching of genes encoding for specific fucosyltransferases [103]. Interestingly, interac-
tion between DC-SIGN and these two pathogens described above result in the modulation of 
the DC to escape immunity [17,103]. Dectin-1 specifically recognizes C. albicans yeast and 
not the filamentous form. This is accomplished by the exposure of the Dectin-1 ligand ß-glu-
can on bud scars in C. albicans yeast. In C. albicans filaments this budding does not occur and 
therefore no ß-glucan is exposed. Triggering Dectin-1 by C. albicans yeast results in a potent 
antifungal inflammatory response [104].
Figure 2
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shift mutations and in C. jejuni by phase-variable genes encoding for enzymes 
involved in biosynthesis of carbohydrates [80,89]. 
Pathogen-derived glycoconjugates
The cell wall of pathogens is decorated with a wide array of carbohydrates. 
These are derived from genes of the pathogen itself, but also from genes of the 
host by horizontal transfer [1]. Especially viruses use this latter mechanism to 
escape the immune system by mimicking glycosylation of endogenous glyco-
sylated proteins [85]. Moreover, enveloped viruses are also able to acquire host 
cell membrane glycoproteins. HIV-1 acquires ICAM-1, CD43, and many other 
cellular proteins when it buds from the infected host cells [105]. 
The main function of CLRs after binding pathogens is internalization, which 
leads to lysosomal degradation and subsequent loading of peptide fragments 
into MHC molecules (Fig. 3). When this MHC-peptide complex is recognized 
by T cells, the adaptive immune system is activated [30]. However, several 
pathogens escape the immune system by exploiting specific CLRs. For instance, 
HIV-1 binds to DC-SIGN on DC at the site of infection and exploits the migra-
tory capacity of DC to gain access to T cells in the lymph node [15]. Also other 
viruses target DC-SIGN to promote their dissemination like HCV [106] and 
severe acute respiratory syndrome coronavirus [107]. HIV-1 and HCV are inter-
nalized after binding to DC-SIGN (Fig. 3) into the DC, but instead of undergo-
ing lysosomal degradation these virus particles reroute from endosomes to the 
cell surface and subsequently infect T cells in trans [106,108]. In addition to 
DC-SIGN, the MR on macrophages is also exploited by HIV-1 for transmission 
to permissive T cells. The half-life of HIV-1 bound to MR is lower compared 
to virus bound to DC-SIGN, indicating different internalization routes for MR 
and DC-SIGN [96]. 
Besides targeting of CLRs by viruses for transmission to permissive cells, non-
viral pathogens exploit CLRs for immune escape in other ways. M. tuberculosis 
targets DC-SIGN and causes the inhibition of the immunostimulatory function 
of the DC by producing the immune response dampening cytokine IL-10 [17]. 
The human gastric pathogen H. pylori also modulates the function of DC via 
DC-SIGN by blocking the polarization towards a T helper type 1 response [103]. 
Another CLR that might be exploited by pathogens to modulate the DC func-
tion is BDCA-2. This CLR is specifically expressed by plasmacytoid DC and is 
able to change the direction of the immune system by mediating the produc-
tion of specific cytokines [109]. 
Despite the various cases of immune evasion by pathogens via CLRs, CLRs still 
play an important role in limiting the spread of infectious organisms. Mice 
lacking SIGN-R1, the murine homologue of DC-SIGN, fail to clear Streptococ-
cus pneumoniae from the circulation and are therefore more susceptible to 
infection with this pathogen [110]. MBL-null mice die 48 hours after exposure 
to Staphylococcus aureus underlining the importance of MBL in restricting the 
complications when infected with this pathogen [111]. A complete comparison 
between these mouse disease models and infectious diseases in man is difficult 
since remarkable differences exist between human DC-SIGN and mouse SIGN-
R1 with respect to cell type specific expression patterns (reviewed in [112]).  
Next to CLR binding, a pathogen also interacts with other receptors present on 
the DC, such as members of the TLR family. These TLRs recognize characteristic 
patterns on specific pathogens. For instance, TLR-4 recognizes LPS on Gram-
negative bacteria [3]. The engagement of a specific TLR with associated signal-
ing complexes results in an appropriate response against the pathogen involved 
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[59]. CLRs can cooperate with these receptors, like Dectin-1 does with TLR-2, 
but can also interfere, like DC-SIGN does with TLR-4 [17,60,113]. Recently, it 
was reported that SIGN-R1 associates with TLR-4 to capture gram-negative 
bacteria and to facilitate signal transduction to activate innate macrophage 
responses [76]. Apparently, in this kind of response SIGN-R1 cooperates with 
TLR-4 instead of interfering like observed for the human DC-SIGN. 
Several CLRs can interact with more than just one pathogen as exemplified 
for DC-SIGN and MR [5,114]. The multiple engagement of a pathogen with a 
CLR in combination with other molecules expressed on the DC will result in a 
unique response. The response is also dependent on the structure of the CLR 
ligand. To illustrate this, the DC-SIGN ligands Lewis X antigen and HCV show 
different internalization routes in immature DC. The Lewis X antigen is inter-
nalized into lysosomes upon binding DC-SIGN, whereas HCV virus-like par-
ticles are targeted to nonlysosomal compartments [106]. Similar to HCV, HIV-1 
binds the same binding site on DC-SIGN and is also targeted to nonlysosomal 
compartments via DC-SIGN [15,106].
Endogenous glycoconjugates
Carbohydrate structures that decorate proteins and lipids on the cell surface are 
representatives of normal self. These carbohydrate structures usually terminate 
with sialic acids in vertebrates. Those sialic acids are recognized by a variety 
of receptors involved in intercellular communication like the Siglecs group [1]. 
The Siglecs group contain ITIM motifs in their cytoplasmic tail which indicates 
that they negatively regulate the function of leukocytes upon binding sialic 
acids [115]. For instance, CD33 a member of the Siglec family is expressed on 
monocytes and constitutively represses monocyte activation due to interactions 
with sialic acids residues [116]. Lack of sialic acid on most micro-organisms 
and on transformed cells is recognized as missing self, thus overcoming the 
inhibitory effect of the Siglecs [1]. Several studies indicate a tolerizing function 
for CLRs upon binding endogenous ligands. For instance, the MR mediates tis-
sue homeostasis and resolution of inflammation by the clearance of potential 
harmful endogenous products [4,13,114]. This function is also ascribed to MGL 
since it has a specificity for terminal α- and β-linked GalNAc residues that 
naturally occur as parts of glycoproteins or glycosphingolipids [117]. Moreover, 
Bonifaz et al. show that ovalbumin protein targeting to DEC-205 in mice re-
sults in tolerance induction, when no danger signal is present [118]. 
The in vivo localisation of CLRs in peripheral tissues also points to a tolerance 
inducing function for several CLRs. In the placenta, expression of DC-SIGN and 
MR is observed on decidual immature DC and macrophages whereas L-SIGN 
is detected on endothelial cells [95,119-121]. The presence of these CLRs in the 
placenta suggests that these CLRs play a role in the balance between defense 
against pathogens and tolerance of the fetal allograft [95,122]. Moreover, ex-
pression of DC-SIGN, L-SIGN and MR is detected on specific cells in the brain, 
an immunologically privileged organ [123,124]. This implies a role for these 
CLRs in limiting the spread of inflammation in the brain in order to avoid 
threatening of organ integrity and function [125,126]. Besides endothelial cells 
in the placenta and brain, L-SIGN is also expressed on liver sinusoidal endothe-
lial cells which are tolerogenic organ-resident antigen-presenting cells [127]. 
Several CLRs are involved in cell-cell adhesion processes. DC-SIGN, Dectin-
1, Dectin-2, and Dendritic Cell Associated Lectin (DCAL) mediate DC-T cell 
interactions [19,77,128,129]. These interactions result either in augmentation 
of T cell proliferation, as in the case of Dectin-1 [77] and DCAL [129], or in 
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abrogation of the immune response as observed for Dectin-2 [128]. Dectin-1 
and DCAL His-tagged fusion proteins deliver costimulatory signals to T cells in 
the presence of anti-CD3 antibodies [77,129]. In rat, Dectin-2 binds to regula-
tory T cells and mediates hapten-specific tolerance which is induced by UV 
radiation [128]. DC-SIGN (Fig. 3) is able to perform a stimulatory as well as an 
inhibitory role in DC-T cell interactions depending on the strength of the T cell 
stimulus [19,130]. 
Besides DC-T cell interactions, DC-SIGN mediates DC migration across the en-
dothelium by binding to ICAM-2 (Fig. 3) [18]. For MR a trafficking function 
has been proposed by binding to sulphated carbohydrate ligands such as sulfo-
Lewis A and X sequences. The recognition of sulfo-Lewis A and X sequences 
overlaps with the binding specificity of selectins, a CLR family specialized in 
leukocyte trafficking [131,132]. 
As mentioned previously, DC-SIGN is also involved in mediating interactions 
between DC and neutrophils. This interaction is established by DC-SIGN bind-
ing to Lewis X expressed on the β2-integrin Mac-1. In contrast to most of 
the endogenous ligands, this interaction takes place during an inflammation 
when neutrophils infiltrate inflamed tissue where they meet DC. The interac-
tion results in a modulation of the immune response [33]. Interestingly, only 
clrS expreSSed on dc Involved In recoGnItIon oF pAthoGen-derIved And en-
doGenouS GlycoconjuGAteS. DC-SIGN and MR function as PRRs by internalizing patho-
gens that are subsequently processed and loaded into MHC molecules for antigen-presentation. 
To take up large quantities of antigen, the MR recycles back to the cell surface via early endo-
somes [57]. Several pathogens exploit CLRs to escape immunity. HIV-1 and HCV exploit DC-SIGN 
to escape from the lysosomal degradation pathway remaining alive in endosomal compartments 
[106,108]. Moreover, the non-viral pathogens H. Pylori and M. tuberculosis escape immunity 
by modulating DC to produce anti-inflammatory cytokines upon binding DC-SIGN [17,103]. 
Besides functioning as PRRs, DC-SIGN and MR also function as adhesion and homing receptors by 
mediating contacts between DC and T cells (DC-SIGN), DC and endothelium (DC-SIGN) and 
T cells and endothelium (MR) [18,19,32]. As clearance receptor, MR internalizes lysosomal 
hydrolases and agalactosyl IgG to mediate homeostasis [13,134]. 
Figure 3
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Mac-1 expressed by neutrophils contain the Lewis X structure and not when 
expressed by other immune cells like T cells (Fig. 2) [33]. This emphasizes the 
specificity of glycan expression on special cells and function of CLRs. Dying 
as well as malignant cells frequently have an altered glycosylation that results 
in the modification of glycans marking them as altered self (Fig. 2). These 
modified self carbohydrates are detected by several CLRs like DEC-205, which 
participates in the clearance of apoptotic thymocytes, or MBL, which binds to 
apoptotic cell lines [6,102]. The clearance of apoptotic cells prevents the release 
of inflammatory intracellular components that are normally hidden inside the 
cells [1]. In addition, MBL can bind to carcinoma cell lines thereby mediating 
the clearance of these cells in a non-inflammatory way [6]. In analogy, DC-
SIGN can bind colorectal cancer cells and may provide a way for these tumor 
cells to escape from immunological attack [7]. 
The endogenous ligands for DC-SIGN appear to be predominantly cell- 
associated, but recently a soluble ligand for DC-SIGN in the female genital tract 
was discovered. This naturally occurring glycoprotein is observed in 12.6% of 
the women studied and may provide innate protection against HIV-1 infection 
[133]. As mentioned previously, MR also binds soluble ligands (Fig. 3) such as 
lysosomal hydrolases to prevent tissue damage [13]. Moreover, MR can also 
bind agalactosyl immunoglobulins (IgG) which are increased in autoimmune 
disorders [134]. 
Concluding remarks
CLRs were primarily considered to be PRRs in recognizing glycosylated li-
gands on pathogens. However, this view is changing since many endogenous 
glycoconjugates are being discovered as ligands for the CLRs. The functional 
outcome upon interaction with a CLR, depends on the interplay with other 
antigen-sensing receptors like TLRs. The balance between CLRs and TLRs is 
critical for the type of immune response, resulting in either immune escape 
or complete elimination of a specific pathogen. Glycosylation differences on 
microbes and endogenous proteins can have profound impacts on the binding 
capacity of a CLR. With the use of glycan arrays the exact binding epitopes 
can be determined and will provide more information regarding the conditions 
a CLR will bind to its ligand. Unraveling the specific signaling pathways and 
interactions with other ligand recognition systems will be essential for a full 
understanding of the CLR biology. This knowledge about the CLR biology can 
be applied in therapeutic settings like in antigen targeting to CLRs [135] to 
either evoke an immune response in the case of cancer or dampen an immune 
response in the case of autoimmunity.  
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Aim of this thesis
DC-SIGN is a C-type lectin specifically expressed on DC that recognizes high-
mannose and fucose glycans. This carbohydrate specificity of DC-SIGN enables 
recognition of a large array of ligands which include both pathogen-derived as 
well as endogenous glycoconjugates. 
Because of the wide expression of DC-SIGN ligands, DC-SIGN is involved in 
several aspects of the immune system like immune defense, tolerance induction 
and cell-cell communication. This broadens the role of DC-SIGN since C-type 
lectin receptors were primarily considered as pattern-recognition receptors that 
recognize pathogen-associated molecular patterns. Therefore, the aim of this 
thesis was to investigate the various implications of DC-SIGN in interacting 
with foreign and endogenous ligands. 
In chapter 2 and 3 the pathogenic DC-SIGN ligand Candida albicans was 
examined. The fungus C. albicans was discovered as a ligand for DC-SIGN in 
chapter 2. DC-SIGN expressed on transfected cell lines and on monocyte-de-
rived DC was able to bind the yeast form of C. albicans. After binding, the fungi 
were internalized into DC-SIGN enriched vesicles that may lead to antigen 
presentation. In chapter 3 the interaction of DC with C. albicans was further 
studied. We compared the anticandidal properties of DC with monocytes and 
macrophages and observed that DC were significantly less efficient in killing C. 
albicans. Moreover, DC released less pro-inflammatory cytokines in response to 
this fungus compared to monocytes and macrophages underlining the role of 
DC in antigen presentation. In chapter 4, 5 and 6 the endogenous ligands of 
DC-SIGN are described. The interaction of DC-SIGN with ICAM-3 was analyzed 
in chapter 4 to study the relevance of DC-SIGN in DC-T cell communication. 
DC-SIGN mediates DC-induced T cell proliferation, but this effect was only 
visible when the MLR is weak and the number of DC-SIGN binding PBL is 
high. In chapter 5 the interaction between DC-SIGN and monocytes via Lewis 
X is shown. This interaction depends on the density of Lewis X molecules ex-
pressed by monocytes. The density was modified by uncovering hidden Lewis 
X residues by removing sialic acid residues. In chapter 6 the binding capac-
ity of DC-SIGN and L-SIGN to leukemic cells is described and this lead to the 
discovery that a high binding of DC-SIGN/L-SIGN to peripheral blood cells is 
correlated with a poor survival. Finally, in chapter 7 the potential of using 
DC-SIGN as a target to deliver antigens to dendritic cells is explored. In this 
chapter the effectiveness of an anti-DC-SIGN antibody coupled to KLH (hD1-
KLH) to target DC and to induce an effective immune response against KLH is 
investigated. hD1-KLH specifically bound DC-SIGN, was internalized into the 
lysosomal compartment of DC and induced T cell proliferation at a 100-fold 
lower concentration than KLH alone. 
Chapter 1 General Introduction
28
 [1] Medzhitov, R. and Janeway, C. A., Jr.(2002) Science, 296, 298-300.
 [2] McGreal, E. P.; Miller, J. L. and Gordon, S.(2005) Curr. Opin. 
Immunol., 17, 18-24.
 [3] Takeda, K. and Akira, S.(2005) Int. Immunol., 17, 1-14.
 [4] McGreal, E. P.; Martinez-Pomares, L. and Gordon, S.(2004) Mol. 
Immunol., 41, 1109-1121.
 [5] Cambi, A. and Figdor, C. G.(2005) Curr. Opin. Immunol., 17, 1-7.
 [6] Saevarsdottir, S.; Vikingsdottir, T. and Valdimarsson, H.(2004) 
Scand. J. Immunol., 60, 23-29.
 [7] van Gisbergen, K. P.; Aarnoudse, C. A.; Meijer, G. A.; Geijtenbeek, 
T. B. and van Kooyk, Y.(2005) Cancer Res., 65, 5935-5944.
 [8] Drickamer, K.(1999) Curr. Opin. Struct. Biol., 9, 585-590.
 [9] Mitchell, D. A.; Fadden, A. J. and Drickamer, K.(2001) J. Biol. 
Chem., 276, 28939-28945.
 [10] Feinberg, H.; Guo, Y.; Mitchell, D. A.; Drickamer, K. and Weis, W. 
I.(2005) J. Biol. Chem., 280, 1327-1335.
 [11] Weis, W. I.; Taylor, M. E. and Drickamer, K.(1998) Immunol. Rev., 
163, 19-34.
 [12] Hansen, S. and Holmskov, U.(1998) Immunobiology, 199, 165-
189.
 [13] Taylor, P. R.; Gordon, S. and Martinez-Pomares, L.(2005) Trends 
Immunol., 26, 104-110.
 [14] Cambi, A. and Figdor, C. G.(2003) Curr. Opin. Cell Biol., 15, 539-
546.
 [15] Geijtenbeek, T. B.; Kwon, D. S.; Torensma, R.; Van Vliet, S. J.; 
van Duijnhoven, G. C.; Middel, J.; Cornelissen, I. L.; Nottet, H. S.; 
KewalRamani, V. N.; Littman, D. R.; Figdor, C. G. and van Kooyk, 
Y.(2000) Cell, 100, 587-597.
 [16] Cambi, A.; Gijzen, K.; de Vries, J. M.; Torensma, R.; Joosten, B.; 
Adema, G. J.; Netea, M. G.; Kullberg, B. J.; Romani, L. and Figdor, 
C. G.(2003) Eur. J. Immunol., 33, 532-538.
 [17] Geijtenbeek, T. B.; Van Vliet, S. J.; Koppel, E. A.; Sanchez-
Hernandez, M.; Vandenbroucke-Grauls, C. M.; Appelmelk, B. and 
van Kooyk, Y.(2003) J. Exp. Med., 197, 7-17.
 [18] Geijtenbeek, T. B.; Krooshoop, D. J.; Bleijs, D. A.; Van Vliet, S. J.; 
van Duijnhoven, G. C.; Grabovsky, V.; Alon, R.; Figdor, C. G. and 
van Kooyk, Y.(2000) Nat. Immunol., 1, 353-357.
 [19] Geijtenbeek, T. B.; Torensma, R.; Van Vliet, S. J.; van Duijnhoven, 
G. C.; Adema, G. J.; van Kooyk, Y. and Figdor, C. G.(2000) Cell, 
100, 575-585.
 [20] Matzinger, P.(2002) Science, 296, 301-305.
 [21] Rifkin, I. R.; Leadbetter, E. A.; Busconi, L.; Viglianti, G. and 
Marshak-Rothstein, A.(2005) Immunol. Rev., 204, 27-42.
 [22] Kronenberg, M. and Rudensky, A.(2005) Nature, 435, 598-604.
 [23] Banchereau, J. and Steinman, R. M.(1998) Nature, 392, 245-252.
 [24] Gordon, S.(2002) Cell, 111, 927-930.
 [25] Takeda, K.; Kaisho, T. and Akira, S.(2003) Annu. Rev. Immunol., 
21, 335-376.
 [26] Mahnke, K. and Enk, A. H.(2005) Curr. Top. Microbiol. Immunol., 
293, 133-150.
 [27] Geijtenbeek, T. B.; Van Vliet, S. J.; Engering, A.; ‘t Hart, B. A. and 
van Kooyk, Y.(2004) Annu. Rev. Immunol., 22, 33-54.
 [28] Thery, C. and Amigorena, S.(2001) Curr. Opin. Immunol., 13, 45-51.
 [29] Larsson, M.; Beignon, A. S. and Bhardwaj, N.(2004) Semin. 
Immunol., 16, 147-161.
 [30] Figdor, C. G.; van Kooyk, Y. and Adema, G. J.(2002) Nat. Rev. 
Immunol., 2, 77-84.
 [31] Pontow, S. E.; Kery, V. and Stahl, P. D.(1992) Int. Rev. Cytol., 
137B, 221-244.
 [32] Irjala, H.; Johansson, E. L.; Grenman, R.; Alanen, K.; Salmi, M. 
and Jalkanen, S.(2001) J. Exp. Med., 194, 1033-1042.
 [33] van Gisbergen, K. P.; Sanchez-Hernandez, M.; Geijtenbeek, T. B. 
and van Kooyk, Y.(2005) J. Exp. Med., 201, 1281-1292.
 [34] Liew, F. Y.(2002) Nat. Rev. Immunol., 2, 55-60.
 [35] van de Wetering, J. K.; van Golde, L. M. and Batenburg, J. 
J.(2004) Eur. J. Biochem., 271, 1229-1249.
 [36] Soilleux, E. J.; Barten, R. and Trowsdale, J.(2000) J. Immunol., 
165, 2937-2942.
 [37] Santis, A. G.; Lopez-Cabrera, M.; Hamann, J.; Strauss, M. and 
Sanchez-Madrid, F.(1994) Eur. J. Immunol., 24, 1692-1697.
 [38] Liu, W.; Tang, L.; Zhang, G.; Wei, H.; Cui, Y.; Guo, L.; Gou, Z.; 
Chen, X.; Jiang, D.; Zhu, Y.; Kang, G. and He, F.(2004) J. Biol. 
Chem., 279, 18748-18758.
 [39] Sobanov, Y.; Bernreiter, A.; Derdak, S.; Mechtcheriakova, D.; 
Schweighofer, B.; Duchler, M.; Kalthoff, F. and Hofer, E.(2001) 
Eur. J. Immunol., 31, 3493-3503.
 [40] Yokota, K.; Takashima, A.; Bergstresser, P. R. and Ariizumi, 
K.(2001) Gene, 272, 51-60.
 [41] Bates, E. E.; Fournier, N.; Garcia, E.; Valladeau, J.; Durand, I.; 
Pin, J. J.; Zurawski, S. M.; Patel, S.; Abrams, J. S.; Lebecque, S.; 
Garrone, P. and Saeland, S.(1999) J. Immunol., 163, 1973-1983.
 [42] Arce, I.; Roda-Navarro, P.; Montoya, M. C.; Hernanz-Falcon, P.; 
Puig-Kroger, A. and Fernandez-Ruiz, E.(2001) Eur. J. Immunol., 
31, 2733-2740.
 [43] Drickamer, K. and Fadden, A. J.(2002) Biochem. Soc. Symp., 69, 
59-72.
 [44] Kogelberg, H. and Feizi, T.(2001) Curr. Opin. Struct. Biol., 11, 
635-643.
 [45] Weis, W. I. and Drickamer, K.(1996) Annu. Rev. Biochem., 65, 
441-473.
 [46] Drickamer, K.(1992) Nature, 360, 183-186.
 [47] Snyder, G. A.; Colonna, M. and Sun, P. D.(2005) J. Mol. Biol., 
347, 979-989.
 [48] Drickamer, K. and Taylor, M. E.(2002) Genome Biol., 3, 1034.1-
1034.4.
 [49] Galustian, C.; Park, C. G.; Chai, W.; Kiso, M.; Bruening, S. A.; 
Kang, Y. S.; Steinman, R. M. and Feizi, T.(2004) Int. Immunol., 
16, 853-866.
 [50] Feizi, T. and Chai, W.(2004) Nat. Rev. Mol. Cell Biol., 5, 582-
588.
 [51] Guo, Y.; Feinberg, H.; Conroy, E.; Mitchell, D. A.; Alvarez, R.; 
Blixt, O.; Taylor, M. E.; Weis, W. I. and Drickamer, K.(2004) Nat. 
Struct. Mol. Biol., 11, 591-598.
 [52] Van Liempt, E.; Imberty, A.; Bank, C. M.; Van Vliet, S. J.; van 
Kooyk, Y.; Geijtenbeek, T. B. and Van, D., I(2004) J. Biol. Chem., 
279, 33161-33167.
 [53] Weber, K. S.; Alon, R. and Klickstein, L. B.(2004) Inflammation, 
28, 177-188.
 [54] Engering, A.; Geijtenbeek, T. B. and van Kooyk, Y.(2002) Trends 
Immunol., 23, 480-485.
 [55] Engering, A.; Geijtenbeek, T. B.; Van Vliet, S. J.; Wijers, M.; Van 
Liempt, E.; Demaurex, N.; Lanzavecchia, A.; Fransen, J.; Figdor, 
C. G.; Piguet, V. and van Kooyk, Y.(2002) J. Immunol., 168, 
2118-2126.
 [56] Ezekowitz, R. A.; Sastry, K.; Bailly, P. and Warner, A.(1990) J. 
Exp. Med., 172, 1785-1794.
 [57] Sallusto, F.; Cella, M.; Danieli, C. and Lanzavecchia, A.(1995) J. 
Exp. Med., 182, 389-400.
 [58] Mahnke, K.; Guo, M.; Lee, S.; Sepulveda, H.; Swain, S. L.; 
Nussenzweig, M. and Steinman, R. M.(2000) J. Cell Biol., 151, 
673-684.
 [59] Underhill, D. M.(2003) Eur. J. Immunol., 33, 1767-1775.
 [60] Rogers, N. C.; Slack, E. C.; Edwards, A. D.; Nolte, M. A.; Schulz, 
O.; Schweighoffer, E.; Williams, D. L.; Gordon, S.; Tybulewicz, V. 
L.; Brown, G. D. and Reis E Sousa(2005) Immunity., 22, 507-517.
 [61] Geijtenbeek, T. B.; van Vliet, S. J.; Koppel, E. A.; Sanchez-
Hernandez, M.; Vandenbroucke-Grauls, C. M.; Appelmelk, B. and 
van Kooyk, Y.(2003) J. Exp. Med., 197, 7-17.
 [62] Kanazawa, N.; Okazaki, T.; Nishimura, H.; Tashiro, K.; Inaba, K. 
and Miyachi, Y.(2002) J. Invest Dermatol., 118, 261-266.
 [63] Nigou, J.; Zelle-Rieser, C.; Gilleron, M.; Thurnher, M. and Puzo, 
G.(2001) J. Immunol., 166, 7477-7485.
References
29
Chapter 1 General Introduction
 [64] Chieppa, M.; Bianchi, G.; Doni, A.; Del Prete, A.; Sironi, M.; 
Laskarin, G.; Monti, P.; Piemonti, L.; Biondi, A.; Mantovani, A.; 
Introna, M. and Allavena, P.(2003) J. Immunol., 171, 4552-4560.
 [65] Zhang, J.; Zhu, J.; Imrich, A.; Cushion, M.; Kinane, T. B. and 
Koziel, H.(2004) Infect. Immun., 72, 3147-3160.
 [66] Dzionek, A.; Sohma, Y.; Nagafune, J.; Cella, M.; Colonna, 
M.; Facchetti, F.; Gunther, G.; Johnston, I.; Lanzavecchia, A.; 
Nagasaka, T.; Okada, T.; Vermi, W.; Winkels, G.; Yamamoto, T.; 
Zysk, M.; Yamaguchi, Y. and Schmitz, J.(2001) J. Exp. Med., 194, 
1823-1834.
 [67] Cambi, A.; Koopman, M. and Figdor, C. G.(2005) Cell Microbiol., 
7, 481-488.
 [68] Taylor, M. E.; Bezouska, K. and Drickamer, K.(1992) J. Biol. 
Chem., 267, 1719-1726.
 [69] Snyder, G. A.; Ford, J.; Torabi-Parizi, P.; Arthos, J. A.; Schuck, P.; 
Colonna, M. and Sun, P. D.(2005) J. Virol., 79, 4589-4598.
 [70] Cambi, A.; de Lange, F.; van Maarseveen, N. M.; Nijhuis, M.; 
Joosten, B.; van Dijk, E. M.; De Bakker, B. I.; Fransen, J. A.; 
Bovee-Geurts, P. H.; van Leeuwen, F. N.; Van Hulst, N. F. and 
Figdor, C. G.(2004) J. Cell Biol., 164, 145-155.
 [71] Simons, K. and Toomre, D.(2000) Nat. Rev. Mol. Cell Biol., 1, 31-
39.
 [72] Kiely, J. M.; Hu, Y.; Garcia-Cardena, G. and Gimbrone, M. A., 
Jr.(2003) J. Immunol., 171, 3216-3224.
 [73] Soong, G.; Reddy, B.; Sokol, S.; Adamo, R. and Prince, A.(2004) J. 
Clin. Invest, 113, 1482-1489.
 [74] Triantafilou, M.; Miyake, K.; Golenbock, D. T. and Triantafilou, 
K.(2002) J. Cell Sci., 115, 2603-2611.
 [75] Triantafilou, M. and Triantafilou, K.(2003) J. Endotoxin. Res., 9, 
331-335.
 [76] Nagaoka, K.; Takahara, K.; Tanaka, K.; Yoshida, H.; Steinman, 
R. M.; Saitoh, S.; Akashi-Takamura, S.; Miyake, K.; Kang, Y. S.; 
Park, C. G. and Inaba, K.(2005) Int. Immunol., 17, 827-836.
 [77] Ariizumi, K.; Shen, G. L.; Shikano, S.; Xu, S.; Ritter, R., III; 
Kumamoto, T.; Edelbaum, D.; Morita, A.; Bergstresser, P. R. and 
Takashima, A.(2000) J. Biol. Chem., 275, 20157-20167.
 [78] Bonifacino, J. S. and Dell’Angelica, E. C.(1999) J. Cell Biol., 145, 
923-926.
 [79] Shen, L.; Lang, M. L. and Wade, W. F.(2000) 
Immunopharmacology, 49, 227-240.
 [80] Szymanski, C. M. and Wren, B. W.(2005) Nat. Rev. Microbiol., 3, 
225-237.
 [81] Rudd, P. M.; Wormald, M. R. and Dwek, R. A.(2004) Trends 
Biotechnol., 22, 524-530.
 [82] Holemann, A. and Seeberger, P. H.(2004) Curr. Opin. Biotechnol., 
15, 615-622.
 [83] Wildt, S. and Gerngross, T. U.(2005) Nat. Rev. Microbiol., 3, 119-
128.
 [84] Varki, A., Cummings, R., Esko, J., Freeze, H., Hart, G., and Marth, J. 
(1999) in Essentials of glycobiology, (The Consortium of Glycobiology 
Editors.), Cold Spring Harbor Laboratory Press, New York.
 [85] Jimenez, D.; Roda, P.; Springer, T. A. and Casasnovas, J. M.(2005) 
J. Biol. Chem., 280, 5854-5861.
 [86] Lozach, P. Y.; Lortat-Jacob, H.; de Lacroix, d. L.; Staropoli, 
I.; Foung, S.; Amara, A.; Houles, C.; Fieschi, F.; Schwartz, O.; 
Virelizier, J. L.; Arenzana-Seisdedos, F. and Altmeyer, R.(2003) J. 
Biol. Chem., 278, 20358-20366.
 [87] Lin, G.; Simmons, G.; Pohlmann, S.; Baribaud, F.; Ni, H.; Leslie, 
G. J.; Haggarty, B. S.; Bates, P.; Weissman, D.; Hoxie, J. A. and 
Doms, R. W.(2003) J. Virol., 77, 1337-1346.
 [88] Leonard, C. K.; Spellman, M. W.; Riddle, L.; Harris, R. J.; Thomas, 
J. N. and Gregory, T. J.(1990) J. Biol. Chem., 265, 10373-10382.
 [89] van Kooyk, Y.; Engering, A.; Lekkerkerker, A. N.; Ludwig, I. S. 
and Geijtenbeek, T. B.(2004) Curr. Opin. Immunol., 16, 488-493.
 [90] Mengeling, B. J. and Turco, S. J.(1998) Curr. Opin. Struct. Biol., 
8, 572-577.
 [91] Upreti, R. K.; Kumar, M. and Shankar, V.(2003) Proteomics., 3, 
363-379.
 [92] Messner, P.(1997) Glycoconj. J., 14, 3-11.
 [93] Nosjean, O.(1998) Nat. Biotechnol., 16, 799.
 [94] Hiltbold, E. M.; Vlad, A. M.; Ciborowski, P.; Watkins, S. C. and 
Finn, O. J.(2000) J. Immunol., 165, 3730-3741.
 [95] Laskarin, G.; Cupurdija, K.; Tokmadzic, V. S.; Dorcic, D.; Dupor, 
J.; Juretic, K.; Strbo, N.; Crncic, T. B.; Marchezi, F.; Allavena, 
P.; Mantovani, A.; Randic, L. and Rukavina, D.(2005) Hum. 
Reprod., 20, 1057-1066.
 [96] Nguyen, D. G. and Hildreth, J. E.(2003) Eur. J. Immunol., 33, 
483-493.
 [97] Carlow, D. A.; Corbel, S. Y.; Williams, M. J. and Ziltener, H. 
J.(2001) J. Immunol., 167, 6841-6848.
 [98] Renkonen, J.; Tynninen, O.; Hayry, P.; Paavonen, T. and 
Renkonen, R.(2002) Am. J. Pathol., 161, 543-550.
 [99] Daniels, M. A.; Hogquist, K. A. and Jameson, S. C.(2002) Nat. 
Immunol., 3, 903-910.
 [100] Dube, D. H. and Bertozzi, C. R.(2005) Nat. Rev. Drug Discov., 4, 
477-488.
 [101] Turner, G. A.(1992) Clin. Chim. Acta, 208, 149-171.
 [102] Small, M. and Kraal, G.(2003) Int. Immunol., 15, 197-203.
 [103] Bergman, M. P.; Engering, A.; Smits, H. H.; Van Vliet, S. 
J.; van Bodegraven, A. A.; Wirth, H. P.; Kapsenberg, M. L.; 
Vandenbroucke-Grauls, C. M.; van Kooyk, Y. and Appelmelk, B. 
J.(2004) J. Exp. Med., 200, 979-990.
 [104] Gantner, B. N.; Simmons, R. M. and Underhill, D. M.(2005) 
EMBO J., 24, 1277-1286.
 [105] Tremblay, M. J.; Fortin, J. F. and Cantin, R.(1998) Immunol. 
Today, 19, 346-351.
 [106] Ludwig, I. S.; Lekkerkerker, A. N.; Depla, E.; Bosman, F.; 
Musters, R. J.; Depraetere, S.; van Kooyk, Y. and Geijtenbeek, T. 
B.(2004) J. Virol., 78, 8322-8332.
 [107] Yang, Z. Y.; Huang, Y.; Ganesh, L.; Leung, K.; Kong, W. P.; 
Schwartz, O.; Subbarao, K. and Nabel, G. J.(2004) J. Virol., 78, 
5642-5650.
 [108] Kwon, D. S.; Gregorio, G.; Bitton, N.; Hendrickson, W. A. and 
Littman, D. R.(2002) Immunity., 16, 135-144.
 [109] Dzionek, A.; Inagaki, Y.; Okawa, K.; Nagafune, J.; Rock, J.; 
Sohma, Y.; Winkels, G.; Zysk, M.; Yamaguchi, Y. and Schmitz, 
J.(2002) Hum. Immunol., 63, 1133-1148.
 [110] Lanoue, A.; Clatworthy, M. R.; Smith, P.; Green, S.; Townsend, 
M. J.; Jolin, H. E.; Smith, K. G.; Fallon, P. G. and McKenzie, A. 
N.(2004) J. Exp. Med., 200, 1383-1393.
 [111] Shi, L.; Takahashi, K.; Dundee, J.; Shahroor-Karni, S.; Thiel, 
S.; Jensenius, J. C.; Gad, F.; Hamblin, M. R.; Sastry, K. N. and 
Ezekowitz, R. A.(2004) J. Exp. Med., 199, 1379-1390.
 [112] Koppel, E. A.; van Gisbergen, K. P.; Geijtenbeek, T. B. and van 
Kooyk, Y.(2005) Cell Microbiol., 7, 157-165.
 [113] Gantner, B. N.; Simmons, R. M.; Canavera, S. J.; Akira, S. and 
Underhill, D. M.(2003) J. Exp. Med., 197, 1107-1117.
 [114] Allavena, P.; Chieppa, M.; Monti, P. and Piemonti, L.(2004) Crit 
Rev. Immunol., 24, 179-192.
 [115] Crocker, P. R. and Varki, A.(2001) Trends Immunol., 22, 337-
342.
 [116] Lajaunias, F.; Dayer, J. M. and Chizzolini, C.(2005) Eur. J. 
Immunol., 35, 243-251.
 [117] Van Vliet, S. J.; Van Liempt, E.; Saeland, E.; Aarnoudse, C. A.; 
Appelmelk, B.; Irimura, T.; Geijtenbeek, T. B.; Blixt, O.; Alvarez, 
R.; Van, D., I and van Kooyk, Y.(2005) Int. Immunol., 17, 661-
669.
 [118] Bonifaz, L.; Bonnyay, D.; Mahnke, K.; Rivera, M.; Nussenzweig, 
M. C. and Steinman, R. M.(2002) J. Exp. Med., 196, 1627-1638.
 [119] Kammerer, U.; Eggert, A. O.; Kapp, M.; McLellan, A. D.; 
Geijtenbeek, T. B.; Dietl, J.; van Kooyk, Y. and Kampgen, 
E.(2003) Am. J. Pathol., 162, 887-896.
References
Chapter 1 General Introduction
 [120] Soilleux, E. J.; Barten, R. and Trowsdale, J.(2000) J. Immunol., 
165, 2937-2942.
 [121] Dietl, J.; Honig, A.; Kammerer, U. and Rieger, L.(2006) Placenta, 
27, 341-347.
 [122] Rieger, L.; Honig, A.; Sutterlin, M.; Kapp, M.; Dietl, J.; Ruck, P. 
and Kammerer, U.(2004) J. Soc. Gynecol. Investig., 11, 488-493.
 [123] Mukhtar, M.; Harley, S.; Chen, P.; BouHamdan, M.; Patel, C.; 
Acheampong, E. and Pomerantz, R. J.(2002) Virology, 297, 78-88.
 [124] Regnier-Vigouroux, A.(2003) Int. Rev. Cytol., 226, 321-342.
 [125] Ferguson, T. A.; Green, D. R. and Griffith, T. S.(2002) Int. Rev. 
Immunol., 21, 153-172.
 [126] Pachter, J. S.; de Vries, H. E. and Fabry, Z.(2003) J. Neuropathol. 
Exp. Neurol., 62, 593-604.
 [127] Knolle, P. A. and Limmer, A.(2003) Swiss. Med. Wkly., 133, 501-
506.
 [128] Aragane, Y.; Maeda, A.; Schwarz, A.; Tezuka, T.; Ariizumi, K. and 
Schwarz, T.(2003) J. Immunol., 171, 3801-3807.
 [129] Ryan, E. J.; Marshall, A. J.; Magaletti, D.; Floyd, H.; Draves, K. E.; 
Olson, N. E. and Clark, E. A.(2002) J. Immunol., 169, 5638-5648.
 [130] Martinez, O.; Brackenridge, S.; El Idrissi, M. E. and Prabhakar, B. 
S.(2005) Int. Immunol., 17, 769-78.
 [131] Leteux, C.; Chai, W.; Loveless, R. W.; Yuen, C. T.; Uhlin-Hansen, 
L.; Combarnous, Y.; Jankovic, M.; Maric, S. C.; Misulovin, Z.; 
Nussenzweig, M. C. and Feizi, T.(2000) J. Exp. Med., 191, 1117-
1126.
 [132] Feizi, T.(1993) Curr. Opin. Struct. Biol., 3, 701-710.
 [133] Jendrysik, M. A.; Ghassemi, M.; Graham, P. J.; Boksa, L. A.; 
Williamson, P. R. and Novak, R. M.(2005) J. Infect. Dis., 192, 
630-639.
 [134] Dong, X.; Storkus, W. J. and Salter, R. D.(1999) J. Immunol., 163, 
5427-5434.
 [135] Tacken, P. J.; de Vries, I. J.; Gijzen, K.; Joosten, B.; Wu, D.; 
Rother, R. P.; Faas, S. J.; Punt, C. J.; Torensma, R.; Adema, G. J. 
and Figdor, C. G.(2005) Blood, 106, 1278-1285.
30


33
Alessandra Cambi, Karlijn Gijzen, I. Jolanda M. de Vries, Ruurd Torensma, 
Ben Joosten, Gosse J. Adema, Mihai G. Netea, Bart-Jan Kullberg, Luigina 
Romani, and Carl G. Figdor
European Journal of Immunology, 2003 Feb; 33(2):532-538
Chapter 2
The C-type lectin DC-SIGN (CD209) is 
an antigen-uptake receptor for Candida 
albicans on dendritic cells

Chapter 2 The C-type lectin DC-SIGN binds Candida albicans
35
Abstract
Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) 
are located in the submucosa of tissues, where they mediate HIV-1 entry. 
Interestingly, the pathogen Candida albicans, the major cause of hospital-
acquired fungal infections, penetrates at similar submucosal sites. Here we 
demonstrate that DC-SIGN is able to bind C. albicans both in DC-SIGN-
transfected cell lines and in human monocyte-derived DC. The binding was 
shown to be time- as well as concentration-dependent, and live as well as 
heat-inactivated C. albicans were bound to the same extent. Moreover, in 
immature DC, DC-SIGN was able to internalize C. albicans in specific DC-
SIGN-enriched vesicles, distinct from those containing the mannose receptor, 
the other known C. albicans receptor expressed by DC. Together, these results 
demonstrate that DC-SIGN is an exquisite pathogen-uptake receptor that not 
only captures viruses but also fungi.
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Introduction
Epithelial surfaces form the first line of defense against microbes. A small 
proportion of incoming microbes that enter at sites of microlesions is handled 
by APC, in particular DC [1]. Among pathogens that invade mucosal surfaces, 
Candida albicans is among the most frequently isolated from humans [2]. As 
C. albicans is the major cause of hospital-acquired fungal infections [3], its 
recognition by cell surface receptors has major pathogenetic consequences. 
Nevertheless, only limited information is available on the molecular mecha-
nisms involved in recognition of this fungus. C. albicans can switch from a 
unicellular yeast form into various filamentous forms, all of which can be 
found in infected tissues [4]. The ability to reversibly switch between these 
forms is thought to be important for C. albicans virulence. Several studies 
now demonstrate that DC can bind and phagocytose fungi such as C. albi-
cans [5-7]. Protection from mucocutaneous candidiasis clearly relies on cell- 
mediated immunity induced after DC process C. albicans and then present 
antigens that prime T cells [8].
Recent studies in mice demonstrate that whereas the yeast-form activates DC 
to produce IL-12 and primes Th1 cells, the hyphal-form inhibits IL-12 and 
Th1 priming and induces IL-4 production [5]. These results indicate that DC 
fulfill the requirement of a cell uniquely capable of sensing the two forms of 
C. albicans [5]. In addition, it was recently reported that human DC are also 
able to bind C. albicans, and that this interaction is mediated by the mannose 
receptor (MR, CD206), which is also found on macrophages [8].
However, the observation that C. albicans, both as a commensal as well as 
a true pathogen, is also found in areas (sub-mucosa) highly enriched in DC-
specific ICAM-3 grabbing non-integrin (DC-SIGN)-positive DC prompted us 
to investigate whether C. albicans could be bound by DC-SIGN as well. Re-
cently, we isolated this novel C-type lectin (also designated CD209) from 
monocyte-derived DC. We discovered that DC-SIGN acts as a binding partner 
for ICAM-3, mediating the early contact between DC and T cell and there-
fore the initiation of primary immune responses [9]. In addition, DC-SIGN 
displays a high affinity for ICAM-2, supporting transendothelial migration of 
DC and DC trafficking [10]. Moreover, DC-SIGN binds and captures HIV-1 at 
mucosal sites of initial infection, and protects the virus from degradation for 
subsequent transport by DC to lymphoid organs [11].
Here we demonstrate for the first time that as well as viruses, fungi are also 
recognized by DC-SIGN. 
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Candida albicans is a ligand of DC-SIGN
We used the erythroleukemic cell line K562 transfectants stably expressing 
DC-SIGN (K-DC-SIGN) [9] to investigate the potential of C. albicans to bind 
DC-SIGN in the absence of any other known C. albicans receptors. Binding to 
ICAM-3-coated fluorescent beads was used as a positive control for DC-SIGN 
function. K562 cells (K-ALCAM) transfected with the homotypic activated-leu-
kocyte cell adhesion molecule (ALCAM) [12], which is expressed by DC but does 
not bind any of the known ligand of DC-SIGN, were used as negative control. 
The K562 transfectants stably express DC-SIGN and ALCAM (Fig. 1A) with ex-
DC-SIGN SpeCIFICAlly bINDS The yeAST Form oF C. AlbICANS. (A) Transfectants (K562) stably expressing DC-
SIGN or ALCAM were used for binding studies. The mAb AZN-D1 and AZN-L50 were used to detect DC-SIGN and ALCAM, 
respectively; isotype-matched Ab was used as control. (B) C. albicans binds to DC-SIGN but not to ALCAM: transfectants 
were labeled with CD45-allophycocyanin to discriminate cells binding FITC-labeled yeast from yeast aggregates. A repre-
sentative experiment out of five is shown. (C) C. albicans– and ICAM-3-specific adhesion was determined in the presence 
of blocking anti-DC-SIGN mAb (20 µg/ml). The addition of EGTA (5mM) showed that DC-SIGN-mediated binding is Ca2+ 
dependent. One representative experiment out of three is shown. (D) C. albicans binding to DC-SIGN increases with in-
creasing Candida:cell ratio. Aliquots of 50x103 DC were incubated with various concentrations of heat-killed Candida cells 
for 30 min at 37°C. (E) Binding of C. albicans increases over time. One of two experiments is shown.
Figure 1
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pression levels similar to those observed for immature DC [9;12].
Binding studies demonstrated that DC-SIGN clearly mediates adhesion to both 
C. albicans and ICAM-3-Fc-coated beads (Fig. 1b). In contrast, K-ALCAM cells 
bound neither ICAM-3 nor C. albicans, but did bind ALCAM-Fc beads. Block-
ing antibodies against DC-SIGN significantly inhibited binding of C. albicans 
by K-DC-SIGN; in addition, the calcium chelator EGTA completely abrogated 
binding (Fig. 1C). This Ca2+ dependence confirms that the C-type lectin domain 
of DC-SIGN mediates binding to C. albicans. With increasing concentrations of 
C. albicans (Fig. 1D) and increasing incubation time (Fig. 1e), binding of K-DC-
SIGN to the yeast cells increased significantly.
DC-SIGN binds both live and heat-inactivated  
yeast forms of C. albicans
To exclude the possibility that the binding of DC-SIGN to heat-inactivated 
C. albicans was due to artifacts derived from the heat treatment, K-DC-SIGN 
were allowed to interact with both live and heat-inactivated (see Materials and 
Methods) C. albicans yeast. As shown in Fig. 2, the percentage of binding did 
not increase significantly upon heat inactivation of the yeast, when compared 
with binding to live yeast cells. In addition, the blocking of binding by Ab 
against DC-SIGN was not profoundly altered by heat treatment.
Monocyte-derived DC also bind C. albicans through DC-SIGN
DC are specialized in binding and uptake of antigen [13] and recently it has been 
shown that the interaction between DC and C. albicans is mediated by the MR 
[5;8]. Our findings with K-DC-SIGN cells and the observation that C. albicans 
can be found in areas of the body (sub-mucosa) that are highly enriched in DC-
SIGN-positive cells [11] suggested that DC-SIGN could contribute to the binding 
of C. albicans to immature DC.
In Fig. 3A, it is shown that human monocyte-derived immature DC are able to 
bind C. albicans, and that this interaction increases with time. This is in agree-
ment with previously published work showing that DC rapidly internalize C. al-
bicans: within 10-20 min of incubation at 37ºC, already 40-50% of the particles 
are ingested, reaching a maximum after 60 min [5;8]. 
To determine the contribution of both MR and DC-SIGN to mediate binding of 
C. albicans, immature DC were incubated with specific inhibitors before inter-
acting with the yeast particles. As shown in Fig. 3b, antibodies against DC-SIGN 
significantly blocked binding, though only partially (approximately 25-30%), 
lIve or heAT-kIlleD yeAST FormS 
oF C. AlbICANS Are bouND by DC-
SIGN. CD45-allophycocyanin-labeled 
K-DC-SIGN transfectants (50x103) 
were incubated for 30 min at 37°C with 
FITC-labeled C. albicans (500X103), 
either live or heat-inactivated (at 56°C 
or 100°C). A representative experiment 
out of two is shown.
Figure 2
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whereas mannose, which is known to specifically inhibit the MR, was respon-
sible for blocking about 65-70% of the binding. Interestingly, mannose did not 
show any significant blocking of C. albicans binding to DC-SIGN on K-DC-
SIGN cells (not shown). Moreover, by combination of both anti-DC-SIGN Ab 
and mannose, binding of C. albicans was almost completely inhibited (80-85%). 
This notion is supported by the observation that EGTA blocked binding of C. 
albicans to DC to a similar level, also indicating that probably no other C-type 
lectins were involved. Furthermore, the finding that binding of C. albicans was 
mediated by DC-SIGN and MR, in a ratio of roughly 1:3, respectively, was in 
agreement with the observation that the expression of MR on the surface of 
immature DC appears to be higher than that of DC-SIGN (Fig. 3C). However, no 
real quantitative evaluation can be made.
DC bIND C. AlbICANS AlSo ThrouGh DC-SIGN. (A) Binding of immature DC to C. albi-
cans increased over time. CD45-allophycocyanin-labeled DC (50 x 103) were incubated with 
FITC-labeled heat-inactivated C. albicans (500 x 103). One representative experiment out of 
two is shown. (B) Immature DC bind C. albicans through C-type lectins. CD45-allophycocya-
nin-labeled DC (50 x 103) were incubated with FITC-labeled heat-inactivated Candida (500 
x 103) in the absence or presence of anti-DC-SIGN mAb (20 µg/ml), mannose (100 mM), a 
mixture of anti-DC-SIGN Ab (20 µg/ml) and mannose (100 mM), or EGTA (5 mM). The average 
of six independent experiments is shown. The binding to C. albicans in absence of inhibitors 
(with isotype-matched control) was set as 100%. The significance levels (*p<0.01 and **p< 
0.001) derive from comparing the percentage of binding in the presence of blocking agent 
versus the percentage of binding in absence of blocking agent. (C) FACS profile of immature 
DC expressing MR and DC-SIGN. mAb clones 19.2 and AZN-D1 were used to label MR and 
DC-SIGN, respectively. Cells were gated on forward-side scatter, and the mean fluorescence 
is shown in the top right corner of the histograms.
Figure 3
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In addition, besides DC-SIGN and the MR, DC are known to express high 
levels of the ß2-integrin MAC-1, which has already been implicated in the 
binding of C. albicans to lymphocytes [6]. However, we could not detect any 
blocking when anti-ß2-integrin antibody (NKI-L19) was used, suggesting that 
MAC-1 is not likely to be involved in C. albicans binding on human imma-
ture monocyte-derived DC (data not shown). Moreover, the use of laminarin, 
reported to interfere with the interaction between another DC-specific C-type 
lectin, Dectin-1, and C. albicans, did not show any blocking effect either 
(data not shown). Together, these findings strongly suggest that binding of 
C. albicans to immature DC is predominantly mediated by the C-type lectins 
DC-SIGN and MR.
DC-SIGN mediates phagocytosis of C. albicans
We recently demonstrated that DC-SIGN can act as an antigen-uptake recep-
tor and facilitates phagocytosis within minutes [14]. To determine whether 
DC-SIGN could contribute also to the internalization of C. albicans by im-
mature DC, we incubated DC with FITC-labeled C. albicans particles for 60 
min at 37ºC to allow phagocytosis. Subsequently, we fixed, permeabilized, 
and fluorescently labeled DC with specific Ab against various receptors, and 
analyzed by confocal microscopy.
In general, we observed that after 1 h of incubation, about 40% of immature 
DC have ingested C. albicans, ranging from 1 to 9 particles (average of 3) 
per DC. The results in Fig. 4A show that DC-SIGN clearly co-localizes with 
C. albicans particles, indicating the involvement of this lectin in binding and 
uptake of this pathogen. By contrast, neither MAC-1 nor ALCAM were found 
to localize around the yeast particles (Fig. 4b, C). 
Fig. 4D shows colocalization between MR and ingested Candida. In order to 
determine whether DC-SIGN was also able to internalize C. albicans in pres-
ence of inhibitors of MR, DC were allowed to phagocytose the yeast particles 
in presence of mannose. As shown in Fig. 4e, vesicles containing DC-SIGN 
colocalizing with FITC-labeled Candida can still be clearly observed. To prove 
that C. albicans were indeed ingested, we made Z-scans, unequivocally de-
monstrating that the yeast particles are ingested (Fig. 4F). The presence of 
EGTA almost completely blocked phagocytosis (data not shown).
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DC-SIGN meDIATeS phAGoCyToSIS oF C. AlbICANS IN DC. Immature DC were incubated 
with C. albicans yeasts at a DC:C. albicans ratio of 1:5 for 1 h at 37°C to allow phagocytosis. 
Subsequently, samples were fixed and labeled for confocal microscopy: the images show 
FITC-labeled C. albicans (green), Cy5-labeled adhesion receptors on immature DC (blue) and 
colocalization (merged) (see Materials and Methods). (A) Colocalization of DC-SIGN with 
FITC-labeled C. albicans was clearly observed. Labeling of ß2-integrins (B) as well as ALCAM 
(C) showed no colocalization in the vesicles containing the pathogen. (D) Labeling of MR, 
the other receptor for C. albicans on immature DC, showed considerable colocalization with 
the yeast. In addition, DC-SIGN-enriched vesicles were observed also in presence of 100 mM 
mannose, which inhibits the MR (E). The Z-scan (F) indicates that the yeast particles were 
indeed ingested by the DC. 
Figure 4
A
C
b
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Conclusions
We showed that as well as viruses (HIV-1, SIV, Ebola) [11;15;16] and parasites 
(Leishmania) [17], the C-type lectin DC-SIGN can also bind yeast (C. albi-
cans). These observations, together with the discovery that DC-SIGN acts as 
an antigen-uptake receptor, provide further evidence that C-type lectins on 
DC are major pathogen-recognition receptors [18]. Distinct from the Toll like 
receptors [19], they mediate antigen uptake rather than activating DC. 
Our findings clearly show that C. albicans has two major receptors on hu-
man monocyte-derived DC; DC-SIGN and MR. DC-SIGN is expressed at sites 
in the skin (dermis) and the mucosa [11] where C. albicans is known to enter 
the host. Therefore, DC-SIGN-positive DC might, through these C-type lectin 
receptors, form the first encounter with these pathogens and the host immune 
system and, after antigen presentation, initiate a cellular response [5;8].
It remains to be elucidated whether the destiny of the C. albicans-containing 
vesicles enriched in DC-SIGN is different from those enriched in MR. Though 
we observed some vesicles containing both receptors (not shown), it was 
intriguing that colocalization of both C-type lectins seemed not to occur 
in most C. albicans-containing vesicles. Therefore, it will be interesting to 
characterize these vesicles in more detail (this work is in progress in our 
laboratory) and to investigate if both lectins recognize similar or distinct 
carbohydrate moieties on C. albicans. This is of particular interest because 
MR is known as a recycling receptor, whereas DC-SIGN targets much deeper 
in the endosomal compartments [14].
Detailed knowledge of the recognition receptors for C. albicans on DC, to-
gether with the specific down-stream cellular events initiated by receptor 
engagement, may increase our understanding of possible immune dysfunc-
tions in patients with mucocutaneous candidiasis and may offer new targets 
for immunotherapy of candidal infections and diseases.
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Materials and Methods
Reagents and antibodies
FITC was from Fluka. Mannan and D-mannose were from SIGMA Chemical 
Co., St. Louis, MO. IL-4 and GM-CSF used for culturing monocyte-derived DC 
were from Schering-Plough (International, Kenilworth, USA). The following 
antibodies were used: AZN-D1, AZN-D3 (mouse IgG1, anti-DC-SIGN [11]); 
AZN-L50 (mouse IgG1, anti-ALCAM) [12] ; NKI-L19 (mouse IgG1 anti-ß2 in-
tegrins); mAb clone 19.2 against MR was from BD Biosciences PharmIngen; 
the directly allophycocyanin-conjugated mAb against CD45RO was from 
Becton Dickinson; Cy5-conjugated goat-anti-mouse IgG was from Molecular 
Probes.
C. albicans culture conditions
C. albicans, strain UC820, a clinical isolate that has been well described [20], 
was maintained on agar slants at 4°C. Previous experiments showed that 
strain UC820 can develop hyphae and pseudohyphae in vitro and in vivo to 
the same extent as a panel of virulent control strains. C. albicans UC820 was 
inoculated into 100 ml of Sabouraud broth and was cultured for 24 h at 37°C. 
After three washes with pyrogen-free saline by centrifugation at 1500×g, the 
number of yeast cells was counted in a hemocytometer; occasional strings 
of two yeasts were counted as one colony-forming unit of C. albicans. The 
suspension was diluted to the appropriate concentration with pyrogen-free 
saline. Microscopy confirmed that the suspension consisted of blastoconidia. 
When necessary, the blastoconidia were heat-killed either at 56°C for 1 h or 
at 100°C for 30 min.
Cells
Immature DC were generated from human peripheral blood monocytes as 
described previously [9]. Briefly, monocytes were isolated by adherence to 
plastic and cultured in the presence of IL-4 (500 U/ml) and GM-CSF (800 
U/ml) for 6-7 days. K562 transfectants either expressing DC-SIGN or ALCAM 
were generated by transfection of K562 cells with 10 µg of plasmid by elec-
troporation as described previously [11;12]. Positive cells were sorted several 
times to obtain stable transfectants with expression levels of DC-SIGN and 
ALCAM similar to immature DC.
Immunofluorescence 
Labeling of Candida cells was performed as follows: yeast cells were resus-
pended to 2 x 108/ml in 0.01 mg/ml FITC in 0.05 M carbonate-bicarbonate 
buffer (pH 9.5). After incubation for 15 min at room temperature in the dark, 
FITC-labeled Candida cells were washed twice in PBS containing 1% BSA 
(PBA buffer), heat-killed for 60 min at 56°C, and subsequently analyzed by 
flow cytometry.
DC were stained in PBA with primary antibodies and FITC-conjugated sec-
ondary antibodies and were analyzed by flow cytometry using the FACS-
calibur (BD Biosciences, Mountain View, CA). Isotype-matched controls were 
included. 
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C. albicans binding studies 
DC or transfected K562 cells were stained with anti-CD45-allophycocyanin 
prior to exposure to FITC-labeled live or heat-inactivated C. albicans yeast 
forms. Before adding C. albicans, cells were or were not preincubated for 10 
min at room temperature with mannose (100 mM), EGTA (5 mM), isotype 
control (mouse IgG1) or a mixture of anti-DC-SIGN mAb, AZN-D1 and AZN-
D3 (20 µg/ml), in 20 mM Tris pH 8.0, containing 150 mM NaCl, 1 mM CaCl2, 
2 mM MgCl2, and 1% BSA (TSA buffer) or, when EGTA was used, in PBS. 
Subsequently, FITC-labeled C. albicans were resuspended to the appropriate 
concentrations either in TSA or PBS and added in various cell:Candida ratios. 
After incubation, cell-Candida conjugates were analyzed by flow cytometry, 
and the relative difference in mean fluorescence intensity of the double- 
labeled events in comparison with that of control cells was calculated. Cells 
were labeled with anti-CD45-allophycocyanin to discriminate cells binding 
FITC-labeled yeast particles from yeast aggregates. 
Fluorescent-bead adhesion assay
The fluorescent-bead adhesion assay was performed as described earlier 
[12;21]. Briefly, carboxylate-modified TransFluorSpheres (488/645 nm, 1.0 
µm; Molecular Probes, Eugene, OR) were coated with ICAM-3-Fc or ALCAM-
Fc, and adhesion was determined by measuring the percentage of cells that 
had bound fluorescent beads, by flow cytometry. In inhibition studies, the 
bead-adhesion assay was performed in presence of 0.3 mg/ml mannan, 5 mM 
EGTA, or 20 µg/ml antibodies against DC-SIGN or ALCAM. 
Phagocytosis
Immature DC (5 x 105) were incubated with unopsonized heat-inactivated 
FITC-labeled C. albicans (2.5 x 106) in a total volume of 500 µl at 37°C in 
a water bath with orbital shaking at 150 rpm for 60 min. At the end of the 
incubation period, the DC binding C. albicans were separated from unbound 
Candida by a Ficoll gradient.
The samples were then mounted on poly-L-lysine-coated glass coverslips by 
centrifugation at 250 rpm for 3 min. Subsequently, the samples were fixed in 
1% PFA in PBS for 15 min at room temperature, and permeabilized in cold 
methanol for 5 min on ice. After a blocking step in PBS/3% BSA for 60 min 
at room temperature, cells were labeled with monoclonal antibody (10 µg/ml 
in PBS/3% BSA) for 60 min at room temperature and subsequently incubated 
with Cy5-conjugated Goat-anti-Mouse (Fab’)2 fragments for 30 min at room 
temperature. Finally, samples were sealed in Mowiol and analyzed using a 
MRC1024 confocal microscope (Bio-Rad).
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Abstract
Dendritic cells (DC) function as professional phagocytes to kill Candida albi-
cans and subsequently present it to the adaptive immune system. Monocytes, 
macrophages and DC were generated from five individual donors and their 
Candida-killing capacity and cytokine release were assessed. Compared to 
monocytes and macrophages, DC from healthy volunteers were significantly 
less effective in C. albicans–stimulated cytokine release, killing of C. albi-
cans blastoconidia and damaging of C. albicans hyphae. In conclusion, while 
important as antigen-presenting cells and initiators of the adaptive immune 
system, DC are poor in both intracellular killing and damaging of C. albicans 
hyphae. Effective handling of large numbers of C. albicans is the prime task 
of the innate immune system consisting of large numbers of neutrophils and 
monocytes.
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Introduction
Candida albicans is present in the microflora of the digestive tract and muco-
cutaneous membranes of healthy individuals. While harmless under normal 
conditions, deficiencies in the host defense system or an imbalance in the 
normal microflora may lead to infections of the host with C. albicans. These 
infections can manifest either as acute or chronic candidiasis of the skin and 
mucosae, or as invasive or disseminated candidiasis, occurring primarily in 
the immunocompromized host. Mortality associated with disseminated can-
didiasis is around 30%, and has changed little despite the availability of new 
antifungal drugs [1, 2], while oropharyngeal and vulvovaginal candidiasis 
cause considerable morbidity in certain groups [3, 4].
In spite of the importance of C. albicans in human pathology, much has to 
be learned about the mechanisms through which this fungus is recognized 
by the immune cells to trigger the host defense. Neutrophils and macropha-
ges are known to be the major cell populations involved in the host defense 
against candidal infection. It has been recently proposed that dendritic cells 
(DC) also play a central role in the defense against C. albicans. DC discrimi-
nate between the yeast and hyphal forms of C. albicans and initiate T-helper 
cell immunity, which is required for long-term protection against mucocuta-
neous candidiasis [5]. We have recently demonstrated that DC recognize and 
ingest C. albicans blastospores using the C-type lectin DC-SIGN [6]. It has 
been suggested that DC, for their function as antigen-presenting cells, not 
only phagocytose, process and present candidal antigens to T cells, but also 
kill C. albicans yeasts as efficient as macrophages do [7]. 
The aim of the present study was to extend these observations and compare 
the anticandidal properties of human DC, monocytes and macrophages in 
terms of proinflammatory cytokine release, intracellular killing of C. albicans 
blastospores, and extracellular damage of C. albicans hyphae.
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Isolation of monocytes and generation of macrophages 
and DC
Blood mononuclear cells were isolated from five healthy volunteers as 
described elsewhere [8]. The adherent fraction of monocytes was obtained 
after 2 h incubation at 37ºC and divided in three populations: one subset of 
monocytes was used for direct assessment of anti-candidal activities, one 
subset was allowed to differentiate into macrophages by incubation with 
10% fresh human serum at 37ºC for 7 days, and one subset was induced 
to transform into DC by incubation with recombinant IL-4 (500 U/ml) and 
granulocyte-macrophage colony-stimulating factor (800 U/ml, both from 
Schering-Plough, Kenilworth, USA) for 7 days [6]. The cell populations were 
phenotypically characterized through FACS analysis, by assessing the cell-
membrane expression of CD14 and DC-SIGN, respectively (Fig. 1).
Stimulation of cytokine production 
The monocytes, macrophages and DC were collected and resuspended in cul-
ture medium (RPMI 1640 supplemented with 10 mg/ml of gentamicin, 10 
mM L-glutamine and 10 mM pyruvate), and the number was adjusted to 
5x106 cells/ml. Aliquots of 5x105 cells in a 100 µl volume were incubated 
in 96-wells plates with 100 µl of either culture medium or heat-killed (30 
min, 100°C) C. albicans yeasts or hyphae (ATCC 10231; 107 cfu/ml). Cytokine 
release was measured after 24 h of incubation at 37ºC by specific commercial 
ELISA (BioSource International, Camarillo, CA; detection limit 16 pg/ml). 
Candida-killing assays
Intracellular killing of C. albicans conidia was assessed microbiologically, as 
described [9]. Cells (5 x 105) in 100 µl of RPMI-dm were dispensed into the 
wells of a 96-well flat bottom plate (Costar) and incubated at 37°C and 5% 
PhenotyPiC CharaCterization oF monoCytes, maCroPhages anD DC. The various 
cell populations were characterized by measuring the expression of CD14 and DC-SIGN (CD209) 
by flow cytometry. Data are presented as an overlay graph of the isotype control (thin line) and 
the molecule of interest (bold line). Markers were set based on the results obtained with isotype 
controls (thin line). The percentage of positive cells, based on these markers is indicated. 
Figure 1
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CO2. Cells were incubated with 1 x 10
4 cfu C. albicans, which were opsonised 
with 2.5% fresh mouse serum (E:T ratio, 40:1) in modified Eagle’s medium 
(Gibco Life Technologies, Paisley, Scotland; MEM), for 45 min at 24ºC. The 
choice of this particular cell-to-target ratio was carefully decided after initial 
pilot experiments, in such a way that the killing percentage in monocytes 
would be between 30% en 70%. This percentage in the control cell population 
is necessary in order to be able to demonstrate either increased or decreased 
killing of Candida in other cell populations (e.g. macrophages and DC).
After removal of the non-phagocytized Candida blastoconidia, 200 µl of cul-
ture medium, consisting of Sabouraud in MEM (50% v/v), was added to the 
monolayers. After 4 h of incubation at 37°C and 5% CO2, the wells were gently 
scraped with a plastic paddle and washed with 200 µl distilled H2O to achieve 
lysis of macrophages. This procedure was repeated three times, after which the 
pooled washes were adjusted to a final volume of 1 ml with distilled water. 
Microscopic examination of the culture plates showed that there was a complete 
removal of phagocytes. To quantify the number of viable intracellular Candida 
blastoconidia, 10-fold dilutions of each sample were spread on Sabouraud agar 
plates and incubated at 37°C for 24 h. The percentage of yeast killed by the 
macrophages was determined as follows: (1 – (cfu after incubation/ number of 
phagocytized cfu)) x 100. Cell-free incubations of blastoconidia were included 
as a control for yeast viability. 
Extracellular hyphal damage was investigated by an XTT-conversion method, 
as previously described [9, 10]. Candida blastoconidia (strain UC820) grown on 
Sabouraud agar plates were suspended at a final concentration of 1 x106 cfu/
ml in RPMI 1640 Dutch modification (with 20mM Hepes, without glutamine, 
ICN Biomedicals, Eschwege, Germany) supplemented with 1% gentamicin, 1% 
L-glutamine and 1% pyruvate. The pH of the suspension was adjusted to 6.4 
using hydrochloric acid. Hyphae were obtained by incubating 10 ml of the 
suspension at 37ºC for 24 h. After incubation, the hyphae were centrifuged 
(1800 rpm, 10 min) and resuspended in RPMI 1640 without phenol red and 
L-glutamine (RPMI-wp; ICN). Aliquots (160 µl) of a suspension containing 1 
x 105 hyphae were dispensed into a 24-well flat bottom plate (Costar). Cells 
were collected and resuspended in RPMI: 8 x 105 cells (200 µl) were added to 
the wells containing hyphae at a final E:T ratio of 8:1, in the presence of 10% 
fresh mouse serum. Control wells contained either hyphae or cells only. After 
incubation for 2 h, 800 µl of sterile H2O was added to the wells and the plate 
was rocked at room temperature to achieve lysis of cells. After 15 min., 800 
µl sterile saline-solution containing XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfo-
phenyl)-2H-tetrazolium-5-carboxanilide; Sigma Chemical, St. Louis, MO) and 
coenzyme Q0 (2,3-dimethoxy-5-methyl-1,4-benzoquinone; Sigma) were added 
to each well at a final concentration of 400 µg/ml XTT and 50 µg/ml coen-
zyme Q0. After 1 h of incubation at 37ºC, the plate was centrifuged (1800 rpm, 
10 min) and 150 µl of the supernatant of each well was transferred to a well 
of a 96-well microtiter plate. The absorbance of each well was measured in a 
spectrophotometer at 450 nm. The percentage of fungal damage was defined as 
1– ((A450 hyphae + PMN – A450 PMN) / E450 hyphae) x 100.
Statistical analysis
Five separate experiments were performed in duplicate on separate days, and 
the results presented are pooled data. The comparison between the various cell 
populations isolated from the same healthy donors were analysed by paired 
non-parametric Wilcoxon test. The level of significance was set at 0.05.
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Results
When the different cell populations from the same volunteers were compared, 
DC were significantly less effective in the intracellular killing of C. albicans 
blastoconidia (13.6 ± SD 5.4% after 3 h of incubation), than macrophages 
or monocytes (25.7 ± 12.3% and 34.7 ± 10.7%, respectively, p<0.05; Fig. 2). 
Similarly, hyphal damage induced by DC was lower (29.8 ± 12.7% after 3 h of 
incubation) than that induced by macrophages (61.8 ± 16.7%) or monocytes 
(72.7 ± 12.1%, p<0.05; Fig. 2). 
Although DC produced significant amounts of tumor necrosis factor (TNF, 
243 ± 34 and 370 ± 65 pg/ml) and interleukin-8 (IL-8, 2430 ± 840 and 12910 
± 2345 pg/ml) after stimulation with C. albicans blastoconidia or hyphae, 
TNF and IL-8 release by DC was only 5-10% of that released by mono-
cytes or macrophages (Fig. 3, p<0.01). Virtually no release of IL-6 by DC was 
measured, whereas both monocytes and macrophages produced significant 
amounts of these cytokines. The interferon-γ (IFN-γ) production stimulated 
by conidia was also lower after stimulation of DC, whereas its release after 
stimulation with candidal hyphae was similar between the three cell popula-
tions (Fig. 3).
Killing oF C. albiCans Cells by monoCytes, 
maCroPhages anD DC. Intracellular killing of yeasts or 
extracellular damage to hyphae of C. albicans by monocytes 
(open bars), macrophages (hatched bars) or DC (solid bars) 
was assessed after 3 h of incubation at 37°C. Data are pre-
sented as means + SD of percentages of killing (n=5, *p<0.05 
by Mann-Whitney U-test).
stimulation oF ProinFlammatory CytoKine re-
lease From human monoCytes, maCroPhages 
anD DC by C. albiCans. Monocytes (open bars), macro-
phages (hatched bars) or DC (solid bars) were stimulated with 
107 cfu/ml heat-killed C. albicans yeasts (panel A) or hyphae 
(panel B). TNF, IL-6, IL-8 and IFN-γ were measured 24 h later. 
Cytokine production in unstimulated cells was below the 
detection limit. Data represent means + SD of 5 volunteers 
(*p<0.05, **p<0.01; by Mann-Whitney U-test).
Figure 2
Figure 3
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Discussion
Recent studies have suggested that DC have a role as professional candida-
cidal cells, and that they are as efficient as macrophages in killing C. albicans 
blastoconidia [7]. In the present study, we have extended these observations 
by comparing DC with monocytes and macrophages from the same healthy 
volunteers. In contrast to the previous report of Newman and Holly [7], we 
found that DC are significantly less efficient than monocytes and macro-
phages in both intracellular killing of blastoconidia and extracellular hyphal 
damage.
The differences between our data and the previous reports are likely due to 
differences in the methodology. We have recently shown that assays using 
yeast-phagocyte suspensions may be inappropriate for the assessment of in-
tracellular killing of C. albicans yeasts, due to strong adherence of C. albicans 
to the test tubes, or clumping of the yeast cells [9]. These methods may result 
in artifacts suggesting increased candidacidal activity. It cannot be excluded 
that such mechanisms may have played a role in earlier reports, reporting 
80-90% killing of C. albicans blastoconidia by DC, while agents inhibiting 
either phagocytosis or oxygen radical and nitric oxide production failed to 
decrease the observed killing [7].
It has been demonstrated earlier that C. albicans is phagocytosed and pro-
cessed by DC for presentation of candidal antigen [5, 7], and pulsing of DC 
with fungal RNA induces protective immunity to C. albicans infection [11]. 
It has therefore been assumed that DC kill C. albicans blastoconidia during 
the process of phagocytosis and presentation. Our data confirm this assump-
tion but demonstrate, however, that DC are not as efficient as monocytes 
and macrophages are in killing C. albicans cells. This is in agreement with 
the concept that the function of DC is to present candidal antigens to T cells 
[12], rather than eliminating the microorganism, whereas neutrophils and 
macrophages are the main populations involved in elimination of the micro-
organisms [13-15]. Taking into account the low numbers of DC present at the 
site of infection, compared to the numbers of neutrophils and macrophages, 
DC are unlikely to play a significant role in the elimination of C. albicans 
organisms at the site of infection.
In addition to antigen presentation, DC are known to be able to produce 
proinflammatory cytokines after stimulation with C. albicans cells [5], and 
we have confirmed this observation by showing a significant release of TNF 
and IL-8 after challenge with C. albicans blastoconidia and hyphae. However, 
the cytokine production by DC was much lower than that by monocytes and 
macrophages, and virtually no release of IL-6 was found. It is likely that the 
low amounts of proinflammatory cytokines exert paracrine and autocrine 
effects during antigen presentation, rather than functioning as potent acti-
vators of anticandidal effector cells such as neutrophils and macrophages. 
Interestingly, differences in the cytokine production between monocytes and 
macrophages were observed. Whereas monocytes released greater amounts of 
cytokines upon stimulation with blastoconidia compared to hyphae, the op-
posite was found for macrophages, which produced more TNF and IL-8 upon 
stimulation with hyphal forms. This suggests an adaptive response during 
the phenotypic switch of C. albicans from the yeast form to the hyphal form 
of the fungus. The yeast form of Candida is most of the time the phenotyp-
ic form which invades the bloodstream and encounter monocytes, whereas 
hyphae cause invasion of the tissues, where they are recognized by tissue 
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macrophages. As the phenotypic switch is considered an important virulence 
trait of C. albicans species, the monocyte/macrophage cell populations seem 
to be adapted to encountering a specific phenotypic form of the fungus.
In conclusion, although DC are capable of phagocytosing and processing C. 
albicans blastoconidia for antigen presentation and initiating the adaptive 
immune response [16], they only release proinflammatory cytokines and kill 
C. albicans cells to a limited extent, when compared with monocytes and 
macrophages. Those innate immune responses provide control of the patho-
gen early on, until the adaptive immune response is launched.
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Abstract
The role of dendritic cell-specific ICAM-3 grabbing non-integrin (DC-SIGN) 
in DC-T cell communication was assessed by analyzing the effect of DC-SIGN 
blocking mAbs in MLR. The results show that the degree of inhibition by DC-
SIGN and LFA-1 mAbs depends on the magnitude of the MLR and the matu-
ration status of the DC. Addition of DC-SIGN mAbs at several time points 
during MLR showed that DC-SIGN is involved early on in DC-T cell contacts. 
This initial role is masked by strong adhesive and costimulatory mechanisms, 
indicating a short-lived effect of DC-SIGN in DC-T cell interactions. 
To examine this concept in more detail, the percentage of PBL capable of 
binding DC-SIGN was determined. Analysis of several donors revealed that 
1 to 20% of PBL bind to beads coated with recombinant DC-SIGN, and the 
DC-SIGN-binding cells comprised all major cell subsets found in blood. PBL 
isolated from a donor with high DC-SIGN-binding capacity were more prone 
to blocking by DC-SIGN mAbs in MLR than PBL from a donor with low DC-
SIGN binding capacity. This study indicates an initial and transient role for 
DC-SIGN in T cell proliferation, which becomes apparent when T cell prolif-
eration is low and when the percentage of DC-SIGN binding PBL is high.
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Introduction
Dendritic cells (DC) and T cells are important players of the immune system. 
Interactions between these two cell types can result in the induction of antigen-
specific immunity or in tolerance [1]. DC are professional APC and reside in 
peripheral tissues on the alert for invading pathogens. After encountering 
and processing antigen, the DC will migrate to the secondary lymphoid or-
gans to present peptides in MHC context to T cells [2]. During inflammation 
DC mature and acquire properties to induce an effective immune response. 
In non-inflamed situations however, DC remain immature and induce tole-
rance [1,2]. In the lymph nodes, naïve T cells and DC interact transiently in an 
antigen-independent manner to enable the T cells to inspect a large number 
of MHC molecules on DC for the presence of a specific peptide [3]. ICAM-3 
is an important adhesion molecule in these antigen-independent interactions 
between T cells and APC [4]. Binding partners for ICAM-3 include the β2-
integrins Leukocyte Functional Antigen-1 (LFA-1) [5] and αdβ2 [6], and the 
C-type II lectin DC-specific ICAM-3 grabbing non-integrin (DC-SIGN) [7]. 
This C-type II lectin is expressed in vitro on monocyte-derived DC and in 
vivo on DC in several tissues including lymph nodes, cervix, mucosa and skin 
[7,8]. In addition, DC-SIGN expression is detected on a subset of myeloid 
blood DC and on blood DC antigen 2+ plasmacytoid DC precursors [8,9]. As 
integrins need activation before appropriate binding can occur, DC-SIGN was 
put forward as an initial binding partner of ICAM-3 [7]. Upon specific peptide 
recognition by a T cell, the transient adhesive interactions between T cells 
and DC are strengthened, resulting in an immunological synapse [3]. This 
structure is formed by the interactions of several adhesion and costimulatory 
molecules such as LFA-1 interacting with ICAM-1 and/or ICAM-3 and CD28 
interacting with CD80 and/or CD86 and provides a platform for sustained 
TCR engagement and signaling [10-12]. Such a mechanism predicts a tran-
sient role for DC-SIGN in DC-T cell interactions and may explain in part the 
conflicting data obtained in T cell activation studies so far [7,13-16]. Studies 
of Geijtenbeek et al. [7] and Puig-Kroger et al.[13] showed that blocking DC-
SIGN mAbs have an inhibitory effect on the proliferation of resting T cells 
induced by allogeneic DC or THP-1 cells differentiated into DC. In contrast, 
Granelli-Piperno et al. [16] did not show a requirement of DC-SIGN in MLR 
driven by DC. Real et al. [14] could not confirm a role for DC-SIGN in early 
DC-T cell contact, as their studies did not reveal an effect of blocking DC-
SIGN on immature DC on CD4+ T cell on CD69 expression, motility, and Ca2+ 
response. However, Martinez et al. [15] analyzed early T cell activation as 
well by measuring IL-2 and IFN-γ secretion by CD4+ T cells and showed that 
DC-SIGN can modulate this secretion dependent on the strength of T the cell 
stimulus. Moreover, these authors showed a modest down-regulation of CD69 
expression on CD4+ T cells in the presence of Chinese hamster ovary cells 
transfected with DC-SIGN.
In the present study, numerous MLR, driven by immature or mature DC, were 
performed to unravel the relevance of DC-SIGN in MLR. We observed that 
blocking DC-SIGN only affects T cell proliferation when immature DC are 
used and when the proliferative response is weak. Likewise, inhibition of T 
cell proliferation by LFA-1 blocking mAbs is also dependent on the strength 
of the T cell response. Moreover, the effect of blocking DC-SIGN in MLR de-
pends on the percentage of PBL that are able to bind DC-SIGN.
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Materials and Methods
Cells
Immature DC were generated from human PBMC as described previously 
[7]. Briefly, PBMC were isolated from buffy coats of donated blood obtained 
from healthy individuals by Ficoll density centrifugation. Monocytes were 
isolated from PBMC by adherence to plastic and cultured in the presence of 
IL-4 and GM-CSF (500 and 800 U/ml, respectively; Schering-Plough, Brus-
sels, Belgium) in RPMI 1640 medium (Gibco, Invitrogen, Breda, The Nether-
lands) containing 10% FCS (Greiner Bio-One B.V. Alphen aan den Rijn, The 
Netherlands) for 6 days. Non-adherent cells (PBL) were collected for later use. 
Mature DC were generated from immature DC by adding 2 µg/ml LPS (Sigma, 
Sigma-Aldrich Chemie B.V. Zwijndrecht, the Netherlands) at day 6. Mature 
DC were harvested on day 7.
For testing DC-SIGN expression, DC were labelled in PBS containing 0.5% 
BSA and 0.01% sodium azide with mAb against DC-SIGN (5 µg/ml AZN-D1) 
or with isotype control mouse IgG1 (5 µg/ml, BD Biosciences, San Diego, CA, 
USA) for 30 min at 4°C. After a washing step, DC were labelled with FITC-
conjugated goat-anti-mouse IgG1 for 30 min at 4°C. After a final washing 
step, the labelled DC were analyzed by flow cytometry (FACScalibur, BD Bio-
sciences, Mountain View, CA, USA). 
HSB-2 cells were cultured in IMDM (Gibco, Invitrogen, Breda, The Nether-
lands) supplemented with 5% FCS. 
T cell proliferation assays
T cell proliferation was assessed by [3H]-thymidine incorporation or by CFSE 
methodology after 6 or 7 days, respectively. For the CFSE methodology; the 
PBL, resuspended at a density of 2×107 cells per ml in PBS, were labeled with 
5 µM CFSE (Molecular Probes, Leiden, The Netherlands) for 10 min at room 
temperature (RT). Free CFSE was quenched by the addition of an equal vol-
ume of FCS. The labeled cells were washed twice in PBS and resuspended in 
RPMI 1640 medium containing 10% FCS [17]. PBL comprise mainly T cells, 
B cells, and NK cells. As those T and B cells are from the same donor no MLR 
will be induced by DC-SIGN expressed by B cells [18]. MLR was induced 
by allogeneic DC. Unlabeled or CFSE-labeled PBL (1×105) were cocultured 
with 1.5×103 allogeneic DC in 96-wells round bottom plates for 6-7 days. 
At 0, 24, and 72 h after the start of the experiment, blocking mAbs directed 
against DC-SIGN (10 µg/ml AZN-D1 and 10 µg/ml AZN-D3), LFA-1 (10 µg/ml 
NKI-L15), or CD6 (5 µg/ml, clone M-T605, mouse IgG1, BD Pharmingen) 
were added where indicated. Control mouse IgG1 (10 µg/ml, R&D Systems, 
Abingdon, UK) or total mouse IgG (10 µg/ml, Jackson ImmunoResearch, West 
Grove, PA, USA) were included as controls. After 6-7 days, PBL prolifera-
tion was assessed by determining CFSE staining intensity by flow cytometry 
(FACScalibur, BD Biosciences, Mountain View, CA) or by measuring [3H]-thy-
midine incorporation (1 µCi/well, 8-16 h pulse; MP Biomedicals Inc., Irvine, 
CA, USA). To enable comparison of data obtained using different donors, 
proliferation data obtained under control conditions were expressed as 100% 
proliferation, and putative blocking was calculated relative to the control 
MLR for that given donor.
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Conjugate formation assay 
Allogeneic DC (105 cells) were mixed with 106 PBL and incubated for 15 min 
at 37°C while shaking. The DC-PBL mixture was allowed to adhere on poly-
L-lysine (50 µg/ml)-coated glass slides for 5 min at RT. Next, cells were fixed 
with 2% paraformaldehyde in PBS at RT for 20 min. Non-specific binding 
sites were blocked with blocking buffer (3% BSA, 10 mM glycine and 1% hu-
man serum in PBS) at RT for 1 h. Cells were triple stained with anti-DC-SIGN 
(DCN46, 10 µg/ml), anti-ICAM-3 (AZN-IC3, 10 µg/ml), and anti-CD3 (T3B, 10 
µg/ml) in blocking buffer at RT for 1 h, followed by incubation with isotype-
specific Alexa-488, -568, or –647-conjugated goat-anti-mouse mAbs for 1 h. 
Samples were analyzed using a MRC1024 confocal microscope (Bio-Rad, 
Hercules, CA, USA) with a 60× objective. 
DC-SIGN-His construct
Recombinant DC-SIGN-His consists of the extracellular domain of DC-SIGN 
harboring a six-His-tag at the N-terminus and was kindly provided by Dr. 
Clark (University of Washington, Seattle) [19]. Bacterial strain Escherichia 
coli M15(Prep4) was transfected with this construct, and expression was 
induced by 0.1 mM isopropylthiogalactoside (Sigma-Aldrich Chemie B.V. 
Zwijndrecht). The protein was solubilized in 8.5 M Urea and subsequently 
refolded by stepwise dialysis against buffers containing decreasing urea con-
centrations. The protein preparation was incubated with mannan agarose 
beads (Sigma-Aldrich Chemie B.V. Zwijndrecht). Only functional protein is 
able to bind to mannan agarose beads. After several washing steps to re-
move unbound protein, the functional DC-SIGN was eluted from the beads by 
EGTA, removing the essential Ca2+-ion from DC-SIGN. After removal of the 
beads by centrifugation, the supernatant containing the functional protein 
was reconstituted with Ca2+-ion containing buffer (20 mM Tris-HCl, pH 8.0, 
150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2 and 0.5% BSA). The six-His tagged, 
humanized, single chain h5G1.1 antibody was used as control and kindly 
provided by Dr. Kretz-Rommel [20].
Binding assay with soluble DC-SIGN-His construct
The soluble DC-SIGN–His construct (10 µg/ml) was incubated with 5×104 
PBL in binding buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM CaCl2, 
2 mM MgCl2 and 0.5% BSA) in a 96-well V-shaped bottom plate at 37°C for 
30 min. Where indicated, DC-SIGN-His constructs were preincubated with 
100 µg/ml mannan (from Saccharomyces cerevisiae, Sigma-Aldrich Chemie 
B.V. Zwijndrecht) prior to the binding assay at RT for 20 min. Subsequently, 
the samples were incubated with mouse-anti-Penta-His Alexa-488 (Qiagen, 
Benelux B.V., Venlo, The Netherlands) at 37°C for 30 min. Cells were analyzed 
by flow cytometry and the percentage of cells that had bound recombinant 
DC-SIGN-His was quantified. 
Bead-binding assay with DC-SIGN–His construct
DC-SIGN–His or control-His were coated onto streptavidin-coated, carboxy-
late-modified TransFluoSpheres (488/645 nm, 1.0 µm; Molecular Probes [21]). 
First, streptavidin-coated beads were incubated with biotinylated horse-anti-
mouse IgG (10 µg; Vector, Brunschwig Chemie, Amsterdam, the Netherlands) 
at 37°C for 2 h, followed by an overnight incubation with mouse-anti-Penta-
Chapter 4 DC-SIGN in DC-induced T cell proliferation
65
His (1 µg; Qiagen) at 4°C. Subsequently, the beads were incubated with 250 ng 
DC-SIGN-His or control-His at 4°C for two days. 
The DC-SIGN and control beads were incubated with 5×104 PBL or HSB-2 
cells in binding buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM CaCl2, 
2 mM MgCl2 and 0.5% BSA) in a 96-well V-shaped bottom plate at 37°C for 
30 min. Where indicated, the beads were preincubated with 100 µg/ml man-
nan, 5 mM EGTA, or 100 µg/ml soluble ICAM-3 (Fc-ICAM-3 [7]) prior to the 
binding assay at RT for 20 min. In some experiments, PBL or HSB-2 cells 
were pre-incubated with 40 µg/ml of ICAM-3 blocking mAbs for 20 min at 
RT prior to the binding assay (CBR3/1 and 3/2 [7]). After washing, adhesion 
of the beads to the cells was assessed by flow cytometry. 
Characterization of DC-SIGN-binding cells by  
flow cytometry
To characterize the DC-SIGN binding cells, PBL were incubated with DC-
SIGN-His coated beads as described above. After washing, the cells were 
labeled for 20 min at RT with combinations of CD3-FITC (DakoCytomation 
B.V., Heverlee, Belgium), CD3-PE (BD Pharmingen), CD4-PE (BD Pharmin-
gen), CD8-FITC (BD Pharmingen), CD19-PE (BD Pharmingen), CD25-PE (Bec-
ton Dickinson), CD45RA-PE (Immunotech), CD45RO-FITC (DakoCytomation 
B.V.), CD56-PE (IQ Products, Groningen, the Netherlands) and/or CD62L-FITC 
(DakoCytomation B.V.). Samples were analyzed by flow cytometry (Cytomics 
Fc 500, Beckman Coulter, Fullerton, CA). The percentage cells, which had 
simultaneously bound beads and the mAb under study, was measured.
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Results
DC maturation state affects contribution of  
DC-SIGN and LFA-1 in MLR
The role of DC-SIGN in T cell proliferation is controversial [7,13-16]. To 
unravel the significance of DC-SIGN in T cell proliferation, numerous MLR 
were performed in the presence of DC-SIGN-blocking mAbs, and mAb di-
rected against LFA-1 was included as a positive control for blocking the MLR. 
Immature and mature allogeneic DC were used as T cell stimulators. T cell 
proliferation was determined by [3H]-thymidine incorporation or by CFSE 
dilution (Fig. 1A, B) which yielded comparable results. As expected, with im-
mature DC, a consistent block in T cell proliferation is observed when LFA-1 
mAb is present (Fig. 1A). Using both methodologies, significant blocking was 
observed for LFA-1, as determined by ANOVA, followed by the Student New-
man Keuls test: * p<0.05. Taking the group as a whole, no significant effect of 
DC-mATurATIoN DepeNDeNT eFFeCTS oF DC-SIGN AND LFA-1 oN T CeLL proLIFerA-
TIoN. PBL (1x105) were cocultured with 1.5x103 immature (A) or mature (B) allogeneic DC. 
After 6-7 days, proliferation was assessed by [3H]-thymidine incorporation or by CFSE dilu-
tion. Control mouse IgG1 or blocking mAbs (10 µg/ml) directed against DC-SIGN (AZN-D1 and 
AZN-D3) or LFA-1 (NKI-L15) were added at the onset of the experiment. Data are percentages 
of control (no addition of mAbs). Each dot represents the average of one independent experi-
ment performed in triplicate. Each MLR experiment consists of a different allogeneic DC-PBL 
combination. Significant difference from mouse IgG control as determined by ANOVA, followed 
by the Student Newman Keuls test: * p<0.05. Confidence interval (99%) of control mouse IgG1, 
Figure 1
B
C
A
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blocking DC-SIGN mAbs was observed in agreement with others [16]. How-
ever, in a subgroup of DC-T cell donor pairs, the presence of DC-SIGN mAbs 
resulted in less T cell proliferation, as illustrated by their location outside the 
99% confidence interval of control mouse IgG1. No correlation between ex-
pression profile of DC-SIGN on immature DC and the extent of the DC-SIGN 
effect on the T cell proliferation was observed (Fig. 1C). 
When mature DC were used as stimulator cells (Fig. 1B), hardly any blocking 
effect is observed with DC-SIGN mAbs. It is surprising that as LFA-1 is an 
effective mediator in MLR [22,23], the blocking potential of the LFA-1 mAb 
is also decreased considerably when mature DC are used as T cell stimulators 
(Fig. 1B+D). The blocking effect of DC-SIGN mAbs is observed when using 
immature DC as stimulator cells, and the blocking effect is absent when ma-
ture DC are used as stimulator cells (Fig. 1e) using the same donor for raising 
immature as well as mature DC and the same allogeneic PBL donor. 
Together, these data show that the use of mature DC as T cell stimulators 
abrogates the contribution of DC-SIGN and LFA-1 in MLR. 
assessed by [3H]-thymidine incorporation (immature DC; 86-161%, mature DC; 81-129%) and 
CFSE dilution (immature DC; 67-130%, mature DC; 63-112%), represented by gray area. (C) 
DC-SIGN (AZN-D1) expression on immature DC from three different donors. These DC were 
cocultured with different allogeneic PBL donors. Proliferation was assessed after 7 days (CFSE 
dilution). The percentage of proliferation with DC-SIGN mAb (relative to control) is depicted 
for each donor. Transparent histograms represent mIgG1 isotype control, and filled histograms 
represent DC-SIGN mAb. MFI, mean fluorescence intensity. (D) Percentage of block in T cell 
proliferation mediated by LFA-1 mAb in MLR driven by allogeneic immature and mature DC. 
Data expressed as percentages of control (no addition of mAbs), are mean ± SEM of 10 inde-
pendent experiments, assessed by [3H]-thymidine incorporation or by CFSE dilution. Each MLR 
experiment consists of a different allogeneic DC-PBL combination. Significant difference from 
immature DC, as determined by unpaired two-tailed Student’s t-test: * p<0.05. (E) CFSE profiles 
of T cells stimulated with immature DC or mature DC in the presence and absence of blocking 
mAbs. Proliferation was assessed after 7 days. In this experiment, the same allogeneic DC-PBL 
combination was used. 
D
e
Chapter 4 DC-SIGN in DC-induced T cell proliferation
68
DC-SIGN, LFA-1, and CD6 differentially influence  
DC-induced T cell proliferation over time 
A full-blown T cell response, when measured at day 7, results in a waning 
effect of DC-SIGN and LFA-1 mAbs in MLR driven by mature DC. This could 
also hold for DC-SIGN in MLR driven by immature DC. Therefore, T cell pro-
liferation was assessed after 3, 5 and 7 days. As positive control for blocking 
MLR driven by mature DC, a CD6 blocking mAb was included, as CD6 plays 
a crucial role in mature DC-T cell interactions [24]. In immature DC-T cell 
donor pairs, which could be blocked by DC-SIGN mAbs, as depicted in Figure 
1A, LFA-1, DC-SIGN and CD6 mAbs blocked T cell proliferation at all time 
points indicated (Fig. 2A). However, T cell proliferation in DC-T cell donor 
TIme-DepeNDeNT, DIFFereNTIAL eFFeCTS oF DC-SIGN, LFA-1, AND CD6 oN T CeLL proLIFerATIoN. (A, B) PBL 
(1x105) were cocultured with 1.5x103 immature (A) or mature (B) allogeneic DC. After 3, 5 and 7 days, proliferation was 
assessed by [3H]-thymidine incorporation. Blocking mAbs (5-10 µg/ml) against LFA-1 (NKI-L15), DC-SIGN (AZN-D1 and 
AZN-D3) and CD6 or control mouse IgG were added at the onset of the experiment. Results are expressed as the mean 
percentage of the control (no addition of mAbs) from triplicate wells. One representative experiment out of three is shown. 
(A) *Time (t) =3, 5, and 7; significant difference from anti-DC-SIGN, anti-LFA-1, and anti-CD6 as determined by ANOVA, 
followed by the Student Newman Keuls test: p<0.01. (B) *t=3, 5; significant difference from anti-LFA-1 and anti-CD6, as 
determined by ANOVA, followed by the Student Newman Keuls test: p<0.05. **T=7; significant difference from anti-DC-
SIGN, anti-LFA-1 and anti-CD6, as determined by ANOVA, followed by the Student Newman Keuls test: p<0.05. (C, D) PBL 
(1x105) were cocultured with 1.5x103 immature (C) or mature (D) allogeneic DC. Blocking mAbs (5-10 µg/ml) against LFA-1 
(NKI-L15), DC-SIGN (AZN-D1 and AZN-D3) and CD6 or control mouse IgG were added to the cocultures at the onset of 
the experiment (t=0), after 24 h, or after 72 h. Proliferation was assessed by [3H]-thymidine incorporation after 6 days. 
Results, expressed as percentage of the control (no addition of mAbs), are the mean ± SD of triplicate wells. A representa-
tive experiment out of three is shown. Significant difference from control mouse IgG according to ANOVA, followed by the 
Student Newman Keuls test: * p<0.01. In (A) and (C) the same allogeneic, immature DC-PBL combination was used, that 
could be blocked by DC-SIGN mAbs. (B and D) The same allogeneic, mature DC-PBL combination was used.
Figure 2
B
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pairs, which could not be blocked by DC-SIGN mAbs when measured after 7 
days, also did not show a blocking effect of DC-SIGN mAbs when measured 
after 3 and 5 days (data not shown). It is remarkable in contrast to LFA-1 
and DC-SIGN mAbs that only the CD6 mAb was able to block proliferation 
induced by mature DC at all time points indicated (Fig. 2B). LFA-1 mAb ef-
fectively blocked T cell proliferation induced by mature DC when measured 
after 3 days, but after 7 days the blocking effect was hardly detectable. To 
further characterize the effect of blocking DC-SIGN during MLR, blocking 
mAbs against DC-SIGN were added at 0, 24 or 72 hours after onset of the 
immature or mature DC-T cell coculture (Fig. 2C, D). The effects of blocking 
mAbs to LFA-1 and CD6 were evaluated in parallel. In immature DC-T cell 
donor pairs, which could be blocked by DC-SIGN mAbs, as depicted in Figure 
1A, LFA-1 and DC-SIGN mAbs blocked T cell proliferation effectively, only 
when added at the onset of the DC-T cell coculture (Fig. 2C). Similarly, LFA-1 
mAb inhibited T cell proliferation induced by mature DC, only when added 
at the onset of the experiment (Fig. 2D). In contrast, CD6 mAb effectively 
blocked T cell proliferation induced by both immature and mature DC when 
added at 0 and 24 hours after onset of the experiment. 
Altogether, these kinetic blocking experiments show that DC-SIGN and LFA-1 
play a role early on in MLR whereas CD6 mediates a long-lived effect. 
DC-SIGN AND LFA-1 mABS mAINLy INhIBIT Low reSpoNDer mLr. CFSE-labeled PBL (1x105) were cocultured with 
1.5x103 immature or mature allogeneic DC. After 7 days, proliferation was determined by flow cytometry. (A) CFSE histogram pro-
files of allogeneic PBL stimulated with immature DC or mature DC. PBL and DC were used from four different PBL and DC donors. 
Markers define the percentage of proliferating cells. One representative experiment out of five is shown. (B, C) T cell proliferation 
in MLR with immature (B) and mature DC (C) in the presence of DC-SIGN (AZN-D1 and AZN-D3) or LFA-1 (NKI-L15)-blocking 
mAbs added at the onset of the experiment. MLR were separated into weak (<60% of PBL proliferate) and strong (>60% of 
PBL proliferate) MLR responses. Data are percentages of control (no addition of mAbs). Each dot represents the average of one 
independent experiment performed in triplicate. Each MLR experiment consists of a different allogeneic DC-PBL combination. 
Significant difference from control mouse IgG according to ANOVA, followed by the Student Newman Keuls test: * p<0.05. 
Figure 3
A
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Contribution of DC-SIGN and LFA-1 to MLR depends  
on strength of T cell response 
In MLR, several T cells will be activated upon recognition of specific MHC 
peptide complexes expressed by the allogeneic DC. The number of T cells re-
acting to these MHC peptide complexes varies between different donors and 
consequently, the strength of the MLR response will vary. Indeed, in some 
MLR, a very strong T cell-proliferative response was detected, whereas in 
others, the response was rather weak (Fig. 3A). This prompted us to separate 
the MLR into weak and strong responses based on the percentage of prolifer-
ating T cells as determined by CFSE staining. Based on several experiments, 
MLR, in which after 7 days, less than 60% of the T cells were detected in the 
proliferative pool could be defined as a weak MLR, whereas MLR, in which 
more than 60% of the T cells were detected in the proliferative pool, could 
be defined as a strong MLR. When taking the group as a whole, no blocking 
effect of anti-DC-SIGN mAbs was observed. However, when categorized in 
this way, the effects of blocking DC-SIGN mAbs were only visible in several 
weak MLR and when immature DC were used as stimulators (Fig. 3B). Similar 
to DC-SIGN mAbs, LFA-1 mAb mostly affected MLR driven by immature DC, 
and the blocking effect was strongest in the weak MLR (Fig. 3C).
Thus, in strong MLR, proliferation cannot be blocked by DC-SIGN mAbs and 
are blocked less efficiently by LFA-1 mAb.
Localization of DC-SIGN in DC-T cell contact area
To visualize the behavior of DC-SIGN in the DC-T cell contact area, we per-
formed DC-T cell conjugate formation experiments. Immature and mature 
DC formed contacts with T cells (Fig. 4). DC-SIGN is present in the DC-T 
cell contact area, although DC-SIGN is not recruited to the contact zone. No 
difference in distribution of DC-SIGN was observed between immature (Fig. 
4A) and mature (Fig. 4B) DC-T cell conjugates. Participation of CD3- cells in 
the DC-PBL conjugates or enrichment of ICAM-3 in the contact site did not 
influence the localization of DC-SIGN.
In conclusion, these data show that DC-SIGN is not enriched in the DC-T cell 
contact area. 
Characterization of DC-SIGN binding to PBL
Various studies indicate that DC-SIGN-ICAM-3 interactions are of a tran-
sient nature [7,25]. To examine this in more detail, we analyzed the binding 
capacity of PBL derived from various donors to a DC-SIGN-His construct 
used in free form or attached to streptavidin-coated fluorescent beads. DC-
SIGN-His-coated beads showed the highest binding to PBL as compared with 
soluble DC-SIGN-His, with an average of 5.4% specific binding (Fig. 5A). 
It is interesting that PBL of some donors showed a much higher binding 
to DC-SIGN-His coated beads. DC-SIGN-specific binding was calculated by 
subtracting binding data determined in the presence of mannan. Determina-
tion of specific binding with EGTA and control-His beads was comparable 
with binding in the presence of mannan (Fig. 5B). PBL isolated from a donor 
whose PBL have a high DC-SIGN-binding capacity (22%) were labeled with 
subset-specific mAbs to characterize the cells that bind DC-SIGN (Fig. 5C). 
All cell subsets displayed a distinct percentage of cells that were positive 
for DC-SIGN binding, which was highest for B cells (Table 1). Of the B cells 
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present in the PBL preparation, approximately 25% are able to bind DC-SIGN 
beads. All the different subsets contribute to the overall binding percentage 
of 20.7%. Similar results were obtained when positive and negative FACS-
sorted T cells, B cells, and NK cells were analyzed for DC-SIGN binding (data 
not shown). 
To determine whether ICAM-3 plays a role in the binding of soluble DC-
SIGN-His-coated beads to PBL, binding studies were performed in the pres-
ence of ICAM-3-blocking mAbs, or by preblocking the DC-SIGN-His coated 
beads with soluble ICAM-3. Although blocking ICAM-3 hardly affected the 
percentage of PBL that bound DC-SIGN-His coated beads (data not shown), 
it reduced the MFI of the binding PBL by 35%. In addition, preblocking the 
preSeNCe oF DC-SIGN IN DC-T CeLL CoNTACT AreA. Overview and zoomed-in pictures 
of conjugates between PBL and immature (A) or mature (B) DC. Allogeneic DC and PBL were 
incubated at 37°C for 15 min and subsequently mounted on poly-L-lysine coated cover-
slips. Cell conjugates were stained for DC-SIGN (blue), ICAM-3 (green) and CD3 (red). Results 
represent two different allogeneic DC-PBL combinations. Representative pictures of three 
independent experiments are shown. 
Figure 4
A
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ChArACTerIzATIoN oF DC-SIGN-hIS BINDING To pBL. (A) The binding of PBL to DC-
SIGN-His construct, in free form or coated to streptavidin-coated fluorescent beads, was 
determined. PBL were allowed to bind 10 µg/ml recombinant soluble DC-SIGN-His construct 
for 30 min at 37°C, followed by incubation with Penta His Alexa-488 for 30 min at 37°C. For 
the beads assay, PBL were incubated for 30 min at 37°C with DC-SIGN-His-coated beads 
and subsequently analyzed by flow cytometry. Aspecific binding was determined by pretreat-
ment of the DC-SIGN-His construct with 100 µg/ml mannan. Data are percentages of PBL 
isolated from several donors that displayed specific binding to the DC-SIGN-His construct. 
(B) Determination of aspecific binding of DC-SIGN-His beads to PBL by incubation cells with 
control-His beads or preincubation of DC-SIGN-His beads with 100 µg/ml mannan or 5 mM 
EGTA. One typical result out of 10 is depicted. (C) Characterization of DC-SIGN-His binding 
PBL by double/triple labeling FACS analysis. PBL isolated from a donor whose PBL showed 
high DC-SIGN-binding capacity were incubated with DC-SIGN-His-coated beads for 30 min 
at 37°C. Subsequently, the cells were labeled with FITC- and/or PE- conjugated mAbs for 20 
min at RT where indicated. Samples were analyzed by flow cytometry, and FACS pictures are 
depicted. Left column represents FACS pictures with the specific cell populations gated (gate 
A, B or C with percentage positive cells) for testing binding capacity to DC-SIGN-His beads. 
Right columns represent binding results of the specific cell populations to DC-SIGN-His 
beads (percentage binding indicated in picture). SSC, Side-scatter; FSC, forward-scatter. (D) 
DC-SIGN-His beads were preincubated in binding buffer, or in binding buffer supplemented 
with 100 µg/ml soluble ICAM-3. The DC-SIGN-His beads preincubated in binding buffer were 
added to PBL, which were preincubated in binding buffer or in binding buffer supplemented 
with 20 µg/ml of the ICAM-3 blocking mAbs CBR3/1 and 3/2 (anti-ICAM-3 Ab). DC-SIGN-
His beads preincubated in binding buffer supplemented with soluble ICAM-3 were added to 
PBL preincubated in binding buffer (soluble ICAM-3). Aspecific binding was determined by 
incubating PBL with DC-SIGN-His beads in the presence of 5 mM EGTA. PBL were allowed to 
bind DC-SIGN-His-coated beads for 30 min at 37°C. The mean cell fluorescence of DC-SIGN-
His bead-binding PBL was determined by FACS analysis, and the percentages of the binding 
buffer control value were calculated. Data are mean ± SD of three experiments. Significant 
difference from binding buffer control, as determined by ANOVA and Dunnett’s test: * p < 
0.05. (E) The experiments shown in D were repeated using the T cell line HSB-2 instead of 
PBL. The mean cell fluorescence was determined by FACS analysis, and the percentages of 
the binding buffer control value were calculated. Data are mean ± SD of three experiments. 
Significant difference from binding buffer control, as determined by ANOVA and Dunnett’s 
test: ** p < 0.01.
A B
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ChArACTerIzATIoN oF DC-SIGN-hIS BINDING pBL By DouBLe/TrIpLe LABeLING 
FACS ANALySIS. PBL from the same donor as described in Figure 5C were incubated with 
DC-SIGN-His-coated beads for 30 min at 37°C. Subsequently, the cells were labeled with 
FITC- and/or PE- conjugated mAbs for 20 min at RT where indicated. Samples were analyzed 
by flow cytometry. Data are percentages of cells within the indicated cell populations that 
displayed binding to the DC-SIGN-His-coated beads.
Cell population ................... % Binding 
PBL total ................................................20.7
T cells (CD3+) .......................................... 4.7
CD3+CD4+ ................................................ 5.3
CD3+CD8+ ................................................ 6.6
CD3+CD25+ .............................................. 4.1
CD3+CD25-............................................... 4.2
CD3+CD62L-............................................. 4.7
CD3+CD62L+ ............................................ 4.4
CD45RA+CD45RO- ................................. 3.9
CD45RA-CD45RO+ ................................. 2.5
NK cells (CD3-CD56+) ........................... 7.7
NKT cells (CD3+CD56+)  .....................12.1
B cells (CD19+) .....................................24.4
C
D e Table1
Table 1
73
Chapter 4 DC-SIGN in DC-induced T cell proliferation
74
DC-SIGN-His-coated beads with soluble ICAM-3 resulted in a 34% reduction 
in the MFI of the binding PBL (Fig. 5D). As only a relatively low percentage 
of PBL bound DC-SIGN-coated beads, and the percentage of binding T cells 
in the PBL population was even lower (Table 1), the T cell line HSB-2 was 
used as a model to determine whether ICAM-3 on the T cell interacts with 
the DC-SIGN-coated beads. On average, approximately 80% of HSB-2 cells 
bound DC-SIGN-coated beads (data not shown). Preblocking DC-SIGN-His-
coated beads with soluble ICAM-3, as well as blocking ICAM-3 on the cell 
surface with mAbs, significantly reduced binding of the DC-SIGN-His beads 
to HSB-2 cells (Fig. 5e).  
Together, these data show that approximately 5% of PBL bind DC-SIGN beads 
and that binding is at least partly mediated by ICAM-3. The cells that bind 
DC-SIGN beads comprise all major cell subsets of PBL. 
DC-SIGN-binding capacity parallels blocking capacity
As the number of PBL that bind DC-SIGN beads differs between donors, we 
tested whether this difference in binding could explain why some MLR are 
BLoCkING eFFeCTS wITh DC-SIGN mABS IN mLr AND wITh pBL ShowING A hIGh DC-
SIGN-hIS BINDING CApACITy. CFSE-labeled PBL (1x105) from a donor whose PBL showed 
high DC-SIGN-His-binding capacity (22%, squares) or from a donor whose PBL showed low 
DC-SIGN-His-binding capacity (8%, circles) were cocultured with the same 1.5x103 immature 
(A) or mature (B) allogeneic DC obtained from five different donors. After 7 days, proliferation 
was determined by flow cytometry. Control mouse IgG or blocking mAbs (10 µg/ml) directed 
against DC-SIGN (AZN-D1 and AZN-D3) or LFA-1 (NKI-L15) were added at the onset of the 
experiment. Data are percentages of control (no addition of mAbs). Each dot represents the 
average of one experiment performed in triplicate. Significant difference from control mouse 
IgG according to ANOVA, followed by the Student Newman Keuls test: * p<0.05. 
A B
Figure 6
immature DC mature DC
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blocked by mAbs against DC-SIGN, and others are not. PBL obtained from 
the donor characterized in Table 1/Fig. 5C and PBL from another donor show-
ing lower DC-SIGN binding were cocultured with the same DC isolated from 
five different allogeneic donors. Based on the definitions given above and in 
the legend of Figure 3B, all the MLR belong to the low-responder category. 
Upon stimulation with immature DC, PBL with high DC-SIGN binding ca-
pacity showed an overall decrease in T cell proliferation in the presence of 
blocking DC-SIGN and LFA-1 mAbs (Fig. 6A). It has to be noted that addition 
of control mIgG itself influenced T cell proliferation. In contrast to the PBL 
showing a high DC-SIGN-binding capacity, DC-SIGN mAbs did not block 
proliferation of PBL with low DC-SIGN-binding capacity. Nevertheless, LFA-1 
mAb blocked T cell proliferation considerably. 
In MLR driven by mature DC, the presence of DC-SIGN mAbs also resulted 
in a decrease in overall T cell proliferation when PBL with high DC-SIGN-
binding capacity were used (Fig. 6B). It is striking that PBL with low DC-
SIGN-binding capacity displayed slightly enhanced T cell proliferation in the 
presence of DC-SIGN-blocking mAbs. The blocking effect of LFA-1 mAb on 
T cell proliferation is more pronounced in PBL with high DC-SIGN-binding 
capacity as compared to PBL with low DC-SIGN-binding capacity.
In conclusion, PBL isolated from the donor with high DC-SIGN-binding ca-
pacity were more prone to blocking by DC-SIGN mAbs in MLR than PBL from 
the donor with lower DC-SIGN-binding capacity.
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Discussion
In the present study, we analyzed the relevance of DC-SIGN in DC-induced 
T cell proliferation. Our data indicate that its relevance in allogeneic T cell 
proliferation depends on the strength of the T cell response and on the per-
centage of PBL that are able to bind recombinant DC-SIGN.
A dependence on the strength of T cell response suggests an initiating role 
for DC-SIGN in DC-T cell interaction followed by other adhesive and co-
stimulation events, that will boost T cell proliferation. The latter interaction 
is DC-SIGN-independent and therefore, not inhibitable by DC-SIGN mAbs. 
The height of a MLR response is directly proportional to the number of T 
cells that are activated by APC. The number of T cells that are activated is, 
besides efficient costimulation, dependent on the integrated outputs of all 
TCR signaling events per cell. Consequently, a weak MLR is observed when 
fewer cells are able to evoke sufficient TCR signaling events compared with a 
strong MLR. Sufficient TCR signaling is attained by clustering the TCR-MHC 
complexes, as the affinity of the TCR is very low [26]. Sustained signaling 
was also observed when the formation of the immunological synapse is in-
hibited [27]. DC-SIGN-ICAM-3 interactions prolong initial cell-cell contact 
and thereby prolong TCR signaling. Such prolonged cell-cell contact will 
result in a higher integrated signaling and thereby lowering the threshold for 
an immune response. Consequently, when more TCR-MHC are involved in the 
interaction, sufficient microclusters will be formed to initiate effective signal-
ing and thereby minimizing the role for DC-SIGN-ICAM-3 interactions. 
The proliferation data show that the degree of inhibition of T cell prolifera-
tion by LFA-1 and DC-SIGN blocking mAbs depends on the DC maturation 
state. Moreover, when using immature DC, DC-SIGN blocking mAbs only 
have an effect on some of the MLR that are categorized as weak MLR (<60% 
of PBL proliferate). Therefore, the variable blocking potential of DC-SIGN 
mAbs on the MLR, as shown in this study and by Granelli-Piperno et al. [16] 
is explained either by testing strong MLR or using mAbs that do not bind to 
the carbohydrate-recognition domain of DC-SIGN.
It is interesting that the degree of inhibition of T cell proliferation by LFA-1 
mAb is also dependent on the strength of the T cell response. In MLR driven 
by mature DC, LFA-1 mAb could only block MLR with a weak response. 
The kinetic-blocking experiments indicate that DC-SIGN and LFA-1 exert 
initial effects in DC-T cell communication, which are dominated readily by 
other adhesive and costimulatory mechanisms. Such a dominating effect will 
be more pronounced with mature DC in comparison with immature DC be-
cause of their stronger T cell stimulation capacity [28,29]. Indeed, relatively 
more low-responder MLR are observed when immature DC are used as T cell 
stimulators compared with mature DC as T cell stimulators (Fig. 3B). In con-
trast to DC-SIGN and LFA-1 mAbs, T cell proliferation could be blocked over 
a long period of time by blocking CD6 mAb, which indicates CD6 plays an 
important and long-lasting role in DC-T cell contacts.
An initial effect of LFA-1 in DC-T cell communication is supported by a study 
of Bachmann et al. [30]. They demonstrate that LFA-1 induces T cell activa-
tion by promoting adhesion of T cells to APC instead of providing long-lived 
costimulatory signals [30]. Another study also indicates that LFA-1 is not 
able to provide strong costimulatory signals such as CD28, which is the most 
dominant costimulatory molecule [31].
The dominating role of other adhesive and costimulatory mechanisms may 
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play a minor role when less professional APC are used such as THP-1 cells 
differentiated into DC-SIGN+ cells. These DC-like cells induce T cell prolif-
eration, which is blocked by DC-SIGN mAbs [13]. Probably, the effect of 
DC-SIGN on T cell proliferation is more easily over-ruled than that of LFA-1 
because of the transient nature of the DC-SIGN/ICAM-3 interaction. It has 
been reported that DC-SIGN/ICAM-3-dependent adhesion between DC and T 
cells varies and reaches an optimum after 20 min [7]. In addition, DC-SIGN 
can recruit LFA-1 to the contact site and shift from initial transient DC-
SIGN-ICAM-3 interactions to more stable LFA-1-ICAM-3 interactions [25]. 
Furthermore, ICAM-3 is a dynamic molecule, as it is recruited rapidly to the 
APC-T cell contact site followed by a redistribution to the outer zone of the 
cell-cell interface upon contact stabilization [4]. 
In agreement with previous studies [32,33], our DC-T cell conjugates do not 
show an enriched distribution of DC-SIGN in the DC-T cell contact area, re-
gardless of the use of immature or mature DC and of the distribution pattern 
of ICAM-3. Apparently, sufficient DC-SIGN molecules are present on the DC 
membrane to establish a transient interaction with ICAM-3. 
Funatsu et al. [34] reported that ICAM-3 molecules isolated from human PBL 
only contain 6% high mannose-type oligosaccharides of the total ICAM-3 
oligosaccharide pool. The authors of this study suggest that these high man-
nose-type oligosaccharides are expressed on a special subset of T cells [34]. 
However, we could not pinpoint the DC-SIGN-binding cells to one specific T 
cell population. Instead, we observed that all cell populations analyzed bind 
DC-SIGN to a similar degree, except for B cells, which showed a much higher 
specific binding (Table 1). Thus, besides major T cell subsets, DC-SIGN beads 
also bind B cells and NK cells. Interactions between DC and B cells and DC 
and NK cells modulate DC function and can indirectly have an impact on T 
cell response [35,36]. 
It seems likely that high mannose-type oligosaccharides are expressed at low 
levels on all T cells and underlie the transient binding of DC-SIGN to T cells. 
This concept is supported by the finding that DC-SIGN-His-coated beads were 
superior in binding to PBL as compared with soluble DC-SIGN-His. Multiple 
DC-SIGN-His molecules are attached to each fluorescent bead, endowing it 
with a high avidity, thus improving stable interactions between the bead and 
the low number of specifically glycosylated ICAM-3 molecules expressed on 
PBL. DC-SIGN–His, in soluble form, may at best form tetramers [37] and thus, 
will have a lower avidity. 
PBL isolated from some donors showed a considerable higher binding to DC-
SIGN-His-coated beads than other donors. This high-binding potential was 
consistent over time, as PBL with a high DC-SIGN-binding capacity from a 
specific donor still showed a high specific binding to DC-SIGN-His-coated 
beads when measured 6 and 18 months later (data not shown). 
Snyder et al. [38] found submicromolar binding affinities when using ICAM-3, 
which was produced in the mouse cell line NSO. Glycosylation is impor-
tant for reactivity of DC-SIGN, as Snyder et al. [38] show in their paper for 
gp120, the other ligand of DC-SIGN. Mouse cells are known to glycosylate 
incompletely in vitro-produced proteins. As DC-SIGN recognizes high man-
nose-type oligosaccharides, it is not surprising that those authors find submi-
cromolar-binding affinities. The ligand is simply not expressed at sufficient 
levels. As reported above, ICAM-3 isolated from human PBL is expressing 
only 6% high mannose-type oligosaccharides [34]. Moreover, the same au-
thors show that for binding, tetrameric DC-SIGN is adamant [38]. Chimeric 
Fc-ICAM-3 is believed to be dimeric, which adds to their poor binding results. 
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Geijtenbeek et al. [7] used beads that harbor multiple Fc-ICAM-3 ligands for 
binding studies to circumvent those valency issues. It seems likely that the 
donors whose PBL bind DC-SIGN with high capacity express an increased 
level of specifically glycosylated ICAM-3 and possibly other specifically gly-
cosylated ligands. Changes in glycosylation can be related to the differentia-
tion status of a cell, as a T cell displays several glycosylation patterns during 
its development [39]. Ryan et al. [19] showed a preferential binding of naïve 
CD45RA+ cells to DC-SIGN-His. However, in our study no clear differences 
were observed between naïve/resting cells (CD45RA+, CD62L+) and memory/
activated cells (CD45RO+, CD25+) [40-42]. 
PBL, with a high DC-SIGN-binding capacity, were more prone to DC-SIGN-
blocking mAbs in the MLR, even when mature DC were used to stimulate 
the T cells. In these MLR, DC-SIGN can bind firmly to a higher percentage 
of T cells and may have a prolonged effect on these cells compared with 
cells that bind transiently. In a MLR, only 1 to 10% of the T cells are able to 
respond to the allogeneic MHC-peptide complexes expressed on DC. There-
fore, only a relatively small number of T cells binding firmly to DC-SIGN 
might be required to have a substantial effect in the MLR. Because of the 
higher frequency of firm binding cells in the donor whose PBL have a high 
DC-SIGN-binding capacity, the effect of blocking DC-SIGN in the MLR is 
observed more rapidly. Accordingly, the level of DC-SIGN-binding capacity 
of PBL may explain why not all weak MLR stimulated by immature DC are 
down-regulated by DC-SIGN-blocking mAbs. 
The MLR experiments in Figure 6 show that the inhibitory action of DC-SIGN 
mAbs is not DC donor-specific or dependent on level of DC-SIGN expression. 
This can be concluded from the fact that the use of the same DC donor and 
therefore, the same DC-SIGN expression level, in combination with two PBL 
donors, resulted in different effects of the DC-SIGN mAbs.
Our data indicate that DC-SIGN is involved in early contacts between DC and 
T cells. It is tempting to speculate that DC-SIGN is involved in the initial ex-
ploratory contact of T cells with DC in a similar way as described for ICAM-3 
[4]. In this regard, DC-SIGN may act like a selectin by mediating the ‘rolling’ 
of T cells over DC in a similar way as selectins do by mediating the rolling 
of T cells along the endothelium [43]. Future dynamic studies performed in a 
three-dimensional setting could address this phenomenon. 
Summarizing, this study indicates an initial and transient role for DC-SIGN 
in T cell proliferation, which becomes apparent in weak MLR and when the 
percentage of DC-SIGN binding PBL is high. 
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Abstract
Soluble DC-SIGN (CD209) bind unsialylated Lewis X epitopes that are abun-
dantly expressed on neutrophils. Due to the low expression of unsialylated 
Lewis X epitopes on monocytes, no binding of soluble DC-SIGN molecules 
was seen. In contrast, beads coated with multiple DC-SIGN molecules show a 
high percentage of binding to monocytes. The increased number of DC-SIGN 
molecules present on the beads enable multivalent interactions between the 
DC-SIGN molecules and the scarce Lewis X epitopes present on monocytes. 
Increased expression of unsialylated Lewis X epitopes on monocytes after 
neuraminidase treatment coincided with enhanced binding to soluble DC-
SIGN. Multiple unsialylated Lewis X epitopes in close proximity of each other 
are now able to interact multivalently to soluble DC-SIGN. From these find-
ings, we conclude that firm interactions between DC-SIGN and monocytes 
can be established by either increasing the density of DC-SIGN molecules at 
the cell surface or by increasing the number of Lewis X epitopes. Regulating 
the number of ligands endows monocytes with the capacity to modulate 
binding to DC-SIGN. This may result in a bi-directional cross-talk between 
DC and monocytes, to modulate innate and/or adaptive immune responses. 
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Introduction
Dendritic cell specific ICAM-3 grabbing non-integrin (DC-SIGN) belongs to 
the C-type lectin family and is expressed on dendritic cells (DC) and certain 
macrophages [1-3]. It acts as adhesion and pathogen recognition receptor 
by recognizing a broad array of ligands which have high-mannose residues 
or fucose residues in common [4,5]. The DC-SIGN molecule forms tetramers 
endowing the molecule with multiple binding sites to its ligands [6]. On DC, 
DC-SIGN is organized in microdomains of 200 nm in diameter that enable 
binding to small virus-sized particles [7]. Based on these findings, oligomeric 
DC-SIGN molecules in close proximity of each other are adamant to estab-
lish firm multivalent interactions with its ligands. Those ligands have to be 
properly spaced to enable multivalent binding [8]. Soluble DC-SIGN is able 
to bind to neutrophils in a MAC-1 dependent manner [9]. Here, the binding 
of soluble DC-SIGN as well as multivalent DC-SIGN to monocytes is reported. 
Moreover, sialic acid residues were removed from monocytes by treatment 
with neuramidase to reveal putative DC-SIGN binding entities.
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Materials and Methods
Production of DC-SIGN beads
DC-SIGN-His [10] or control-His (six-His tagged humanized single chain 
h5G1.1 antibody [11]) were coated onto carboxylate-modified TransFluo-
Spheres (488/645 nm, 1.0 µm; Molecular Probes, Leiden, The Netherlands 
[12]) First, beads coated with streptavidin were incubated with biotinylated 
horse-anti-mouse IgG (Vector, Brunschwig Chemie, Amsterdam, the Nether-
lands) at 37°C for 2 h followed by an overnight incubation with mouse-anti-
Penta-His (Qiagen, Benelux B.V., Venlo, The Netherlands) at 4°C. Subsequent-
ly, the beads were incubated with His-constructs at 4°C for two days.
Determination of the specificity
Specificity was determined by preincubation with 100 µg/ml mannan in 
binding buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM CaCl2, 2 mM 
MgCl2 and 0.5% BSA) at room temperature for 20 min. Subsequently, 5×10
4 
PBMC were added to the beads and incubated at 4°C for 30 min. After wash-
ing, adhesion of the beads to the cells was assessed by flow cytometry.
Isolation of CD14+ monocytes
CD14+ cells were isolated from PBMC by performing positive selection with 
CD14+ micro magnetic beads (Miltenyi Biotec., Bergisch-Gladbach, Germany) 
according to the manufacturer’s instructions.
Removal of sialic acid residues
CD14+ monocytes (2×106 cells/ml in PBS) were incubated with 20×10-3 
units/ml neuraminidase (type V, from Clostridium perfringens, Sigma) at 37°C 
for 10 min.
Electron microscopic analysis 
TEM labeling was performed as described previously [7]. Briefly, monocytes 
were labeled with isotype control (mIgM, Ancell, Kordia BV, Leiden, The Nether-
lands) or anti-CD15 (clone 80H5, Immunotech) followed by incubation with 
rabbit anti-mouse IgM (µ chain specific, Jackson Immunoresearch, Brunschwig 
Chemie B.V., Amsterdam, The Netherlands) and a final incubation with Protein 
A gold 10 nm diameter (kind gift of M. Wijers and H. Croes, Nijmegen Centre 
for Molecular Life Sciences). Specimens were observed in a transmission elec-
tron microscope (model 1010; JEOL), operating at 60–80 kV.
Binding of soluble DC-SIGN
Neuraminidase-treated and untreated monocytes (5×104) were incubated with 
soluble DC-SIGN-Fc (10 µg/ml, [13]) in binding buffer at 4°C for 30 min. 
Where indicated, DC-SIGN was preincubated with 100 µg/ml mannan or 5 
mM EGTA prior to the binding assay at room temperature for 20 min. Subse-
quently, the samples were incubated with FITC-conjugated goat-anti-human 
Fc (Cappel, Irvine, CA, USA) at 4°C for 30 min.
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Results
The spatial requirements for binding were unravelled using oligomeric solu-
ble DC-SIGN molecules and multivalent beads coated with DC-SIGN. Bind-
ing of DC-SIGN beads to PBMC was evident from an increased side scatter 
of the monocyte population (Fig. 1A). Control beads lack and blocking with 
mannan abolished this increase in side scatter. After subtracting the binding 
in the presence of mannan, the latter representing non-DC-SIGN mediated 
binding, 45% of the monocytes bound to DC-SIGN beads (Fig. 1B). Isolation 
of monocytes with the aid of CD14+ MicroBeads showed a similar binding 
percentage whereas only 3% of the CD14- cells bound the DC-SIGN beads 
(Fig. 1C). Thus, demonstrating monocyte specific binding. 
Recently, it was reported that soluble DC-SIGN binds neutrophils via Mac-1 
that expresses Lewis X epitopes [9]. In contrast, monocytes did not bind 
soluble DC-SIGN due to lack of Lewis X expression [9]. However, we now 
observed that monocytes did show low Lewis X expression when using an-
DC-SIGN BeADS BIND to moNoCyteS. (A) Scatterplots and (B) histogram profiles of PBMC 
binding to coated beads. (A) gate A represents free beads, gate B: lymphocytes, and gate C: 
monocytes. Percentage of gated monocytes (gate C) that have bound beads is depicted in 
(B). (C) Binding of DC-SIGN beads to CD14+ and CD14- cells as determined with the flowcyto-
meter. Where indicated, beads were preincubated with 100 µg/ml mannan, 5 mM EGTA or 20 
µg/ml AZN-D1 [1]. One representative experiment out of 5 is depicted. 
A
B
C
Figure 1
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INCreASeD eXpreSSIoN oF LewIS X By moNoCyteS reSuLtS IN INCreASeD BINDING to DC-SIGN. (A) CD15-
PE (clone 80H5; Immunotech, Beckman Coulter B.V., Mijdrecht, The Netherlands) staining of neuraminidase-treated and 
untreated monocytes. MFI of Lewis X (CD15) expression and percentage of positive cells of 1 representative experiment 
out of five are depicted. (B) TEM pictures of Lewis X expression on monocytes untreated or treated with neuraminidase. 
(C) Flowcytometric analysis of soluble DC-SIGN binding to untreated and neuramidase-treated monocytes. Percentage of 
cells that have bound DC-SIGN (left panel), MFI (right panel) and FACS histograms of one representative experiment out 
of five are depicted. (D) Flowcytometric analysis of DC-SIGN coated beads binding to untreated and neuramidase-treated 
monocytes. Percentage of cells that have bound DC-SIGN (left panel), MFI (right panel) and FACS histograms of one re-
presentative experiment out of four are depicted. 
A
C
D
B
Figure 2
87
Chapter 5 DC-SIGN-monocyte binding via Lewis X
other anti-Lewis X antibody (Fig. 2A). This is in agreement with a study of 
Nakayama et al. [14] who reports that the lower but significant expression 
level of Lewis X on monocytes compared to neutrophils is due to exclusive 
expression of the potent Lewis X-generating enzyme α1,3-fucosyltransferase 
IX in neutrophils. 
This notion was further substantiated by the finding that monocytes after treat-
ment with neuraminidase, to remove terminal sialic residues of various glyco-
molecules, showed a significant increase in Lewis X expression (Fig. 2A). This 
indicates that Lewis X epitopes on monocytes are predominantly masked by 
sialyl groups as also reported by Ohmori et al. [15]. To visualize the distribution 
of Lewis X, transmission electron microscopy (TEM) pictures of monocytes were 
made before and after neuraminidase treatment (Fig. 2B). Before neuraminidase 
treatment, only a few randomly spaced Lewis X epitopes were observed on the 
monocyte membrane. After neuraminidase treatment the distribution, albeit 
still random, showed a significant increase in the number of Lewis X epitopes 
as is also evident from the FACS staining profiles. Interestingly, treatment of 
monocytes with neuraminidase also resulted in an increased specific binding 
to soluble DC-SIGN (Fig. 2C). This increased binding is also observed with 
DC-SIGN beads and is reported by the mean fluorescence intensity (MFI) (Fig. 
2D). The increased MFI demonstrates that per cell more DC-SIGN beads bind 
to neuraminidase-treated monocytes when compared to untreated monocytes. 
The discrepancy between DC-SIGN beads and soluble DC-SIGN in binding to 
monocytes can be explained by the fact that beads of 1 µm in diameter have a 
large interaction surface saturated with numerous DC-SIGN molecules that can 
engage simultaneous interactions with several spatially dispersed unsialylated 
muLtIvALeNt INterACtIoNS eNhANCe BINDING BetweeN DC-SIGN AND moNoCyteS. 
Beads saturated with numerous DC-SIGN molecules that engage simultaneous interactions 
with several individual unsialylated Lewis X molecules. In contrast, when soluble DC-SIGN 
is used, the contact surface and therefore, the number of interacting unsialylated Lewis X 
molecules is much smaller. For that reason, stable interactions only form between soluble 
DC-SIGN and monocytes when the number of unsialylated Lewis X are increased by neur-
aminidase treatment. 
Figure 3
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Lewis X epitopes (Fig. 3). This results in a stable binding to monocytes whereas 
soluble DC-SIGN can not establish a stable binding to monocytes because of 
a smaller contact surface and, therefore, the number of interacting molecules 
remains low. For that reason, only stable interactions between soluble DC-SIGN 
and monocytes are formed when the number of unsialylated Lewis X molecules 
is increased by neuraminidase treatment. 
Discussion
A difference in multivalent presentation of DC-SIGN molecules and its gly-
cosylated ligand is sustained by the glycan array studies of Guo et al. [4] and 
Blixt et al. [16]. In these studies, it was reported that soluble DC-SIGN-Fc is 
less capable of binding a series of natural branched high-mannose N-glycans 
than tetrameric recombinant DC-SIGN. This may be explained by the valency 
of the DC-SIGN molecules (dimeric DC-SIGN-Fc vs tetrameric DC-SIGN) and 
the difference in density of the coated glycans [16]. Also Snyder et al. [6] 
reported that a multivalent presentation of DC-SIGN molecules is important 
for its binding potential. These authors showed that tetrameric DC-SIGN had 
a substantial increased avidity for the HIV-1 envelope glycoprotein gp120 
compared to monomeric DC-SIGN [6]. 
Approximately 40% of the untreated monocytes could bind to the DC-SIGN 
beads. As human blood monocytes consist of a heterogeneous population 
this finding may indicate that DC-SIGN beads bind to a subpopulation of 
monocytes [17]. Obviously, this can be related to expression levels of Lewis 
X. Interestingly, expression of Lewis X seems to be associated with the ac-
tivation status of the monocyte as Lewis X expression is increased by pro-
inflammatory cytokines as well as LPS [18,19]. 
While the physiological significance of DC-SIGN interacting with monocytes 
remains to be determined, it is tempting to speculate that DC-SIGN expressed 
on DC mediates bidirectional cross-talk between DC and monocytes. This may 
for instance result in activation of monocytes upon engagement of Lewis X 
by DC-SIGN like is shown for several Lewis X antibodies [20]. Activated 
monocytes may, in a similar way as described for activated neutrophils [9], 
induce DC maturation via delivery of TNF-α to DC in DC-monocyte contacts. 
Moreover, interactions between DC and monocytes may result in antigen 
transfer as reported for macrophages and DC [21]. Monocytes transfer anti-
gens, taken up in the periphery, to lymph node resident DC that will on their 
turn induce an effective primary immune response against these antigens. 
Interactions between DC and monocytes may occur in inflamed peripheral 
lymph nodes as large numbers of monocytes are recruited to these sites [22]. 
Moreover, interactions between DC and monocytes may occur in peripheral 
tissues once monocytes enter peripheral tissues to differentiate into macro-
phages or DC [23,24]. Possibly, communication with DC in peripheral tissues 
control the differentiation fate of the monocyte in addition to cytokines and 
environmental factors [25]. 
In summary, this study shows that firm interactions between DC-SIGN and 
monocytes can be established by increasing the number of DC-SIGN mo-
lecules or the number of Lewis X epitopes. As expression levels of DC-SIGN 
on DC and Lewis X on monocytes are subject to activation stimuli this may 
have important physiological implications on the innate and adaptive im-
mune system [1,18,19,26]. 
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Abstract 
Background and objectives. DC-SIGN and L-SIGN recognize carbohydrates 
expressed on pathogens and cells. These C-type lectins are expressed on 
dendritic cells (DC) and/or liver sinusoidal endothelial cells (LSEC) which 
can modulate immune responses. In acute lymphoblastic leukaemia (ALL), 
aberrant glycosylation of blast cells may alter their interaction with DC-SIGN 
and L-SIGN and thereby affecting their immunological elimination. 
Design and Methods. Recombinant DC-SIGN and L-SIGN were coated to fluo-
rescent beads and adhesion to blood and bone marrow cells from B- and T-
ALL patients was assessed by flow cytometry. Peripheral blood lymphocytes 
from healthy donors were included as control. 
Results. Overall, increased binding of ALL cells to DC-SIGN and L-SIGN was 
observed compared to cells from healthy donors. L-SIGN bound a higher 
percentage of leukemic and normal cells than DC-SIGN. The highest percent-
age of binding to L-SIGN was found for B-ALL bone marrow cells. DC-SIGN 
bound equally to B-ALL and T-ALL cells. Within ALL subtypes, DC-SIGN 
binding was higher with mature T-ALL. Interestingly, our data demonstrate 
that increased binding of DC-SIGN and L-SIGN to peripheral blood cells from 
B-ALL patients is associated with poor survival. 
Interpretation and Conclusions. These data demonstrate that ALL cells have 
an aberrant glycosylation compared to their normal counterparts. Moreover, 
high binding of B-ALL peripheral blood cells to DC-SIGN and L-SIGN cor-
relates with poor prognosis. Apparently, when B-ALL cells enter the blood 
circulation and are able to interact with DC-SIGN and L-SIGN the immune 
response is shifted towards tolerance. These findings open prospects for DC-
SIGN and L-SIGN as novel prognostic and therapeutic tools in ALL.
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Introduction
Acute lymphoblastic leukaemia (ALL) is an uncontrolled proliferation of lympho-
blasts committed to either the B-cell (B-ALL) or the T-cell (T-ALL) lineage. 
The cells fail to differentiate and accumulate in the haematopoietic tissues 
[1]. In childhood ALL is the most frequent acute leukaemia and children have 
a much better prognosis than adults diagnosed with ALL. This is explained by 
the higher frequency of high-risk ALL with greater drug resistance in adults 
but also due to poorer tolerance of intensive treatment schemes in adults [2]. 
Identification of prognostic factors to stratify into standard-, intermediate-, 
and high-risk forms and adaptation of the chemotherapy regimens has im-
proved the prognosis of ALL in children during the last three decades [3]. Risk 
classification in ALL is based on several factors like age, leukocyte count, 
cytogenetics, and ALL lineage [4,5]. Since a role for aberrant glycosylation 
in cancer is more and more appreciated [6], we hypothesize that the glyco-
sylation status of ALL might be a prognostic factor. 
Glycosylation is frequently altered in tumor cells compared to their normal 
counterparts. This altered glycosylation is usually the result of differences in 
expression levels of glycosyltransferases that catalyze the stepwise synthesis 
of both N- and O-linked oligosaccharides [7,8]. An aberrant glycosylation pat-
tern can be beneficial for the tumor cell because it enables migration and 
metastasis as well as escape from immune surveillance [8]. Glycosylation pat-
terns are recognized by C-type lectins, that bind carbohydrate structures in 
a Ca2+-dependent manner [9]. In the immune system, C-type lectins act as 
adhesion and/or as pathogen recognition receptors [10]. As pathogen recogni-
tion receptor, C-type lectins recognize specific carbohydrate moieties that are 
present on pathogens and play an important role together with other receptors 
in the immune defense against pathogens [11,12]. As adhesion receptors, C-
type lectins mediate interactions between different haematopoietic cells [11]. 
Since the C-type lectin DC-SIGN mediates dendritic cell (DC)-T cell interactions 
by binding to T cells [13], DC-SIGN is a prime candidate to test differential 
binding to peripheral blood lymphocytes (PBL) from healthy donors and their 
malignant counterparts from ALL patients. DC-SIGN is expressed on dendritic 
cells and certain macrophages and besides functioning as adhesion receptor 
it also acts as pathogen recognition receptor by recognizing a variety of mi-
croorganisms [10]. The ligands for DC-SIGN contain high-mannose or fucose 
residues [14]. L-SIGN (CD299) is a close homologue of DC-SIGN that shares 
77% homology in amino acid sequence [15,16]. This C-type lectin is expressed 
on sinusoidal endothelial cells in liver and lymph nodes [16]. Liver sinusoidal 
endothelial cells (LSEC) have been implicated in tolerance induction [17,18]. 
L-SIGN also recognizes high-mannose residues, but it does not have a similar 
fucose-binding specificity [14,19]. The tolerance inducing capacity of the cells 
that express L-SIGN prompted us to study the binding to L-SIGN besides bind-
ing to DC-SIGN. Since binding to DC-SIGN is dependent on the valency of 
the interacting partners [20], beads coated with multiple DC-SIGN and L-SIGN 
molecules were used throughout the study.
This study demonstrates increased binding of recombinant DC-SIGN and L-
SIGN to cells isolated from T- and B-ALL patients when compared to PBL 
from healthy donors. This indicates an altered glycosylation pattern on ALL 
cells exemplified by the increased expression of Lewis X (CD15). In B-ALL 
patients, increased binding of DC-SIGN and L-SIGN to peripheral blood cells 
is correlated with a shorter relapse-free-survival.
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Materials and Methods
Cells
PBL from healthy donors were isolated from buffy coats of volunteers by Ficoll 
density centrifugation. After a 1 h adherence step to plastic the non-adherent 
cells (PBL) were collected. ALL samples were obtained from untreated T- and 
B-lineage ALL patients that were 2 to 64 years of age at the time of diagnosis. 
Diagnosis was based on morphological/cytochemical evaluation according to 
standard French-American-British criteria as well as by immunophenotyping 
using a panel of monoclonal antibodies. Mononuclear cell fractions were isolated 
from peripheral blood (PB) or bone marrow (BM) samples by Ficoll density gra- 
dient centrifugation. The ALL T cell line HSB2 was obtained from ATCC (CCL-
120.1) and cultured in Iscove’s modified Dulbecco’s medium containing 5% FCS.
Recombinant His constructs
Recombinant DC-SIGN- and L-SIGN-His consist of the extracellular domain 
of DC-SIGN or L-SIGN harboring a six-His-tag at the N-terminus. The DNA 
construct of DC-SIGN-His was kindly provided by Dr. Clark [21]. L-SIGN-
Fc construct was kindly provided by Dr. Kretz-Rommel [22]. The following 
primers were used to make the L-SIGN-His construct using the pQE30-vector 
(Qiagen, Chatsworth, CA); BamH1, 5’-acgacgggatcctccaaggtccccagctcc-3’; 
and HinDIII, 5’-acgacgaagcttctattcgtctctgaagcaggctg-3’. Bacterial strain E. 
coli M15(Prep4) was transfected with the DC-SIGN- or L-SIGN-His constructs 
and expression was induced by 0.1 mM IPTG (Sigma, Sigma-Aldrich Chemie 
B.V. Zwijndrecht, the Netherlands). The inclusion bodies were collected and 
the protein was solubilized in 8.5 M Urea and subsequently refolded by step-
wise dialysis against buffers containing decreasing Urea concentrations. The 
protein preparation was incubated with mannan agarose beads (Sigma). Only 
properly refolded and therefore functional protein is able to bind to mannan 
agarose beads. After several washing steps to remove unbound protein the 
functional DC-SIGN and L-SIGN were eluted from the beads by EGTA that 
removes the Ca2+-ion from DC-SIGN and L-SIGN that is essential for proper 
binding. The six-His tagged humanized single chain h5G1.1 antibody was 
used as control and kindly provided by Dr. Kretz-Rommel [23]. 
Coating of fluorescent microspheres with recombinant His 
constructs
Control-His, DC-SIGN–His, and L-SIGN-His were coated onto streptavi-
din coated carboxylate-modified TransFluoSpheres (488/645 nm, 1.0 µm; 
Molecular Probes, Leiden, The Netherlands [24]). First, streptavidin-coated 
beads were incubated with biotinylated horse-anti-mouse IgG (10 µg; Vector, 
Brunschwig Chemie, Amsterdam, the Netherlands) at 37°C for 2 h followed by 
an overnight incubation with mouse-anti-Penta-His (1 µg; Qiagen, Benelux 
B.V., Venlo, The Netherlands) at 4°C. Subsequently, the beads were loaded 
with 250 ng recombinant His constructs at 4°C for two days. 
Fluorescent beads adhesion assay 
The DC-SIGN, L-SIGN and control beads were incubated with 105 cells in binding 
buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2 and 
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0.5% BSA) in a 96-wells V-shaped bottom plate at 37°C for 30 min. Where in-
dicated, the beads were pre-incubated with 100 µg/ml mannan or 5 mM EGTA 
prior to the binding assay at room temperature (RT) for 20 min. After washing, 
binding of the beads to the cells was assessed by flow cytometry. 
 
Characterization of DC-SIGN- and L-SIGN-binding cells by 
flow cytometry
Cells were incubated with DC-SIGN, L-SIGN, or control beads as described 
above. After washing, the cells were labeled for 20 min at RT with combina-
tions of either CD5-PE (clone BL1a; Immunotech, Beckman Coulter B.V., Mij-
drecht, The Netherlands) or CD7-FITC (clone 8H8.1; Beckman Coulter, Beckman 
Coulter B.V., Mijdrecht, The Netherlands) or CD10-FITC (clone ALB1; Beckman 
Coulter), and CD34-PE (clone 581; Beckman Coulter). Samples were analyzed 
by flow cytometry (Cytomics Fc 500, Beckman Coulter, Fullerton, CA). 
FACS staining
ALL cells were labeled for 20 min at RT with either CD15-PE (clone 80H5; 
Immunotech), or CD24-FITC (clone CLB-gran-B-ly/1, 1B5; PeliCluster, San-
quin, Analis SA/N.V., Namen, Belgium), or CD7-FITC (clone 8H8.1; Beckman 
Coulter). Samples were analyzed by flow cytometry. 
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Differences in binding capacity of DC-SIGN  
and L-SIGN to HSB2 and PBL
The large difference in binding capacity of HSB2 and PBL to DC-SIGN and 
L-SIGN beads was the incentive to study the binding capacity of other ALL 
samples. The HSB2 cell line was originally derived from a T-ALL patient, 
whereas PBL comprise mainly T cells (±73%), B cells (±7%) and NK cells 
(±5%) [25]. Both C-type lectins bind over 90% of the HSB2 cells whereas a 
much lower specific binding to PBL was observed (Fig. 1A). Binding to HSB2 
and PBL is blocked by both mannan and EGTA, indicating that the binding is 
C-type lectin dependent. Remarkably, the binding capacity of L-SIGN beads 
to PBL is higher than found for DC-SIGN beads. DC-SIGN beads bind to 1-
15% of PBL from normal donors whereas L-SIGN beads bind 10 to 45% of 
PBL (Fig. 1B). The substantial higher binding of HSB2 cells to both lectins 
indicates aberrant glycosylation of the HSB2 cells when compared to normal 
T cells. 
DIFFereNCeS IN BINDING CApACIty oF DC-SIGN AND L-SIGN to HSB2 AND pBL. 
(A) The binding of HSB2 cells and PBL by DC-SIGN- and L-SIGN-His constructs coated to 
fluorescent beads was determined. A control-His construct was included to determine aspecific 
binding. The cells were incubated for 30 min at 37°C with the His-construct coated beads and 
subsequently analyzed by flow cytometry. Aspecific binding was also determined by pretreat-
ment of the DC-SIGN- and L-SIGN-His constructs with 100 µg/ml mannan or 5 mM EGTA. Data 
are percentages of cells that displayed binding to the DC-SIGN- and L-SIGN-His constructs. (B) 
Overview of specific binding (determined by subtracting background binding obtained in the 
presence of mannan) of PBL isolated from several donors to DC-SIGN- and L-SIGN-His coated 
fluorescent beads. 
Figure 1
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Increased binding of DC-SIGN to ALL cells 
The binding of DC-SIGN beads to patient T-ALL cells was assessed to unravel 
a putative common denominator for ALL cells. If the same glycosylation 
pattern as found for the HSB2 cells is found in all T-ALL cells, the same 
high binding is expected. ALL cells committed to the B cell lineage (B-ALL) 
were taken along. Compared to PBL from healthy donors, an increased bind-
ing was observed for DC-SIGN beads to T-ALL and B-ALL cells (Fig. 2A). 
However, the binding was much lower than was observed for the T-ALL cell 
line HSB2. No significant differences in binding to DC-SIGN were observed 
between T-ALL and B-ALL patient cells. Also, no clear differences were seen 
between the overall binding of PB and BM cells. 
Analysis of PB and BM cells from individual ALL patients resulted in a com-
parable binding to DC-SIGN in about 50% of the patients (Fig. 2B). These 
patients showed a similar percentage of lymphoblasts in their PB and BM 
samples. The other ALL patients showed clear differences in binding to DC-
SIGN and, except for T-ALL patient no.1, is correlated with the difference in 
percentage of blasts between PB and BM samples (Fig. 2B). This indirectly 
indicates that DC-SIGN binds to the leukemic cells. 
The binding results were also analysed according to developmental stage 
of the T- and B ALL cells, since differentiation of leukocytes can affect gly-
cosylation of cell surface proteins [26]. Based on immunophenotyping, the 
T-ALL samples were subdivided into immature T-ALL, common T-ALL, and 
mature T-ALL [1,27]. Mature T-ALL showed an increased binding to DC-SIGN 
in comparison to immature T-ALL and common T-ALL (Fig. 2C, p<0.05). 
B-ALL was subdivided into pro-B-ALL, common B-ALL, and pre-B-ALL [1], 
but no clear differences in binding to DC-SIGN were detected (Fig. 2C).
In conclusion, the increased binding of DC-SIGN to both B- and T-ALL cells 
indicates aberrant glycosylation confined to the leukemic cells and develop-
mental stage in case of T-ALL.
Slightly increased binding of L-SIGN beads to ALL cells
Next, the binding capacity of L-SIGN beads to PB and BM cells from T-ALL 
and B-ALL patients was tested. While mannan and EGTA were both equally 
potent in blocking the binding of DC-SIGN to ALL cells, this was not ob-
served for L-SIGN. In 60% of the cases, EGTA was less potent than mannan 
in blocking the binding of L-SIGN beads to the cells (Fig. 3A). Because of this 
partial blocking of EGTA, mannan was used to determine specific binding 
to L-SIGN in the various ALL patients tested (Fig. 3B). BM, but not PB cells 
from B-ALL patients showed a significantly increased binding to L-SIGN 
beads when compared to PBL from healthy donors. PB and BM cells ob-
tained from T-ALL patients both showed increased binding to L-SIGN beads. 
Similar to PBL from healthy donors, L-SIGN bound a higher percentage of 
ALL cells than DC-SIGN. Comparison of PB and BM cells from individual T-
ALL patients showed differences in binding to L-SIGN despite a similar blast 
percentage (Fig. 3C). In B-ALL patients the differences in binding to L-SIGN 
correlated with percentage of blasts. 
The L-SIGN binding results were also studied for the developmental stages of 
T-ALL and B-ALL. This subdivision did not show a preference of L-SIGN in 
binding to a certain subtype (Fig. 3D).
Thus, L-SIGN showed an increased binding to ALL cells, which was most 
pronounced for BM B-ALL cells. The degree of binding to L-SIGN is not de-
pendent on the developmental stage of the ALL.
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DC-SIGN BINDING to ALL. (A) The binding of DC-SIGN-His coated beads to ALL cells derived 
from peripheral blood (PB) and/or bone marrow (BM) of leukaemia patients was determined. 
PBL from healthy donors was taken along for comparison. The cells were incubated for 30 min 
at 37°C with the DC-SIGN-His coated beads and subsequently analyzed by flow cytometry. 
Aspecific binding was determined by pretreatment of the DC-SIGN-His coated beads with 
100 µg/ml mannan. Data are percentages of cells that displayed specific binding to the DC-
SIGN-His coated beads. 95% Confidence interval of PBL from healthy donors (3-9% specific 
binding) represented by grey area. Significant difference from PBL from healthy donors as 
determined by unpaired one-tailed Student’s t-test: * p<0.05. p = 0.012 from comparison 
of PBL healthy donors and PB T-ALL patients; p = 0.005 from comparison of PBL healthy 
donors and BM T-ALL patients; p = 0.006 from comparison of PBL healthy donors and PB 
B-ALL patients; p = 0.006 from comparison of PBL healthy donors and BM B-ALL patients. 
(B) Analysis of percentage of lymphoblasts in relation to DC-SIGN binding capacity. Percent-
age of lymphoblasts in ALL samples was determined morphologically and is depicted as bars. 
Percentage specific binding to DC-SIGN of the same ALL samples is depicted as connected 
dots. PB and BM cells from the same ALL patient is depicted. (C) Analysis of T- and B-ALL 
subtypes in relation to DC-SIGN binding capacity. The DC-SIGN binding data was categorized 
according to developmental stages of T-ALL; im-T-ALL (immature T-ALL), c-T-ALL (common 
T-ALL), and m-T-ALL (mature T-ALL) and B-ALL; pro-B-ALL, c-ALL (common B-ALL), and pre-
B-ALL. Significant difference from immature T-ALL and common T-ALL according to ANOVA, 
followed by the Student Newman Keuls test: * p<0.05. 
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Characterization of DC-SIGN- and L-SIGN-binding ALL cells 
The percentage of blasts did not correlate with the percentage of binding cells 
(Fig. 2B and Fig. 3C). This indicates heterogeneity in glycosylation within 
the blast fraction. To determine which cell population binds to DC-SIGN and 
L-SIGN beads, triple labeling studies were performed. CD10 and CD34 were 
included to define the leukemic B-ALL population. Strikingly, the percent-
ages of CD10 and CD34 positive and negative cells changed in the presence 
of DC-SIGN and L-SIGN beads when compared to control beads (Fig. 4A). In 
the presence of DC-SIGN and L-SIGN beads, more CD10-CD34- cells were de-
tected whereas less CD10+CD34+ cells were found. This phenomenon is more 
pronounced in the presence of L-SIGN beads, which exhibit a higher binding 
to the cells (48%) than DC-SIGN (28%). Apparently, the beads inhibited the 
antibody binding as the cells are first incubated with the beads and then with 
the antibodies. 
HSB2 cells were used to analyze this phenomenon by changing the sequence 
of incubation with beads and antibodies. To do so, one part of the HSB2 
cells was incubated with DC-SIGN beads and subsequently with antibodies 
directed against CD5 and CD7 (Fig. 4B, manner 1). This incubation sequence 
resulted in 36.1% CD5-CD7- and 3.9% CD5+CD7+ HSB2 cells. Strikingly, with-
out DC-SIGN beads there are no CD5-CD7- HSB2 cells and as much as 42.4% 
CD5+CD7+ HSB2 cells (Fig. 4B). Changing the sequence of incubation by incu-
bating HSB2 cells first with antibodies and then with DC-SIGN beads results 
in the presence of only 4.7% CD5-CD7- cells and 21.2% CD5+CD7+ cells (Fig. 
4B, manner 2). Therefore, this latter sequence of incubation comes closest to 
the CD5/CD7 staining pattern of HSB2 cells without any beads. However, this 
sequence of incubation caused a drastic decrease in binding of DC-SIGN to 
the HSB2 cells from 86% to 49% (Fig. 4B). 
Overall, these data indicate that the beads and antibodies interfere in bind-
ing and therefore the triple labeling method can only be used to identify the 
binding population. 
High CD15 (Lewis X) expression on B-ALL cells coincides 
with high binding to DC-SIGN 
It was described that DC-SIGN can bind to colorectal cancer cells via Lewis 
X (CD15) [28]. This carbohydrate ligand is expressed at higher levels on 
colorectal cancer tissue compared to normal colon tissue. In haematopoietic 
tissues, CD15 expression is not associated with normal lymphoid cells, but 
it can be expressed in ALL [3,29]. Therefore, we correlated CD15 expression 
and binding to DC-SIGN beads on cells from the ALL patients. We used the 
80H5 antibody as this antibody specifically recognizes unsialylated CD15, 
a ligand for DC-SIGN [30,31]. Analysis of CD24 expression on B-ALL cells 
was included as it has been suggested that this molecule might be a ligand 
for DC-SIGN and L-SIGN based on its specific surface glycosylation density 
[20]. Expression of CD15 and CD24 ranged from 0-80% and 4-98% positive 
cells in B-ALL respectively. Large differences were observed between the ex-
pression of these markers by individual patients. ALL cells from one patient 
showed 76.4% CD15+ cells and 24.3% CD24+ cells whereas cells from another 
patient showed 5.6% CD15+ cells and as much as 94.9% CD24+ cells (Fig. 4C). 
A high CD15 expression on B-ALL cells (>10%) coincided with a high bind-
ing to DC-SIGN (>9%), but a substantial number of B-ALL patients with low 
levels of CD15 expression (<10%) also had a high binding to DC-SIGN (Fig. 
4D). This indicates that CD15 might be a ligand in some, but not in all B-ALL 
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L-SIGN BINDING to ALL. (A) Binding of DC-SIGN-, L-SIGN- and control-His coated beads to PB cells isolated from a T-
ALL patient. The cells were incubated for 30 min at 37°C with the His-construct coated beads and subsequently analyzed 
by flow cytometry. Aspecific binding was determined by pretreatment of the DC-SIGN- and L-SIGN-His constructs with 
100 µg/ml mannan or 5 mM EGTA. Data are percentages of cells that displayed binding to the His-construct coated beads. 
(B) Analysis binding L-SIGN-His coated beads to PB and/or BM cells isolated from several ALL patients. PBL from healthy 
donors was taken along for comparison. Aspecific binding was determined by pretreatment of the L-SIGN-His coated beads 
with 100 µg/ml mannan. Data are percentages of cells that displayed specific binding to the L-SIGN-His coated beads. 95% 
Confidence interval of PBL from healthy donors (16-32% specific binding) represented by grey area. Significant difference 
from PBL from healthy donors as determined by unpaired one-tailed Student’s t-test: * p<0.05. p = 0.01 from comparison 
of PBL healthy donors and PB T-ALL patients; p<0.0001 from comparison of PBL healthy donors and BM B-ALL patients. (C) 
Analysis of percentage of lymphoblasts in relation to L-SIGN binding capacity. Percentage of lymphoblasts in ALL samples 
was determined morphologically and is depicted as bars. Percentage specific binding to L-SIGN of the same ALL samples is 
depicted as connected dots. PB and BM cells from the same ALL patient is depicted. (D) Analysis of T- and B-ALL subtypes 
in relation to L-SIGN binding capacity. The L-SIGN binding data was separated according to developmental stages of T-ALL; 
im-T-ALL (immature T-ALL), c-T-ALL (common T-ALL), and m-T-ALL (mature T-ALL) and B-ALL; pro-B-ALL, c-ALL (common 
B-ALL), and pre-B-ALL. 
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patients. No relation was observed for CD24 expression (data not shown). 
On T-ALL cells expression of CD15 was determined in combination with CD7 
as the leukemic marker since CD24 is a marker for B cell lineage [32]. All 
T-ALL cells expressed rather low levels of CD15 (0-7%) (Fig. 4C). The high 
binding to DC-SIGN beads as shown in Fig. 2A indicates the expression of 
other DC-SIGN ligands than CD15 in T-ALL. 
Altogether, these data indicate that CD15 might be a ligand for DC-SIGN in 
some B-ALL patients, but due to negligible CD15 levels in other B- and T-ALL 
patients other ligands will play a role in binding to DC-SIGN. 
High binding to BM cells is related to a better relapse-
free-survival than high binding to PB cells
To investigate the prognostic significance of DC-SIGN and L-SIGN binding to 
ALL, we defined a low and high binding group based on the upper 95% confi-
dence interval of the mean binding of PBL from healthy donors (Fig. 2A, 3B). 
The ‘low’ binding group showed comparable binding as in healthy subjects 
(DC-SIGN less than 9%, L-SIGN less than 32%) while the ‘high’ binding group 
showed significant higher binding (DC-SIGN beyond 9%, L-SIGN beyond 
32%). Further subdivision into PB and BM cells resulted in the following four 
groups: Low PB, low BM, high PB and high BM. In B-ALL, the high PB group 
showed the shortest relapse-free-survival, significantly different from the 
high BM group for both DC-SIGN and L-SIGN (Fig. 5A). In T-ALL, the high 
PB group for DC-SIGN also showed a shorter relapse-free-survival although 
not significantly different from any of the other groups (Fig. 5B). For L-SIGN 
the low PB T-ALL binders showed the shortest relapse-free-survival, but is 
not significantly different from any of the other groups (Fig. 5A). 
The four groups are heterogeneous with regard to gender, age, leukocyte 
count and cytogenetic background indicating aberrant glycosylation is not 
directly related to one of these prognostic markers (table 1 and 2) [4,5]. 
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CHArACterIzAtIoN oF DC-SIGN- AND L-SIGN-BINDING ALL CeLLS. (A) CD10-FITC/CD34-PE dot plots of BM cells 
from a B-ALL patient binding to control-, DC-SIGN-, or L-SIGN-His coated beads. ALL cells were first incubated with the 
His-construct coated beads for 30 min at 37°C. Subsequently, the cells were labelled with CD10-FITC and CD34-PE for 20 
min at RT and finally analysed by flow cytometry. Percentage of binding cells to the beads is depicted above the dot plots. 
Insets represent percentage positive cells for each quadrant. (B) HSB2 cells were incubated with DC-SIGN- and L-SIGN-His 
coated beads and antibodies in two different orders of sequence. In the first way (1), HSB2 were incubated with DC-SIGN- 
and L-SIGN-His coated beads for 30 min at 37°C and afterwards incubated with CD5-PE and CD7-FITC for 20 min at RT. 
In the second way (2), HSB2 cells were first incubated with CD5-PE and CD7-FITC for 20 min at RT and then with DC-
SIGN- and L-SIGN-His coated beads for 30 min at 37°C. Finally, samples were analysed by flow cytometry. Percentage of 
binding cells to the beads is depicted above the dot plots. Insets represent percentage positive cells for each quadrant. (C) 
Expression profiles of CD15 and CD24 on B-ALL cells and CD15 and CD7 on T-ALL cells. Cells from several ALL patients were 
labelled with combinations of CD15-PE and CD24-FITC or CD15-PE and CD7-FITC for 20 min at RT. Samples were analysed 
by flow cytometry. Percentage of binding cells to the beads is depicted above the dot plots. Insets represent percentage 
positive cells for each quadrant. (D) Analysis of CD15 expression on B-ALL cells in relation to DC-SIGN binding capacity. 
Percentage of CD15 positive cells on B-ALL cells as determined by 80H5 antibody was plotted against specific binding to 
DC-SIGN beads (determined with mannan). 
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HIGH BINDING to B-ALL pB CeLLS IS CorreLAteD wItH poor DISeASe outCome. 
Analysis of relapse-free-survival of B-ALL (A) and T-ALL (B) patients with regard to DC-SIGN 
and L-SIGN binding capacity. Binding data were categorized into Low (DC-SIGN <9%, L-SIGN 
<32%) and High (DC-SIGN >9%, L-SIGN >32%) PB and BM binding groups based on the up-
per 95% confidence interval of the mean binding of PBL from healthy donors (Fig. 2A-3B). 
Kaplan-Meier curves were made by SPSS software. Significant different from high BM group 
as determined by log-rank test: * p=0.0316 (DC-SIGN), * p=0.0284 (L-SIGN). 
Figure 5
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CHArACterIStICS oF B-ALL StuDy popuLAtIoN. Characteristics of the B-ALL patients 
tested in this study. (Cyto)genetic data were obtained by routine cytogenetics and interphase 
FISH. Data were categorized according to presence of 0 deviations (Normal), 1-2 deviations, 
more than 2 deviations (Complex), more than 46 chromosomes per cell (Hyperdiploid), break-
point cluster region-Abelson translocation (BCR-ABL1), mixed-lineage-leukaemia translocation 
(MLL), and ETS variant gene 6-runt related transcription factor 1 (ETV6-RUNX1). RFS: relapse-
free-survival; CR: complete remission; D: dead; F: female; M: male; NA: not available.
table 1
CHArACterIStICS oF t-ALL StuDy popuLAtIoN. Characteristics of the T-ALL patients 
tested in this study. Cytogenetic data were categorized according to presence of 0 deviations 
(Normal), 1-2 deviations, more than 2 deviations (Complex), more than 46 chromosomes 
per cell (Hyperdiploid), and mixed-lineage-leukaemia translocation (MLL). RFS: relapse-free- 
survival; CR: complete remission; D: dead; F: female; M: male; NA: not available.
table 2
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Discussion
In this study the binding capacity of recombinant DC-SIGN and L-SIGN to 
cells from ALL patients was analyzed. Most ALL cells showed an increased 
binding to these two C–type lectins when compared to PBL from healthy 
donors. This indicates that ALL cells have an altered glycosylation pattern 
resulting in increased expression of DC-SIGN and L-SIGN ligands. Overall, T-
ALL and B-ALL cells showed no difference in DC-SIGN binding. PB and BM 
cells from the same ALL patients demonstrated a similar binding. In contrast, 
L-SIGN showed a higher binding to BM cells isolated from B-ALL patients 
than leukemic cells collected from peripheral blood. The lower binding of 
L-SIGN by PB cells from B-ALL patients might be explained by a lower per-
centage of blasts as depicted in Fig. 3C patient 4 and table 1. The difference 
between B-ALL and T-ALL patients in binding to L-SIGN implies an increased 
expression of L-SIGN ligands on B-ALL cells.
Comparison of PB and BM from an individual ALL patient showed similar 
binding to DC-SIGN or L-SIGN when corrected for the percentage of blast 
cells (Fig. 2B, 3C). However, in some ALL patients (especially T-ALL) this was 
not found suggesting heterogeneity in the levels of aberrant glycosylation. 
Possibly, the location (BM vs. blood) plays a role in the degree of aberrant 
glycosylation [33].
Separation of T- and B-ALL into subtypes according to chronological develop-
ment did not reveal a significant distinction in binding to DC-SIGN and 
L-SIGN beads except for mature T-ALL. This subgroup showed an increased 
binding to DC-SIGN and also slightly to L-SIGN when compared to immature 
and common T-ALL. The high binding might be caused by a higher extend of 
specific glycosylation in this subtype. 
Due to sterical hindrance, the binding populations could not be identified 
unambiguously. Besides sterical hindrance, possibly some quenching of the 
antibodies does take place since incubating first with antibodies and then 
with beads still showed some CD5-CD7- HSB2 cells. 
The higher binding capacity of L-SIGN compared with DC-SIGN in ALL cells 
and PBL from healthy donors suggests the presence of additional ligands 
for L-SIGN. This is unexpected as previous studies indicate DC-SIGN has a 
broader binding specificity than L-SIGN like CD15 that might be a DC-SIGN 
ligand in some B-ALL patients [14,19]. The poor blocking potential of EGTA 
to abrogate binding of L-SIGN to several ALL samples and less frequently 
also to PBL indicates that part of the binding is Ca2+-independent. This is 
quite unusual for a C-type lectin [9]. Interestingly, the C-type lectin Dectin-1 
recognizes an as yet unidentified ligand on D10 T cells in an unconventional 
C-type lectin way as well [34]. To examine this in more detail, future studies 
are required to identify the ligands for both DC-SIGN and L-SIGN expressed 
on the ALL cells. 
The physiological significance of DC-SIGN and L-SIGN interacting with ALL 
cells remains to be determined, but the poorer survival with increased bind-
ing to B-ALL PB cells suggests immune escape of the ALL cells. Escape from 
immune surveillance is not uncommon to ALL and although several factors 
are suggested to play a role like T cell defects, lack of costimulation, and 
immunosuppressive cytokines the mechanism is still unknown [35,36]. We 
suggest that once the leukemic cells enter the blood circulation, and are then 
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considered to be PB cells, they can interact with DC-SIGN and L-SIGN posi-
tive cells. These cells include DC on which DC-SIGN is expressed and are fre-
quently postulated in immune escape of tumor cells [28,37,38]. DC can induce 
tolerance in a steady-state situation when no other antigen-sensing receptors 
like Toll-like receptors are triggered [39]. This is an important mechanism to 
prevent damage against endogenous tissues but for tumor cells this can be 
a way to escape from immune surveillance. Furthermore, interaction of ALL 
cells with DC-SIGN on DC may change the direction of the immune response 
like the pathogens Mycobacterium tuberculosis and Helicobacter pylori do by 
binding to DC-SIGN [40,41]. In this way those pathogens and possibly also 
leukemic cells can escape the immune system. Additionally, LSEC express 
both DC-SIGN and L-SIGN and can induce T cell tolerance [17,42]. This to-
lerance induction is beneficial for innocuous antigens in the circulation, but 
harmful when altered cells like ALL are tolerized. Future studies are necessary 
to test these concepts and may provide new therapeutic tools to treat ALL. 
Moreover, the degree of binding of DC-SIGN- and L-SIGN-beads to B-ALL 
PB cells may be a useful prognostic tool if tested in larger series of patients 
since the clinical significance within this small group of patients has to be 
interpreted with caution.
For T-ALL no significant differences could be detected in the survival analy-
sis (Fig. 5B). However like B-ALL, the high binding PB group to DC-SIGN also 
has a relatively poor survival in comparison to the other groups. This may 
suggest similar immune escape mechanisms. With L-SIGN however, the low 
PB T-ALL group has a lower survival than the high PB T-ALL group which 
indicates that survival of T-ALL is not dependent on binding to L-SIGN posi-
tive cells.
In conclusion, this study demonstrates a generally increased binding of ALL 
cells to DC-SIGN and L-SIGN indicating aberrant glycosylation on these leu-
kemic cells. Increased binding to PB cells from B-ALL patients is associated 
with a poor survival and therefore seems to be beneficial for the leukemic 
cells. This may involve a tolerating mechanism by interacting with DC-SIGN 
and L-SIGN positive cells. 
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Abstract
Current dendritic cell (DC)-based vaccines are based on ex vivo generated 
autologous DC loaded with antigen prior to readministration into patients. A 
more direct and less laborious strategy is to target antigens to DC in vivo via 
specific surface receptors. Therefore, we developed a humanized antibody, 
hD1V1G2/G4 (hD1), directed against the C-type lectin DC-SIGN, to explore 
its capacity to serve as a target receptor for vaccination purposes. hD1 was 
cross-linked to a model antigen, keyhole limpet hemocyanin (KLH). We ob-
served that the chimeric antibody-protein complex (hD1-KLH) bound specifi-
cally to DC-SIGN, was rapidly internalized and translocated to the lysosomal 
compartment. To determine the targeting efficiency of hD1-KLH, monocyte-
derived DC and peripheral blood lymphocytes (PBL) were obtained from pa-
tients who had previously been vaccinated with KLH-pulsed DC. Autologous 
DC pulsed with hD1-KLH induced proliferation of patient PBL at a 100-fold 
lower concentration than KLH-pulsed DC. In addition, hD1-KLH-targeted DC 
induced proliferation of naïve T cells recognizing KLH epitopes in the con-
text of MHC class I and II. We conclude that antibody-mediated targeting 
of antigen to DC via DC-SIGN effectively induces antigen-specific naïve- as 
well as recall T cell responses. This identifies DC-SIGN as a promising target 
molecule for DC-based vaccination strategies.
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Introduction
Dendritic cells (DC) are professional antigen-presenting cells (APCs) that play 
a key role in regulating antigen-specific immunity. DC capture antigens, pro-
cess them into peptides and present these to T cells [1]. The interaction be-
tween DC and T cell controls the type and magnitude of the resulting immune 
response. Recently, preclinical and clinical studies have exploited DC in an 
attempt to improve vaccine efficacy [2]. Most of these studies involve ex vivo 
antigen loading of autologous monocyte-derived DC that are re-adminis-
trated to the patient, a laborious and costly procedure. A more direct strategy 
involves targeting of antigens specifically to antigen uptake receptors on the 
DC in vivo. Potential candidate receptors highly expressed by DC include Fc 
receptors [3-5] and members of the C-type lectin family [6,7]. Whereas Fc 
receptors are expressed by many different cell types, the expression of some 
members of the C-type lectin family are more DC-restricted [8]. 
C-type lectins bind sugar residues in a calcium-dependent manner via a 
highly conserved carbohydrate recognition domain. C-type lectin receptors 
expressed by DC are implicated in immunoregulatory processes, such as an-
tigen capture, DC trafficking and DC-T cell interactions [9]. Based on the 
location of the amino (N) terminus, two types of membrane-bound C-type 
lectins can be distinguished on DC. Type I C-type lectins have their N termi-
nus located outside, while type II C-type lectins have their N terminus located 
inside the cell. Several studies have been conducted on antigen targeting to 
C-type lectin receptors for vaccination purposes, mainly focusing on the type 
I C-type lectins mannose receptor (MR) [10] and DEC-205 [11-13]. Vaccines 
based on natural MR ligands have been shown to effectively induce humoral 
and cellular responses [14]. However, these ligands lack specificity for the 
MR, and may target multiple lectins with overlapping binding specificities, 
including soluble lectins and lectin receptors expressed by cells that are not 
specialized in antigen presentation. More specific receptor targeting can be 
obtained by the use of antibodies directed against specific C-type lectins, a 
strategy that has been successfully applied in MR [15,16] and DEC-205 [17-
19] targeting studies. Antibody-mediated targeting of antigen to the MR on 
human DC results in antigen presentation and activation of naïve T cells in 
vitro [20,21]. Moreover, in vivo studies on antibody-mediated targeting of 
DEC-205 in mice demonstrate presentation of the antigen to naïve CD4+ and 
CD8+ T cells [22,23]. 
DC-specific ICAM-3 grabbing non-integrin (DC-SIGN) represents a member 
of the type II C-type lectin family. We have previously demonstrated that 
DC-SIGN is an endocytic receptor mediating antigen presentation [24]. A 
major advantage of targeting DC-SIGN over other C-type lectin receptors is 
its expression pattern. In humans, DC-SIGN expression is restricted to profes-
sional APCs and expression levels are high. Human DC-SIGN is abundantly 
expressed by DC residing in lymphoid tissues and at mucosal surfaces, dermal 
DC, and by specialized macrophages in placenta and lung [25,26].
Targeting constructs that are to be used in humans should consist of an-
tibodies that do not elicit immune responses directed against the antibody 
itself. Recent developments in antibody engineering provide the tools for the 
production of either humanized or human antibodies [27]. Undesired interac-
tions between the targeting antibody and Fc receptors can be avoided by use 
of single chain Fv constructs or composite IgG molecules [28], thus enhanc-
ing targeting specificity. 
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Here we evaluate the effectiveness of targeting antigen to human DC via 
DC-SIGN. For targeting purposes, keyhole limpet hemocyanin (KLH), a large 
globular protein containing a large array of immunogenic epitopes, was cho-
sen as a model antigen. KLH is widely used in clinical DC-based vaccination 
trials for immunomonitoring purposes, and is thought to stimulate cytotoxic 
T cell responses by recruiting bystander T cell help [29]. KLH was chemically 
cross-linked to a humanized anti-DC-SIGN IgG2/IgG4 composite antibody 
(hD1), resulting in the chimeric hD1-KLH protein. The results demonstrate 
that hD1-KLH was capable of inducing T cell responses at a 100-fold lower 
concentration than KLH alone.
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Materials and Methods
Antibodies and reagents
The following antibodies were used: AZN-D1 (IgG1, mouse anti-human DC-
SIGN) [30], AZN-L19 (IgG1, mouse anti-human CD18) [31], W6/32 (IgG2a, 
mouse anti HLA-A, -B, -C; ATCC, Manassas, VA), IVA-12 (IgG1, mouse anti 
HLA-DR, -DP, -DQ; ATCC), mouse IgG1 isotype (R&D systems, Abingdon, 
UK), total mouse IgG (Jackson ImmunoResearch; Brunschwig Chemie B.V., 
Amsterdam, The Netherlands), Alexa Fluor 647-labeled goat anti-human 
IgG (Molecular Probes, Leiden, The Netherlands) and Alexa Fluor 647-la-
beled goat anti-mouse IgG1 (Molecular Probes). Endotoxin-free KLH was 
purchased from Calbiochem (La Jolla, CA). 
Recombinant antibodies
The humanized anti-human DC-SIGN antibody hD1V1G2/G4 (hD1) was 
generated by complementarity determining region (CDR)-grafting of AZN-
D1 hypervariable domains into human framework regions. The humanized 
variable heavy and variable light regions were then genetically fused with 
a human hybrid IgG2/IgG4 constant domain [32] and a human kappa chain 
constant domain, respectively. This construct was cloned into a mammalian 
expression vector and the final construct transfected into NSO cells. Stable 
transfectants were obtained using glutamate synthetase (GS) selection 
(Lonza Biologics, Portsmouth, NH). Supernatants containing hD1 were pu-
rified over a Protein A column. An isotype control antibody, h5G1.1-mAb 
(5G1.1; Eculizamab; Alexion Pharmaceuticals, Inc.) containing the same 
IgG2/IgG4 constant region, is specific for the human terminal complement 
protein C5 [33].
Generation of hD1-KLH
The chemical cross-linker sulfosuccinimidyl 4-(N-maleimidomethyl)-
cyclohexane-1-carboxylate (sSMCC; Pierce, Rockford, IL) was conjugated 
to KLH according to the manufacturer’s protocol. Protected sulfhydryl 
groups were introduced to the hD1 antibody with N-succinimidyl-S-
acetylthiopropionate (SATP; Pierce), and were reduced with hydroxyl-
amine hydrochloride (Pierce) using the manufacturer’s protocol. Subse-
quently, hD1 was added to sSMCC-treated KLH in phosphate buffered 
saline (pH 7.4) and allowed to react for 16 h at 4ºC. Unbound sites were 
alkylated by adding iodoacetamide (Sigma-Aldrich, St. Louis, MO) to a 
final concentration of 25 mM, followed by 30 min incubation at room 
temperature. The protein mixture was loaded onto a Superose 6 column 
(24 ml bed volume; Amersham Pharmacia Biotech, Uppsala, Sweden), and 
fractions were collected and analyzed by SDS-PAGE. Fractions containing 
hD1-KLH were pooled and fractions containing free hD1 were discarded. 
The efficiency of the cross-linking reaction was estimated by compar-
ing the amount of hD1 relative to KLH before the reaction to the hD1 to 
hD1-KLH ratio after cross-linking. We calculated that, on average, each 
KLH molecule had reacted with 10 hD1 molecules (data not shown). Endo-
toxin levels of the pooled hD1-KLH fractions were below detection levels 
(< 0.04 pg/µg protein) in the QCL-1000 Limulus amebocyte lysate assay 
(BioWhittaker, Walkersville, MD).
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Monocyte-derived DC and PBL
Peripheral blood mononuclear cells (PBMC) were obtained from buffy coats 
of healthy individuals and were purified using Ficoll density centrifugation. 
PBL and immature DC (iDC) were obtained from PBMC as reported elsewhere 
[34]. In brief, PBMC were allowed to adhere for 1 h at 37ºC. Non-adherent 
cells (PBL) were gently removed, washed and cryopreserved. The adherent 
monocytes were cultured in the presence of IL-4 and GM-CSF (500 and 800 
U/ml, respectively; Schering-Plough International, Kenilworth, NJ) for 6 days 
to obtain immature DC. Mature DC (mDC) were obtained by culturing iDC in 
the presence of 2 µg/ml lipopolysaccharide (LPS) for 24h. DC were cryopre-
served until use. Unless indicated otherwise, cells were cultured in X-VIVO 15 
medium (Cambrex, Verviers, Belgium) supplemented with 2% human serum.
Tritiated thymidine incorporation assays
Tritriated thymidine (1 µCi [0.037 Mbq]/well; MP Biomedicals, Amsterdam, 
The Netherlands) was added to the cell cultures. Tritiated thymidine incor-
poration was measured after 16 h in a ß-scintillation counter. Proliferation 
indices higher than 2 were considered positive.
Clinical vaccination protocol
PBL and monocyte-derived DC were isolated from melanoma patients par-
ticipating in a clinical vaccination trial, as described by de Vries et al. [35]. 
Patients were determined to have stage IV disease according to the American 
Joint Committee on Cancer (AJCC) criteria [36]. The study was approved by the 
institutional review board (Radboud University Nijmegen Medical Centre, Com-
missie Mensgebonden Onderzoek). Informed consent was provided according 
to the Declaration of Helsinki. The vaccination protocol consisted of two parts. 
In the first part, antigen-pulsed mDC were administered intravenously and in-
tradermally, 3 times at bi-weekly intervals. In the second part, patients received 
3 monthly intradermal vaccinations with peptides alone (100 µg) and KLH (2 
µg). Patients who remained free of disease progression after the first vaccina-
tion cycle were eligible for maintenance cycles at six-month intervals, each 
consisting of 3 bi-weekly intranodal vaccinations in a clinically tumor-free, 
lymph node region under ultrasound guidance with mDC alternately pulsed 
with wild type or modified gp100 peptides [37], tyrosinase peptides and KLH. 
Clinical grade DC for vaccination purposes were generated from peripheral 
blood mononuclear cells (PBMC) as described previously [38]. 
Humoral responses to KLH
Humoral responses to KLH were determined by enzyme-linked immunosor-
bent assays (ELISA) as described by Holtl et al. [39]. Briefly, 96-well plates 
were coated overnight at 4ºC with the protein KLH (25 µg/ml) in phosphate-
buffered saline (PBS; 0.1 ml/well). Subsequently, plates were incubated with 
serial dilutions of patient serum, obtained before and during the third main-
tenance cycle, for 1 h at room temperature. After extensive washing, human 
IgG-specific antibody labeled with horseradish peroxidase was allowed to 
bind for 1 h at room temperature. Peroxidase activity was revealed using 3,3’ 
5,5’ tetramethyl-benzidine as substrate and measured in a microtiter plate 
reader at 450 nm. A signal detected at ≥ 1:400 dilution of serum was con-
sidered positive.
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Cellular responses to KLH
Cryopreserved PBMC, isolated from peripheral blood samples taken from the 
patients, were thawed, washed and plated at 1x105 PBMC per well of a 96-
well tissue culture microplate either in the presence or absence of 10 µg/ml 
KLH. After 4 days of culture, a tritiated thymidine incorporation assay was 
performed.
Binding and internalization assays
Binding of hD1 and hD1-KLH to iDC was assessed by immunofluorescence 
and flow cytometry. iDC were incubated with or without 10 µg/ml of hD1 or 
hD1-KLH. In some experiments, DC-SIGN was blocked by pretreating iDC 
with 100 µg/ml AZN-D1. After a 1 h incubation at 4ºC, cells were washed 
and incubated with Alexa Fluor 647-labeled anti-human IgG antibody. Cells 
were analyzed on a FACScalibur flow cytometer using CellQuest software (BD 
Biosciences, San Jose, CA). 
 Internalization of hD1 by iDC was determined by flow cytometry as described 
previously [40]. Briefly, iDC were incubated with 10 µg/ml hD1, AZN-D1, 
AZN-L19 or mouse IgG1 and 5G1.1 isotype control antibodies at 4 ºC for 30 
min, washed, and incubated for 0, 15, 30 or 45 min at 37ºC. Subsequently, 
some of the cells were fixed, while others were fixed and permeabilized in 
PBS/0.1% (vol/wt) saponin (Sigma-Aldrich) before addition of the Alexa Flu-
or 647-labeled anti-human IgG secondary antibody. The amount of interna-
lized antibody was calculated by subtracting the mean fluorescence in fixed 
cells (surface-bound) from that recorded with fixed and permeabilized cells 
(internalized and surface-bound) at the various time points.
 Internalization of hD1 and hD1-KLH was confirmed by confocal laser scan-
ning microscopy (CLSM). iDC were incubated with 10 µg/ml hD1, hD1-KLH, 
AZN-D1 or isotype control 5G1.1 and mouse IgG1 antibodies for 1 h at 37ºC. 
Cells were fixed on poly-L-lysine coated glass slides, followed by intracellular 
staining with Alexa Fluor 647-labeled secondary antibodies. Cells were 
imaged with a Bio-Rad MRC 1024 confocal system operating on a Nikon 
Optiphot microscope and a Nikon 60x planApo 1.4 oil immersion lens 
(BioRad, Hercules, CA). Pictures were analyzed with Bio-Rad Lasersharp 2000 
and Adobe Photoshop 7.0 (Adobe Systems, Mountain View, CA) software.
KLH binding and internalization by iDC was assessed by direct labeling of 
KLH using the Alexa Fluor 488 labeling kit (Molecular Probes). iDC were in-
cubated with 10 µg/ml labeled KLH for 1 h at either 4 or 37ºC. Subsequently, 
cells were washed and analyzed by flow cytometry. 
Live imaging of hD1-KLH and KLH uptake by iDC
iDC were labeled with LysoTracker Red (Molecular Probes) in PBS for 10 
min at room temperature. Subsequently, cells were transferred to RPMI 1640 
without phenol red (Gibco; Life Technologies, Breda, The Netherlands) sup-
plemented with 1% human serum. Labeled cells were analyzed at 37ºC with a 
Zeiss LSM 510 microscope equipped with a type S heated stage CO2 controller 
and PlanApochromatic 63x 1.4 oil immersion DIC lens (Carl Zeiss GmbH, 
Jena, Germany). KLH and hD1-KLH, directly labeled with the Alexa Fluor 488 
labeling kit (Molecular Probes), were added to the medium at 10 µg/ml. Cells 
were imaged using Zeiss LSM Image Browser version 3.2 (Carl Zeiss) and 
processed with Image J version 1.32j software (National Institutes of Health, 
http://rsb.info.nih.gov/ij).
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Targeting experiments
iDC were incubated with hD1, hD1-KLH or KLH for 1 h at 4 or 37ºC. Where 
indicated, iDC were matured with LPS. Subsequently, DC were washed and 
cocultured with KLH-responsive PBL (ratio 1:10) at 37ºC. In some experi-
ments, iDC were matured with LPS before addition of PBL. After 16 h of 
coculture, IL-2, IL-4, IL-5, IL-10, TNF-α, and IFN-γ were measured by 
cytometric bead array (CBA) (Th1/Th2 Cytokine CBA 1; BD Pharmingen, 
San Diego, CA) according to the manufacturer’s instructions. After 4 days of 
coculture, a tritiated thymidine incorporation assay was performed.
 
Presentation of KLH epitopes over time
iDC were incubated with 5 µg/ml KLH or 5 µg/ml hD1-KLH for 1 h at 37ºC. 
Following washing, KLH-responsive PBL were added to the iDC either on the 
same day, or 2 or 4 days later. Four days after addition of the PBL, prolifera-
tive responses were determined in a tritiated thymidine incorporation assay. 
Activation and expansion of naïve T cells
Experiments were performed essentially as described previously [41]. Briefly, 
PBL from a healthy donor were used as a source of T cells. Autologous DC 
were incubated with 10 µg/ml hD1-KLH for 1 h at 37ºC, washed, and ma-
tured. Targeted mDC were incubated with PBL (ratio 1:10) in the presence 
of IL-7 (10 ng/ml, day 0), followed by addition of IL-10 (10 ng/ml) on day 1 
and IL-2 (20 U/ml) on day 2. IL-2 was added to the culture every 3 to 4 days. 
PBL were restimulated each week. Restimulations were performed with iDC 
treated with 5 µg/ml hD1-KLH after 1 week, and with iDC treated with 2.5 
µg/ml hD1-KLH after 2, 3 and 4 weeks. Finally, PBL were harvested and co-
cultured with autologous mDC that had been pulsed with KLH, as described in 
“Targeting experiments”. Proliferative responses were determined by tritiated 
thymidine incorporation assays.
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Humanized anti-DC-SIGN antibody hD1  
is internalized by iDC
The CDRs of the mouse anti-human DC-SIGN antibody AZN-D1 were grafted 
onto a human IgG2/IgG4 composite antibody to generate a humanized anti-
body for DC-SIGN targeting, hD1. We have previously shown that the human 
hybrid IgG2/IgG4 constant domain prevents antibodies from binding to Fc 
receptors [42]. The binding affinity of hD1 for DC-SIGN was similar to that 
of AZN-D1 as determined by surface plasmon resonance (3.7 ± 0.7 and 3.8 ± 
1.1, respectively, data not shown).
Flow cytometric analysis revealed specific binding of hD1 to DC-SIGN on iDC, 
as preincubation of iDC with AZN-D1 efficiently reduced binding (Fig. 1A). 
Furthermore, hD1 bound to DC-SIGN expressing K562 cells after transfection 
with DC-SIGN cDNA, whereas it did not bind to untransfected K562 cells 
BINDING oF hD1 To DC-SIGN AND INTerNAlIzATIoN By DC. (A) iDC were treated with 
10 µg/ml hD1 (gray shaded curve), 100 µg/ml AZN-D1 (open dotted curve), or pretreated 
with 100 µg/ml AZN-D1 followed by 10 µg/ml hD1 incubation (open solid curve), followed by 
incubation with an Alexa Fluor 647-labeled goat anti-human IgG antibody. Binding of hD1 was 
analyzed by flow cytometry. (B) iDC were incubated with AZN-D1 (•), hD1 (ο) or AZN-L19 (£) 
at 4ºC for 1 h, and transferred to 37ºC. Cells were fixed at various time points, and stained 
with an Alexa Fluor-labeled secondary antibodies with or without prior permeabilization. The 
mean fluorescence was determined by flow cytometric analysis and the amount of interna-
lized antibody was plotted as a percentage of the amount of total cell-associated antibody. 
Data represent experiments performed in triplicate ± SD. (C) Internalization of hD1 was con-
firmed by CLSM. iDC were incubated with hD1, AZN-D1, or their isotype controls 5G1.1 and 
mouse IgG1 (mIgG) for 1 h at 37ºC. Cells were stained with Alexa Fluor 647-labeled secondary 
antibodies (blue), followed by microscopic analysis. The image represents the middle focal 
plane of the DC, with iris set at 2 nm. Original magnification, × 600.
Figure 1
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BINDING AND upTAke oF hD1-klh By DC. (A) iDC were treated with 10 µg/ml hD1-KLH, 
100 µg/ml AZN-D1, or pretreated with 100 µg/ml AZN-D1 followed by 10 µg/ml hD1 incuba-
tion, followed by incubation with an Alexa Fluor 647-labeled goat anti-human IgG antibody. 
Binding of hD1-KLH was analyzed by flow cytometry. (B) Internalization of hD1-KLH was 
confirmed by CLSM. iDC were incubated with Alexa Fluor 647-labeled hD1-KLH (blue) for 1 h 
at 37ºC, followed by microscopic analysis. The image represents the middle focal plane of the 
DC, with iris set at 2 nm. Original magnification, × 600. (C) iDC were incubated with Alexa 
Fluor 488-labeled KLH for 1 h at 4ºC or 37ºC. Subsequently, cells were fixed and analyzed by 
flow cytometric analysis. (D) iDC were labeled with LysoTracker Red, followed by addition of 
Alexa Fluor 488-labeled (green) hD1-KLH or KLH. Cells were imaged by CLSM. Data represent 
bright field and corresponding fluorescent images of cells at various time points after addition 
of hD1-KLH or KLH to the culture medium. Original magnification, × 630.
Figure 2
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(data not shown). A time-course internalization experiment revealed that 
both the hD1 and the AZN-D1 antibodies were rapidly internalized by iDC, 
although the AZN-D1 antibody was internalized slightly more efficiently 
than hD1. As expected, the control AZN-L19 antibody, directed against 
CD18, was not internalized (Fig. 1B). Analysis by confocal microscopy con-
firmed internalization of the hD1 and AZN-D1 antibodies by iDC, whereas 
the control antibodies 5G1.1, directed against human terminal complement 
protein C5, and mouse IgG1 isotype were not internalized (Fig. 1C). 
hD1-KLH is rapidly internalized and translocated to the 
lysosomal compartment
To further explore the potential of DC-SIGN as a targeting receptor for DC 
vaccination, we studied the uptake of KLH complexed to the humanized 
anti-DC-SIGN antibody hD1. As was observed with the hD1 antibody, hD1-
KLH bound to iDC (Fig. 2A). hD1-KLH binding to DC is mediated by DC-
SIGN, as binding could be blocked by pretreating iDC with AZN-D1 (Fig. 
2A). Analysis by CLSM revealed that hD1-KLH was rapidly internalized by 
iDC (Fig. 2B). After 1 h of incubation at 37ºC, hD1-KLH could be detected in 
74% of the iDC (data not shown). In contrast to hD1-KLH, KLH itself did not 
bind to iDC, but was internalized by iDC following 1 h incubation at 37ºC 
(Fig. 2C). These findings demonstrate that internalization of KLH by DC is 
not receptor-mediated, and likely depends on macropinocytosis. 
Foreign antigens are taken up by DC and shuttled, via endosomes, to the 
lysosomal compartment where they can be processed. In order to establish 
whether hD1-KLH reaches the lysosomal compartment, and to study uptake-
kinetics and routing of KLH and D1-KLH, these proteins were directly 
labeled with Alexa Fluor 488 dye. Live imaging by CLSM revealed rapid 
uptake of hD1-KLH and KLH by iDC. Both hD1-KLH and KLH were detected 
in the lysosomal compartment within 1 h after their addition to the culture 
medium (Fig. 2D; Supplemental Videos S1 and S2; see the Supplemental 
Videos link at the top of the online article, at the Blood website). 
Induction of KLH responses by DC vaccination
In order to compare the antigen presentation capacity of DC pulsed with 
KLH to that of DC targeted by hD1-KLH, we required KLH-specific T cells. 
To this end, PBL were isolated from melanoma patients participating in a 
vaccination study. This study involved vaccination of patients with au-
tologous DC pulsed ex vivo with KLH and melanoma-associated antigens. 
Monocyte-derived DC and PBL from patients showing humoral as well as 
cellular responses against KLH were used for the targeting studies.
All 31 vaccinated patients participating in the clinical vaccination trial 
showed responses against KLH (data not shown). Humoral responses were 
readily detected in the patients’ serum. KLH-specific IgGs were present af-
ter the first vaccination cycle, and their serum levels increased upon the 
second vaccination (Fig. 3A). Cellular responses were analyzed using PBMC 
obtained from patients one week before the start of the third vaccination 
cycle. Typically, PBMC pulsed with KLH showed an increased proliferative 
response compared to unpulsed PBMC, revealing the presence of KLH- 
reactive T cells in peripheral blood (Fig. 3B). These findings show that KLH-
pulsed mDC effectively induced both humoral and cellular responses in 
vivo.
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Targeting of KLH to DC-SIGN results in presentation of 
KLH antigen epitopes
To demonstrate that antibody-mediated targeting of antigen to DC-SIGN 
leads to antigen presentation, autologous iDC were incubated with 5 µg/ml 
KLH (± 0.63 nM) or hD1-KLH (± 0.53 nM) at 4ºC for 1 h, washed to remove 
unbound protein, and added to PBL. Presentation of KLH epitopes to spe-
cific T cells was determined by measuring proliferative responses (Fig. 4A, B) 
and the levels of cytokines secreted in the medium (Fig. 4C). As endocytotic 
processes are inhibited at 4 ºC, and KLH does not bind to iDC (Fig. 2C), hD1-
KLH can only be internalized after binding to DC-SIGN. iDC incubated with 
hD1-KLH induced cellular responses by the PBL, whereas iDC incubated with 
KLH did not (Fig. 4A, C), showing that targeting of KLH to DC-SIGN results in 
antigen presentation. We have previously demonstrated that the clinical vac-
cination protocol used in our studies results in a Th1-type immune response 
[43]. Indeed, stimulation of patient PBL with hD1-KLH treated iDC resulted in 
enhanced secretion of IL-2, IFN-γ and TNF-α (Fig. 4C), while IL-4, IL-5 and 
IL-10 levels were not detectable (data not shown). As expected, iDC incubated 
with KLH at 37ºC induced proliferative responses, as did iDC incubated with 
hD1-KLH (Fig. 4A). 
Presentation of KLH epitopes by iDC incubated with hD1-KLH at 4ºC was 
abolished by preincubation of iDC with the hD1 antibody, but was unaffected 
by preincubation with the isotype control 5G1.1 (Fig. 4B, C). This confirms 
that hD1-KLH targeted specifically to DC-SIGN, resulting in presentation of 
KLH epitopes. Cross-linking of hD1 to KLH was required for induction of DC-
SIGN-mediated presentation of KLH epitopes, since iDC incubated with both 
KLH and hD1 antibody did not induce cellular responses (Fig. 4B, C). 
humorAl AND CellulAr reSpoNSeS AGAINST klh IN pATIeNTS vACCINATeD wITh 
klh-pulSeD DC. (A) Patient serum was obtained both before the first, and after the first, 
second and third vaccination cycles. Total IgG antibodies specific for KLH were detected by 
ELISA. Data represent optical density (OD) 450 values of serially diluted serum samples for a 
representative patient. (B) Patient PBMC were isolated one week prior to the third vaccina-
tion cycle and cultured in the absence (control) or presence of 10 µg/ml KLH (KLH). Cellular 
responses were assessed in a tritiated thymidine incorporation assay. Data represent mean 
± SD of experiments performed in 6-fold for a representative patient. Significant difference 
from control according to Student’s t-test: *p < 0,001. 
BA
Figure 3
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ANTIBoDy-meDIATeD TArGeTING oF ANTIGeN To DC-SIGN reSulTS IN ANTIGeN 
preSeNTATIoN. (A) iDC were incubated with medium (control), 5 µg/ml KLH or 5 µg/ml 
hD1-KLH for 1 h at 4ºC or 37ºC. Subsequently, iDC were washed and cocultured with au-
tologous KLH-responsive PBL, derived from the patients enrolled in the vaccination trial. 
After 4 days, cellular responses were assessed in a proliferation assay. Data are mean pro-
liferation indices relative to medium control for experiments performed in triplicate ± SD. 
Significant difference from medium control according to ANOVA and Bonferroni test: *p 
< 0.05, **p < 0.001. (B) iDC were incubated with medium (control), 5 µg/ml hD1-KLH, 5 
µg/ml hD1-KLH and 100 µg/ml hD1 (hD1-KLH + hD1), 5 µg/ml hD1-KLH and 100 µg/ml 
5G1.1 (hD1-KLH + 5G1.1) or 5 µg/ml hD1 and 5 µg/ml KLH (hD1 + KLH) for 1 h at 4ºC. 
Subsequently, iDC were washed and cocultured with autologous KLH-responsive PBL, de-
rived from patients enrolled in the vaccination trial. After 4 days, cellular responses were 
assessed in a proliferation assay. Data are mean proliferation indices relative to medium 
control for experiments performed in triplicate ± SD. Significant difference from medium 
control according to ANOVA and Dunnett’s test: *p < 0.05, **p < 0.01. (C) Production of 
IFN-γ, TNF-α and IL-2 in the coculture experiment described in (B). After 16 h of cocultur-
ing iDC and PBL supernatants were taken and cytokine levels were determined. Data repre-
sent cytokine levels in pooled samples of experiments performed in triplicate. 
Figure 4
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Targeting KLH to DC-SIGN enhances its immunogenicity
To determine whether DC-SIGN targeting increases the efficiency of antigen 
presentation, immature monocyte-derived DC from previously immunized 
patients were incubated at 37ºC with various concentrations of KLH or hD1-
KLH. Subsequently, iDC were washed, and a portion of the iDC was matured 
with LPS. hD1-KLH by itself did not induce maturation of iDC (data not 
shown). Both hD1-KLH treated iDC (Fig. 5A) and mDC (Fig. 5B) induced cel-
lular responses at 100-fold lower concentrations than KLH-pulsed DC. Thus, 
antigen targeting via DC-SIGN significantly enhances immunogenicity.
KLH epitopes are presented up to 4 days  
after targeting DC-SIGN 
After antigen uptake in the periphery, DC migrate to the draining lymph nodes 
to present the processed antigen to T cells. It is imperative that DC present 
the antigens over a prolonged period of time to initiate a significant immune 
response. We evaluated the efficiency of antigen presentation over time fol-
lowing targeting by incubating patient PBL with autologous iDC that had been 
pulsed with KLH or hD1-KLH 0, 2 or 4 days earlier. The results demonstrate that 
DC targeted with hD1-KLH presented KLH epitopes up to 4 days after target-
ing. Moreover, at all time points evaluated, DC targeted with hD1-KLH induced 
stronger proliferative responses than DC pulsed with KLH (Fig. 6). 
TArGeTING oF ANTIGeN To DC-SIGN eNhANCeS ITS ImmuNoGeNICITy. (A) iDC were incubated with medium, 5 µg/ml 
KLH or 5 µg/ml hD1-KLH for 1 h at 37ºC. Subsequently, iDC were washed and cocultured with autologous KLH-responsive PBL, 
derived from patients enrolled in the vaccination trial. After 4 days, cellular responses were assessed in a proliferation assay. 
Data are mean proliferation indices relative to medium control for experiments performed in triplicate ± SD. (B) Experiment 
performed as described in (A), except that antigen-treated iDC were matured with LPS before addition of PBL. 
Figure 5
A B
ANTIGeN TArGeTeD To DC-SIGN IS preSeNTeD For AT 
leAST 4 DAyS. iDC were incubated with medium, 5 µg/ml KLH 
or 5 µg/ml hD1-KLH for 1 h at 37ºC. Subsequently, iDC were 
washed and cultured for 0, 2 or 4 days before addition of au-
tologous KLH-responsive PBL, derived from patients enrolled in 
the vaccination trial. Four days after addition of PBL, cellular 
responses were assessed in a proliferation assay. Data are mean 
proliferation indices relative to medium control for experiments 
performed in triplicate ± SD. Significant difference from KLH ac-
cording to ANOVA and Bonferroni test: *p < 0.05, **p < 0.01. 
Figure 6
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hD1-KLH targeted to DC activates both MHC class I and II 
restricted naïve T cells recognizing KLH epitopes
To evaluate whether hD1-KLH, besides triggering recall responses, is able to 
activate naïve T cells, hD1-KLH was tested in an autologous in vitro culture 
system. PBL from a healthy donor were stimulated by repetitive cocultur-
ing with hD1-KLH-pulsed autologous DC. Il-10 was added to the cultures to 
stimulate expansion of CD8+ T cells [44]. After 5 rounds of stimulation, PBL 
were cocultured with DC pulsed with KLH or hD1, to evaluate KLH-specific 
proliferative responses. The results demonstrate that hD1-KLH targeted DC 
activated KLH-specific naïve T cells (Fig. 7). Presentation of KLH epitopes 
was mediated by MHC class I and class II, since both class I and class II 
blocking antibodies significantly reduced the proliferative response, while 
an antibody control did not. DC pulsed with hD1 antibody did not induce 
proliferative responses by the PBL (Fig. 7), demonstrating that the T cell 
response is specific for KLH epitopes rather than epitopes contained within 
the hD1 antibody. 
hD1-klh TreATeD DC ACTIvATe NAïve T CellS reCoGNIzING klh epITopeS. iDC 
derived from a healthy donor were incubated with medium (control), 10 µg/ml KLH, or 10 
µg/ml hD1 for 1 h at 37ºC. Subsequently, cells were washed and matured with LPS. mDC 
were cocultured with autologous PBL that had been repeatedly stimulated with DC treated 
with hD1-KLH as described in “Material and methods”. Some cocultures of KLH-pulsed mDC 
and PBL were supplemented with w6/32 antibody (KLH + class I block), IVA-12 (KLH + class 
II block), both w6/32 and IVA-12 (KLH + class I + class II block) or total mouse IgG (KLH + 
antibody control). Data are mean proliferation indices relative to medium control for experi-
ments performed in triplicate ± SD. Significant difference according to ANOVA, followed by 
the Student-Newman-Keuls test: *p < 0.01, **p < 0.001. 
Supplemental video 1. hD1-KLH and KLH are translocated to the lysosomes. iDC were labeled 
with LysoTracker Red and incubated with Alexa Fluor 488-labeled (green) hD1-KLH (A) or 
KLH (B). Uptake of hD1-KLH and KLH was studied by live imaging techniques. The time index 
in the top left-hand corner represents the time elapsed after addition of hD1-KLH or KLH to 
the culture medium. 
Figure 7
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Discussion
In the present study we explored the capacity of the type II C-type lectin DC-
SIGN to function as a target receptor for vaccination purposes. The results 
demonstrate that antibody-mediated targeting of antigen to human DC-SIGN 
was 100-fold more efficient than pulsing DC with antigen, and that antigen 
epitopes were presented for at least 4 days after targeting. 
A critical step in designing a suitable targeting construct is the choice of tar-
geting antibody. Various antibodies directed against the same receptor might 
bind distinct receptor epitopes, thus influencing biological outcome. For 
example, not all antibodies directed against DC-SIGN are internalized following 
binding [45], and the anti-MR antibody PAM-1 induces maturation of iDC, 
in contrast to a different isotype-matched anti-MR antibody [46]. The mouse 
anti-human DC-SIGN antibody AZN-D1 has been previously described to be 
internalized by DC [47], a prerequisite for successful targeting. However, the 
use of murine antibodies in humans presents numerous problems, including 
a short half-life and high immunogenicity [48]. We were able to graft the 
CDR of AZN-D1 hypervariable domains onto a human composite IgG2/IgG4 
antibody without loss of binding characteristics. The resulting hD1 antibody 
exhibited a similar binding affinity for DC-SIGN as AZN-D1, and did not 
induce maturation of iDC (data not shown). hD1 binding induced rapid in-
ternalization of DC-SIGN, while internalization did not result in a lasting 
downregulation of DC-SIGN expression (data not shown), thus minimizing 
the effect a therapeutic intervention might have on the biological function 
of DC-SIGN. hD1 rapidly targeted antigen to the DC lysosomal compartment 
resulting in antigen presentation, and did not induce hD1-specific prolifera-
tive responses in the naïve T cell stimulation experiments. Thus, humaniza-
tion of AZN-D1 resulted in an effective targeting antibody, and will facilitate 
introduction into clinical trials.
Vaccination strategies aimed at inducing cytotoxic T cell help, such as anti-
tumor therapies, require antigen presentation in the context of MHC class I. 
In addition, the induction of CTL responses requires bystander CD4+ T cell 
help [49]. Targeting DC with hD1-KLH resulted in the activation of naïve T 
cells in the context of both MHC class I and II. Although the major route for 
presentation of exogenous antigens is via class II, presentation via class I can 
occur via the process of cross-presentation. This process provides internalized 
proteins access to cytosolic proteasomes and their derived peptides access to 
the endoplasmatic reticulum (ER)-based class I processing machinery [50]. 
Particulate antigens taken up by phagocytosis have access to this machin-
ery since phagosomes fuse with the ER soon after or during their formation 
[51]. Particulate antigens are more efficiently cross-presented than soluble 
antigens [52,53]. However, a recent study by Ackerman et al. reveals that 
internalized soluble proteins can escape proteolysis and also gain access to 
the lumen of the ER [54]. This might explain how antibody-mediated target-
ing of the type I C-type lectins MR [55] and DEC-205 [56] results in class I 
responses. Although we cannot exclude the possibility that, besides receptor-
mediated endocytosis, a portion of our chimeric protein was taken up via 
macropinocytosis, our current findings strongly suggest that antibody-mediated 
targeting of DC-SIGN results in cross-presentation. 
The technique commonly used in current clinical trials to load DC with an-
tigens involves ex vivo incubation with MHC class I and II binding peptides. 
Other techniques involve loading with tumor lysates or apoptotic tumor cells, 
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and the introduction of genetic material to drive expression of specific anti-
gens by the DC itself [57]. Ideally, vaccines should deliver antigens to the DC 
in vivo. Antibody-mediated targeting of antigens to DC surface receptors to 
stimulate antigen presentation in vivo has been shown to be far more potent 
than immunization with antigen in Complete Freund’s Adjuvant or splenic DC 
pulsed with antigen ex vivo [58]. However, mere targeting of antigens to DC 
is not sufficient for induction of immunity. Antibody-mediated targeting of 
antigen to DEC-205 in mice leads to tolerance, and coadministration of a DC 
maturation stimulus is required to induce immunity [59-61]. These findings 
are consistent with DC-based vaccination studies in humans, showing that 
DC maturation is a prerequisite for induction of immunity [62]. Vaccination 
strategies for transplantation, allergy, autoimmunity and chronic inflamma-
tory diseases could exploit the finding that targeted iDC induce tolerance. 
However, strategies aimed at inducing immunity will require a combination 
of antigens and DC activation factors. Agents that have been shown to acti-
vate DC in vivo include anti-CD40 antibody [63], α-galactosylceramide [64] 
and the Toll like receptor ligands LPS [65] and CpG oligonucleotides [66]. A 
better understanding of differences in DC subsets, their activation pathways 
and antigen uptake receptors will provide the information necessary for de-
velopment of effective vaccines. 
In the present study, we used a neo-antigen to study targeting efficiency. A 
major challenge in cancer therapy is to break immunologic tolerance to tumor-
associated self antigens. Tolerance can be the result of clonal deletion, active 
suppression of antigen-specific T cells by regulatory T cells or inadequate 
activation stimuli provided by tumor cells upon antigen presentation, resulting 
in T cell anergy [67]. One way of breaking tolerance is by disruption of 
negative regulatory mechanisms directly at the T cell level. Antibody-me- 
diated blockade of the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) 
breaks tolerance against moderately immunogenic tumors [68], and improves 
the efficiency of tumor cell-based vaccines against poorly immunogenic tu-
mors [69]. Depletion of CD25+ regulatory T cells prior to blocking of CTLA-4 
improves vaccine efficiency even further [70]. A second way of breaking 
tolerance is to recruit DC as potent APCs. DC can overcome the heightened 
threshold of anergic T cells [71] and restore responsiveness of tolerogenic 
tumor-specific T cells [72] in vitro. Moreover, studies in mice demonstrate 
that DC-based vaccines can break tolerance against (tumor-associated) self 
antigens [73-77] resulting in regression of established tumors [78]. Thus, a 
combination of antibody-mediated strategies targeting tumor-associated an-
tigens to DC and strategies modulating regulatory mechanisms at the T cell 
level might provide effective cancer therapies.
In conclusion, antibody-mediated targeting of antigens to DC surface recep-
tors represents an exciting way to induce immune responses. Our results 
demonstrate efficient delivery of antigen to DC via DC-SIGN, resulting in 
naïve as well as recall responses by T cells. These data expose DC-SIGN as a 
promising target molecule for antibody-mediated antigen delivery to DC. 
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Summary and Discussion
DC play a central role in the regulation of the immune system. These cells can 
induce an effective immune response against pathogens, but in case of en­
dogenous ligands DC have to induce tolerance to protect endogenous tissues 
from damage. This is a delicate balance dependent on the context in which 
the antigen is delivered to the DC. In case of a pathogenic antigen, ‘danger’ 
signals will be present that trigger the DC to mature and develop into a power­
ful antigen­presenting cell. These cells will activate T cells that specifically 
recognize the pathogen. In case of an endogenous ligand, no ‘danger’ signals 
are present rendering the DC immature and unable to activate specific T cells 
because of absence of a costimulatory signal. Therefore, immature DC induce 
tolerance against the endogenous ligand [1­3].  
Besides activating or tolerizing T cells, DC also communicate with other 
cell types like B cells, NK cells, and neutrophils to coordinate adaptive and 
innate immune responses. Interactions with these cell types have implica­
tions on cell activation, antigen transfer and modulation of the type of im­
mune response [4­6]. For instance, DC can transfer antigen to naïve B cells 
to initiate a specific antibody response [7] or activate NK cells in antiviral 
responses [4]. 
DC express the C­type II lectin DC­SIGN that recognize high­mannose and 
fucose moieties found on several pathogens, but also on some endogenous 
proteins. DC­SIGN can function both as antigen­uptake receptor as well as 
adhesion receptor and is implicated in several activities of a DC like antigen 
presentation [8], T cell activation [9], and DC migration [10]. The research 
described in this thesis focuses on the diverse implications of DC­SIGN in 
binding to foreign and endogenous ligands.
In Chapter 1 a general introduction is given about the characteristics of 
C­type lectin receptors (CLRs) on DC. CLRs function as pattern recognition 
receptors (PRRs) by recognizing carbohydrate moieties on pathogens and 
thereby play an important role together with other PRRs in the immune de­
fense against pathogens. Nevertheless, several pathogens like HIV­1 and M. 
tuberculosis exploit CLRs to escape from immune surveillance. In addition to 
these foreign ligands, CLRs can also recognize specific carbohydrate moieties 
on endogenous proteins and thereby mediate cell­cell adhesion, clearance of 
abnormal cells and plasma glycoprotein turnover. The CLR DC­SIGN is able 
to recognize both foreign as well as endogenous ligands and is involved in 
many aspects of the immune system. For instance, in Chapter 2 it is shown 
that DC­SIGN can bind the fungus C. albicans. This was demonstrated using 
DC and DC­SIGN transfected cell­lines. Upon binding to DC­SIGN on imma­
ture DC, C. albicans was rapidly internalized into DC­SIGN enriched vesicles. 
These vesicles were distinct from vesicles containing mannose receptor which 
is another receptor for C. albicans on DC. Probably, the destiny of DC­SIGN+ 
vesicles differs from mannose receptor+ vesicles since the mannose receptor 
returns to the cell membrane whereas DC­SIGN ends up in the lysosomal 
compartments [8]. 
C. albicans is harmless under normal conditions, but can lead to severe 
infections in the immunocompromised host [11,12]. Induction of cell­ 
mediated immunity is crucial in the host defense against C. albicans. DC play 
an important role in this cell­mediated induction by processing and presen­
tation of C. albicans to T cells [13]. The specific interaction of C. albicans to 
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DC­SIGN expressed on DC and subsequent internalisation suggest a role in 
this cell­mediated immunity. Likely, this is the most important role for DC 
in interacting with C. albicans as its anticandidal capacity is quite weak in 
relation to monocytes and macrophages as demonstrated in Chapter 3. C. 
albicans can present itself in two forms: blastoconidia, the yeast form and 
hyphae considered as the filamentous form [14]. Besides intracellular killing 
of blastoconidia, also extracellular damage to hyphae induced by DC was 
lower than that of monocytes and macrophages. Moreover, in response to C. 
albicans, DC also produced less TNF­α, IL­6 and IL­8 compared to monocytes 
and macrophages. Interestingly, also differences in cytokine production were 
observed between monocytes and macrophages. Monocytes released greater 
amounts of cytokines upon stimulation with blastoconidia compared to hy­
phae whereas the opposite was found for macrophages. These cells produced 
more TNF­α and IL­8 upon stimulation with the hyphal form. This suggests 
that monocytes and macrophages have adapted to encounter a specific phe­
notypic form of C. albicans. 
 
Originally, DC­SIGN was discovered as adhesion molecule in DC­T cell inter­
actions [9]. It was hypothesised that DC­SIGN­ICAM­3 interactions are the 
first interactions to be established between DC and T cells followed by other 
adhesive molecules like LFA­1­ICAM­1. However, its role in T cell activation 
became controversial as several studies did not show a role for DC­SIGN in T 
cell activation whereas other studies did [15­18]. Therefore, in Chapter 4 the 
relevance of DC­SIGN in DC­induced T cell proliferation is studied. Numerous 
mixed lymphocyte reactions (MLR) were performed and it was observed that 
anti­DC­SIGN antibodies only blocked T cell proliferation in a weak MLR. 
Consequently, as mature DC are more potent APC than immature DC, hardly 
any effect with MLR driven by mature DC was seen. This indicates an initial 
role for DC­SIGN that is dominated by other adhesive and costimulatory 
mechanisms. Interestingly, LFA­1 was dependent on the strength of the T cell 
response as well. With the use of recombinant DC­SIGN we observed that 
approximately 5% of PBL could bind to DC­SIGN. This was not attributed to 
one specific population but comprised all major lymphocyte subsets. There 
was variation among donors with a maximum of 20% binding. PBL of one 
donor showed a high DC­SIGN binding capacity and the MLR with these cells 
was more prone to DC­SIGN blocking antibodies compared to a donor whose 
PBL had a low DC­SIGN binding capacity. In the MLR of the donor whose 
PBL have a high DC­SIGN binding capacity, DC­SIGN can bind firmly to a 
higher percentage of T cells and may have a prolonged effect on these cells 
compared to cells that bind transiently. Therefore, an effect by anti­DC­SIGN 
in MLR may be observed more rapidly.
In Chapter 5 we discovered that the DC­SIGN coated beads bound a sub­
stantial higher percentage of monocytes than PBL. Previously, van Gisberg­
en et al. [19] showed that soluble DC­SIGN could bind neutrophils but not 
monocytes. These authors showed that the binding of DC­SIGN to neutrophils 
occurs via Lewis X which is not present on monocytes [19]. However, a low 
Lewis X expression was observed when using another anti­Lewis X antibody. 
Likely, the DC­SIGN beads can engage simultaneous interactions with several 
spatially dispersed unsialylated Lewis X epitopes on monocytes because of its 
large interaction surface (1 µm diameter beads). This results in a stable bind­
ing to monocytes whereas soluble DC­SIGN can not establish a stable binding 
to monocytes because of a smaller contact surface and therefore the number 
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of interacting molecules remains low. However, the inability of soluble DC­
SIGN to bind monocytes is overcome when the number of Lewis X epitopes is 
increased by neuraminidase treatment of monocytes. Neuraminidase removes 
terminal sialic residues of various glycomolecules. The resulting increased 
Lewis X expression indicates that Lewis X on monocytes is masked by sialyl 
groups. Although the physiological significance of DC­SIGN interacting with 
monocytes remains to be determined, it is tempting to speculate about a role 
in DC­monocyte communication via DC­SIGN­Lewis X interactions.
Glycosylation is frequently altered in tumor cells when compared to their 
normal counterparts. An aberrant glycosylation pattern can be beneficial for 
the tumor cell because it enables metastasis or protection from immune sur­
veillance [20]. In Chapter 6 we studied whether DC­SIGN and its homologue 
L­SIGN could detect aberrant glycosylation on leukemic cells that might be 
of prognostic relevance. DC­SIGN and L­SIGN coated beads showed an in­
creased binding to most acute lymphoblastic leukaemia (ALL) cells compared 
to cells from healthy donors. DC­SIGN did not discriminate between B­ and 
T­ALL cells whereas L­SIGN bound preferentially to B­ALL bone marrow 
cells. T­ALL can be subdivided into immature T­ALL, common T­ALL, and 
mature T­ALL according to the chronological development of T cells [21,22]. 
This revealed a preference of DC­SIGN for binding to mature T­ALL. B­ALL 
can be subdivided into pro­B­ALL, common B­ALL, and pre­B­ALL [22], but 
this yielded no clear differences in binding to DC­SIGN or L­SIGN. Although 
Lewis X is a likely binding partner for DC­SIGN in tumor cells [23], only 
tumor cells of some B­ALL patients showed a high expression of this carbo­
hydrate. Therefore, ligands other than Lewis X on most ALL cells will bind to 
DC­SIGN. Interestingly, increased binding of peripheral blood leukemic cells 
to DC­SIGN and L­SIGN is correlated with a poor survival compared to in­
creased binding of bone marrow cells to DC­SIGN and L­SIGN. Possibly, once 
leukemic cells enter the circulation interactions with DC­SIGN and L­SIGN 
positive cells are possible. As DC­SIGN and L­SIGN are expressed on cells 
that can induce tolerance (liver­sinusoidal endothelial cells, DC) it supports 
a role in favouring immune escape of the leukemic cells. Future studies are 
required to study the potential of developing a therapeutic tool.
Chapter 7 describes the potential of using DC­SIGN as target molecule for 
DC­vaccination strategies. Current DC­based vaccination strategies are based 
on ex vivo­generated autologous DC loaded with an antigen prior to read­
ministration into patients [24]. Targeting antigens to DC in vivo via DC­SIGN 
would be a more direct and less laborious way. For this purpose, a humanized 
DC­SIGN antibody (hD1) was chemically cross­linked to a model antigen 
keyhole limpet hemocyanin (KLH) resulting in the chimeric antibody­protein 
complex hD1­KLH. hD1­KLH specifically bound to DC­SIGN and was inter­
nalized and translocated to the lysosomal compartment of DC. DC targeted 
with hD1­KLH induced memory T cell responses against KLH at 100­fold 
lower concentration than DC targeted with KLH alone. This suggests that 
targeting KLH to DC­SIGN enhances its immunogenicity.
 Moreover, targeting DC with hD1­KLH resulted in the activation of naïve T 
cells in the context of MHC I and II molecules. This indicates activation of 
both CD4+ and CD8+ T cells which is necessary in an effective anti­tumor 
vaccination therapy. The presentation of KLH epitopes in MHC I suggests the 
occurrence of cross­presentation along the major route for presentation of 
exogenous antigens via MHC II [25]. Targeting DC with hD1­KLH four days 
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earlier before contact with T cells still resulted in a specific anti­KLH T cell 
response. This is very important as in vivo after antigen uptake in the periphery 
it will take time for a DC to reach the lymph node. Therefore it is crucial that 
a DC can present antigen for a prolonged time to induce an efficient immune 
response. Altogether, these results demonstrate that DC­SIGN is a promising 
target molecule for antibody­mediated antigen delivery to DC. 
 
In conclusion, this thesis demonstrates that DC­SIGN is involved in many 
aspects of the immune system (Fig. 1). It plays a role in immune defense and 
antigen presentation by taking up C. albicans and the targeting construct 
hD1­KLH. Moreover, this C­type lectin can act as adhesion receptor by me­
diating T cell activation and binding to monocytes and leukemic cells. These 
diverse functions are in line with other DC­SIGN ligands like ICAM­2 for DC 
migration [10], Lewis X on Mac­1 and CEACAM for communication with 
neutrophils [26], and a large array of pathogens (reviewed in [27]) for im­
mune defense and escape mechanisms. Additionally, interaction of DC­SIGN 
with tumor cells has also been demonstrated recently [23]. All these various 
DC­SIGN ligands have in common that they are specifically glycosylated 
since DC­SIGN recognizes highly branched­mannose­ and fucose­contain­
ing glycans [28,29]. The expression of these specific glycans is regulated by 
specific glycosyltransferases that catalyse the synthesis of oligosaccharides 
[30]. The expression of human glycosyltransferases can be tissue specific 
and can depend on differentiation status of the cell and the presence of cy­
tokines [31­34]. Therefore, glycosylation can change in cancer cells [20] and 
activated immune cells like monocytes that upregulate Lewis X expression 
on their cell surface upon activation by LPS or pro­inflammatory cytokines 
[35,36]. Possibly, DC­SIGN plays an important role in these modified glyco­
sylation circumstances as it can bind tumor cells, monocytes and neutrophils. 
DiverSe impliCationS of DC-SiGn in binDinG to itS liGanDS. Because of its carbo-
hydrate specificity DC-SIGN can interact both with pathogen-derived as well as endogenous 
glycoconjugates. Interactions with its different ligands result in involvement of DC-SIGN in 
several aspects of immune system like antigen-presentation and cellular communication.
figure 1
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The functional consequences upon interaction of DC­SIGN with monocytes 
and tumor cells is not known yet, but can be extrapolated from its interac­
tions with neutrophils and pathogens. For instance, interaction of DC with 
activated neutrophils via DC­SIGN results in maturation of the DC [19]. This 
mechanism is expected to be used by activated monocytes as well. 
Many pathogens exploit DC­SIGN to evade immunity. For example, M. tu-
berculosis interacts with DC­SIGN on DC and thereby inhibits the immuno­
stimulatory function of DC by producing the immune response dampening 
cytokine IL­10 [37]. Moreover, the human gastric pathogen H. pylori modu­
lates the function of DC via DC­SIGN by blocking the polarization towards 
a T helper type 1 response [38]. Also several viruses like HIV­1, HCV and 
Measles virus exploit DC­SIGN for their dissemination [39­41]. 
Whether interaction of DC­SIGN with C. albicans may result in immune eva­
sion is not known yet. It seems unlikely, as DC­SIGN preferentially bound 
the blastoconidia form of C. albicans to which a protective response (Th1 
type) is initiated by DC [42]. Interestingly, DC­SIGN hardly bound the hyphal 
form of C. albicans (unpublished results from A. Cambi) to which DC initiate 
a non­protective response (Th2 type) [42]. Possibly, DC­SIGN plays a role in 
induction of Th1 response against the conidia form of C. albicans in a similar 
way as reported for the IgtB polysaccharide from N. meningitides [43]. This 
glycosylated structure binds to DC­SIGN and skews DC immune responses 
towards Th1 helper activity [43].
Nevertheless, DC­SIGN seems to be a popular molecule for most pathogens to 
escape from immune surveillance and this might be the case for cancer cells 
as well. In support of this, there are some indications that tumor carbohydrates 
affect DC via C­type lectins [44,45]. For instance, the tumor­associated antigen 
MUC1 can induce monocytes to differentiate into tolerogenic DC [45]. In 
addition, MUC1 prevents development of a Th1 type anti­tumor response 
upon binding to DC [44]. Possibly, DC­SIGN internalizes specific tumor 
antigens in the absence of danger signals resulting in tolerance of T cells 
specific for the tumor antigen in a similar way as described for DEC­205 
[46]. However, tolerance induction is overcome by addition of a strong DC 
maturation stimulus [47]. Therefore, in future patient tumor vaccination 
studies a DC maturation stimulus should be included together with our 
DC­SIGN targeting construct (Chapter 7) to induce an effective anti­tumor 
response. Interestingly, the fact that targeting an antigen to a C­type lectin 
can either induce antigen­specific immune activation or tolerance depen­
dent on the presence or absence of a DC maturation stimulus provides a 
promising therapeutic tool to be applied not only in cancer, but also in 
infectious­ and autoimmune diseases. 
Targeting DC­SIGN results in rapid internalisation of DC­SIGN, but this in­
ternalisation did not result in a lasting down­regulation of DC­SIGN expres­
sion. Such a temporary down­regulation of DC­SIGN expression minimizes 
its effect on the biological function of DC­SIGN like T cell activation and 
communication with neutrophils and monocytes. In support of this, we did 
not observe an effect on T cell proliferation in the targeting experiments. 
Nevertheless, the role of DC­SIGN in T cell activation is not very robust as its 
effect is only visible in weak MLR and strikingly only a small number of T 
cells can bind to DC­SIGN beads. Apparently, DC­SIGN mediates a subtle role 
in DC­T cell communication which might be involved in tolerance induction 
as well since DC­SIGN is able to stimulate or down­regulate T cell activation 
dependent on the strength of T cell stimulus [18]. 
It is becoming clear that besides T cells, DC can communicate with several 
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types of immune cells to coordinate adaptive and innate immune responses 
[48]. Our binding data suggest a role for DC­SIGN in communication between 
DC and monocytes (Chapter 5), B cells and NK(T) cells (Chapter 4). Several re­
ports describe a role for DC with B cells [5,7,49] and NK(T) cells [50­52], how­
ever as far as we know communication of DC with monocytes has not been 
reported before. Possibly, monocytes and DC meet each other in inflamed 
peripheral lymph nodes since large numbers of monocytes can be recruited 
to these sites [53]. There, bi­directional cross­talk between DC and monocytes 
likely results in an effective innate and adaptive immune response against the 
invaded microorganisms. This can be established by several mechanisms like 
maturation of DC, activation of monocytes, antigen transfer, and modula­
tion type of adaptive immune response (Th1 or Th2). It will be interesting to 
study whether DC­SIGN just serves as an adhesion receptor to bring the cells 
together or whether it is also involved in the possible mechanisms described 
above. Also its function in DC communication with B cells and NK(T) cells 
requires further attention. 
Although most interest goes to DC­SIGN on DC, there are several reports in 
which expression of DC­SIGN is detected on other cells like macrophages 
[54], B cells [55], liver sinusoidal endothelium [56], platelets and megakaryo­
cytes [57,58]. Possibly, interaction of DC­SIGN to several ligands and its re­
lated functional outcomes are more explicitly developed in these cell types. 
For instance, leukemic cells may predominantly interact with DC­SIGN on 
LSEC instead of DC to induce tolerance against the leukemic cells or to me­
diate clearance of these malignant cells from the circulation [59,60]. Also, 
interaction of DC­SIGN to monocytes may be physiologically relevant when 
this interaction takes place between monocytes and platelets in promoting 
atherogenesis and thrombosis [61]. Future studies are required to analyze the 
function of DC­SIGN on these cell types in depth, but the fact that DC­SIGN 
is also expressed on cells other than DC further supports its diverse role in 
the immune system. 
Altogether, the various ligands of DC­SIGN show that this C­type lectin is 
involved in many aspects of the immune system. The different outcomes 
upon interaction with DC­SIGN can be explained by its organization into mi­
crodomains [62] in which associated molecules may collaborate to determine 
the outcome of the interacting ligand. 
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Dendritische cellen (DC) spelen een belangrijke rol in de regulatie van het 
immuunsysteem. Deze cellen kunnen een krachtige afweerreactie opwekken 
tegen ziekteverwekkers, maar in het geval van lichaamseigen stoffen dienen 
DC tolerantie te induceren om de lichaamseigen weefsels te beschermen 
tegen schade. De uiteindelijke reactie van de DC hangt af van de samen-
hang waarin het antigeen aan de DC wordt aangeboden. In het geval van 
een ziekteverwekker zijn er ‘gevaar’ signalen aanwezig die de DC aanzetten 
tot verdere rijping en ontwikkelt de DC zich tot een krachtige antigeen-
presenterende cel. Deze cellen zullen de specifieke T cellen, die uitslui-
tend gericht zijn op de ziekteverwekker, activeren. In het geval van een 
lichaamseigen stof zijn er geen ‘gevaar’ signalen aanwezig waardoor de DC 
‘immature’ (onrijp) blijft en de specifieke T cellen niet kan activeren door 
de afwezigheid van een costimulatie signaal. Daardoor induceren immature 
DC tolerantie tegen de lichaamseigen stof. 
Naast het instrueren van T cellen tot activering of tolerantie, communiceren 
DC ook met andere cel types zoals B cellen, NK cellen, en neutrofielen om 
de adaptieve en aangeboren immuunreacties te coördineren. Communicatie 
met deze cel types heeft gevolgen voor cel activering, antigeen overdracht, 
en sturing van het type immuunreactie. Zo kunnen DC antigenen overdragen 
naar rustende B cellen om een specifieke antistofreactie op te wekken of 
door NK cellen te activeren in antivirale reacties. 
De C-type II lectine DC-SIGN wordt tot expressie gebracht op DC en herkent 
complexe mannose en fucose structuren die aanwezig zijn op ziekteverwek-
kers, maar ook op sommige lichaamseigen eiwitten. DC-SIGN kan zowel als 
antigeen-opname receptor als adhesie receptor functioneren en is betrokken 
in verschillende activiteiten van een DC zoals antigeen presentatie, activering 
van T cellen, en DC migratie. Het onderzoek beschreven in dit proefschrift 
richt zich op de verschillende aspecten van DC-SIGN in de binding aan 
lichaamsvreemde en lichaamseigen stoffen. 
In Hoofdstuk 1 wordt een algemene introductie gegeven over de kenmerken 
van C-type lectine receptoren (CLRs) op DC. CLRs functioneren als patroon-
herkennings receptoren (PRRs) door het herkennen van suikerstructuren op 
ziekteverwekkers en spelen daardoor een belangrijke rol samen met andere 
PRRs in de immuunafweer tegen ziekteverwekkers. Toch zijn er verschei-
dene ziekteverwekkers zoals HIV-1 en Mycobacterium tuberculosis die de 
CLRs uitbuiten om te ontsnappen aan eliminatie door het immuunsysteem. 
Naast deze lichaamsvreemde stoffen, kunnen CLRs ook suikerstructuren her-
kennen op lichaamseigen eiwitten en spelen dan een rol bij cel-cel adhesie, 
opruiming van abnormale cellen en verwijdering van geglycosyleerde plasma 
eiwitten. De CLR DC-SIGN kan zowel lichaamsvreemde als lichaamseigen 
stoffen herkennen en is betrokken bij veel aspecten van het immuunsys-
teem. Zo wordt in Hoofdstuk 2 aangetoond dat DC-SIGN aan de schimmel 
Candida albicans kan binden. Deze binding werd gemeten door gebruik te 
maken van DC en cellijnen die kunstmatig DC-SIGN tot expressie brengen. 
Na binding aan DC-SIGN op immature DC werd C. albicans snel geïnterna-
liseerd in DC-SIGN positieve ‘vesicles’ (blaasjes). Deze vesicles verschilden 
van mannose receptor+ vesicles, een andere receptor voor C. albicans op DC. 
Mogelijk verschilt het lot van de DC-SIGN+ vesicles met die van mannose 
receptor+ vesicles aangezien de mannose receptor een receptor is die terug-
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keert naar de celmembraan terwijl DC-SIGN in lysosomale compartimenten 
eindigt. 
C. albicans is ongevaarlijk in normale omstandigheden, maar kan leiden tot 
ernstige infecties in personen met een verzwakte immuunrespons. Het op-
wekken van cellulaire immuniteit is cruciaal in de afweer van de gastheer 
tegen C. albicans. DC spelen een belangrijke rol in deze cellulaire immuniteit 
door het verwerken en presenteren van C. albicans aan T cellen. De specifieke 
interactie van C. albicans met DC-SIGN op de DC en aansluitende internalisa-
tie maakt een rol in deze cellulaire immuniteit erg aannemelijk. Waarschijnlijk 
is dit de meest belangrijke rol voor DC in zijn interactie met C. albicans aan-
gezien zijn mogelijkheden om C. albicans te doden beperkt zijn in vergelijking 
met monocyten en macrofagen zoals aangetoond in Hoofdstuk 3. C. albicans 
kan voorkomen in twee vormen: ‘blastoconidia’, de gistvorm en ‘hyphae’, de 
draadvorm. Naast intracellulaire doding van de blastoconidia vorm, is ook de 
extracellulaire schade aan hyphae toegebracht door DC kleiner dan die van 
monocyten en macrofagen. Verder produceerden DC ook minder cytokines 
zoals TNF-α, IL-6 en IL-8 vergeleken met monocyten en macrofagen in re-
actie op C. albicans. Interessant genoeg waren er ook verschillen in cytokine 
productie tussen monocyten en macrofagen. Monocyten scheidden grotere 
hoeveelheden cytokines uit na stimulatie met blastoconidia vergeleken met 
hyphae terwijl het tegenovergestelde werd gevonden voor macrofagen. Deze 
cellen produceerden meer TNF-α en IL-8 na stimulatie met de hyphae vorm. 
Dit suggereert dat monocyten en macrofagen zich aangepast hebben om een 
specifieke verschijningsvorm van C. albicans aan te pakken. 
DC-SIGN werd ontdekt als adhesiemolecuul in DC-T cel interacties. Er werd 
gespeculeerd dat de DC-SIGN-ICAM-3 interacties de eerste interacties zijn 
tussen DC en T cellen die opgevolgd worden door andere adhesie mole-
culen zoals LFA-1-ICAM-1. De rol van DC-SIGN in T cel activering werd 
controversieel, omdat in een aantal studies geen rol voor DC-SIGN in T cel 
activering werd beschreven terwijl andere studies dit wel beschreven. In 
Hoofdstuk 4 is daarom de relevantie van DC-SIGN in DC-geïnduceerde T cel 
proliferatie onderzocht. Er werden meerdere ‘mixed lymphocyte reactions’ 
(MLR) uitgevoerd en er kwam naar voren dat anti-DC-SIGN antistoffen 
alleen de T cel proliferatie blokkeerden in een zwakke MLR. Daar ‘mature’ 
(rijp) DC betere antigeen-presenterende cellen zijn dan immature DC, was 
er geen effect te zien in een MLR die door mature DC werd geïnduceerd. 
Dit geeft een initiële rol aan voor DC-SIGN die overgenomen wordt door 
andere adhesie en costimulatoire mechanismen. Interessant genoeg was de 
invloed van LFA-1 ook afhankelijk van de sterkte van de T cel reactie. Met 
het gebruik van recombinant DC-SIGN zagen we dat ongeveer 5% van de 
perifere bloed lymfocyten (PBL) aan DC-SIGN kon binden. Dit bleek niet 
één specifieke populatie, maar bevatte alle lymfocyten subpopulaties. Er 
werd variatie gevonden in het percentage binding door de donoren met 
een maximum van 20% binding. PBL van één donor liet een hoge DC-SIGN 
bindingscapaciteit zien en de MLR met deze cellen bleek gevoeliger voor 
DC-SIGN blokkerende antistoffen vergeleken met een donor wiens PBL een 
lage DC-SIGN bindingscapaciteit had. In de MLR van de donor die PBL 
heeft met een hoge DC-SIGN bindingscapaciteit kan DC-SIGN een hoger 
percentage van T cellen binden op een stabiele manier waardoor het een 
langer effect kan hebben op deze cellen vergeleken met cellen die vluchtig 
binden. Daarom wordt een effect met anti-DC-SIGN in MLR waarschijnlijk 
sneller gezien. 
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In Hoofdstuk 5 staat beschreven dat DC-SIGN gekoppeld aan ‘beads’ (bol-
letjes) een veel hoger percentage monocyten kon binden dan PBL. Eerder 
is door Van Gisbergen et al. aangetoond dat DC-SIGN moleculen neutro-
fielen kunnen binden maar geen monocyten. Deze auteurs toonden aan dat 
de binding van DC-SIGN aan neutrofielen plaatsvindt via Lewis X. Deze 
suiker is niet aanwezig op monocyten. Er werd echter een lage expressie 
van Lewis X op monocyten waargenomen wanneer een ander anti-Lewis 
X antistof werd gebruikt. Waarschijnlijk kunnen de DC-SIGN gekoppelde 
beads gelijktijdig interacties aangaan met verschillende ver verspreide 
Lewis X epitopen op monocyten vanwege zijn grote interactie oppervlakte 
(1 µm diameter). Dit resulteert in een stabiele binding aan monocyten ter-
wijl vrije DC-SIGN moleculen geen stabiele binding aan monocyten kunnen 
bewerkstelligen vanwege een kleiner contact oppervlakte waardoor het 
aantal moleculen die een interactie met elkaar aangaan laag blijft. De 
beperking van vrije DC-SIGN moleculen om monocyten te binden wordt 
overwonnen als het aantal Lewis X epitopen wordt verhoogd door een 
neuraminidase behandeling van de monocyten. Neuraminidase verwijdert 
eindstandige sialyl groepen van verschillende geglycosyleerde eiwitten. 
De resulterende verhoogde Lewis X expressie geeft aan dat Lewis X op 
monocyten gemaskeerd wordt door sialyl groepen. Hoewel de fysiologische 
betekenis van DC-SIGN binding aan monocyten nog bepaald moet worden 
is het aannemelijk om te speculeren over een rol in DC-monocyt communi-
catie via DC-SIGN-Lewis X interacties. 
De glycosylering is vaak veranderd in kankercellen in vergelijking met hun 
normale tegenhangers. Een afwijkende glycosylering kan gunstig zijn voor 
een kankercel omdat het metastasering of ontsnapping aan eliminatie door 
het immuunsysteem mogelijk maakt. In Hoofdstuk 6 werd onderzocht of DC-
SIGN en zijn homoloog L-SIGN afwijkende glycosyleringspatronen op leuke-
mische cellen kunnen detecteren die mogelijk van prognostische waarde zijn. 
DC-SIGN en L-SIGN gekoppeld aan beads bonden beter aan de meeste acute-
lymfoblastaire leukemische (ALL) cellen vergeleken met cellen van gezonde 
donoren. DC-SIGN bond evengoed aan B- als T-ALL cellen terwijl L-SIGN 
bij voorkeur B-ALL beenmerg cellen bond. T-ALL kan onderverdeeld worden 
in ‘immature’ T-ALL, ‘common’ T-ALL, en ‘mature’ T-ALL op basis van de 
chronologische ontwikkeling van T cellen. Een voorkeur voor DC-SIGN voor 
binding aan ‘mature’ T-ALL werd waargenomen. B-ALL kan onderverdeeld 
worden in ‘pro-B-ALL’, ‘common’ B-ALL, en ‘pre-B-ALL’, maar dit resulteerde 
niet in duidelijke verschillen in binding aan DC-SIGN of L-SIGN. Hoewel 
Lewis X een bindingspartner kan zijn voor DC-SIGN in kankercellen, vertoon-
den de kankercellen van slechts een paar B-ALL patiënten een hoge expressie 
van deze suikerstructuur. Daarom zullen andere liganden dan Lewis X op 
de meeste ALL cellen aan DC-SIGN binden. Een interessante bevinding was 
dat verhoogde binding van perifere bloed leukemische cellen aan DC-SIGN 
en L-SIGN gerelateerd is met een slechtere overlevingskans vergeleken met 
verhoogde binding van beenmergcellen aan DC-SIGN en L-SIGN. Waarschijn-
lijk zijn interacties met DC-SIGN en L-SIGN mogelijk zodra de leukemische 
cellen de bloedcirculatie binnendringen. Het feit dat DC-SIGN en L-SIGN tot 
expressie worden gebracht op cellen die tolerantie kunnen opwekken (lever 
sinusoidale endotheelcellen, DC) ondersteunt een rol in het bevorderen van 
ontsnapping van leukemische cellen aan het immuunsysteem. Vervolgstudies 
zijn nodig om de mogelijkheid te onderzoeken voor het ontwikkelen van een 
therapeutisch middel. 
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Hoofdstuk 7 beschrijft de mogelijkheid voor het gebruik van DC-SIGN als 
doelwit molecuul voor DC vaccinatie. Huidige DC-gebaseerde vaccinatie 
methodes zijn gebaseerd op ex vivo-gekweekte eigen DC die beladen zijn met 
een antigeen alvorens ze toegediend worden aan patiënten. Het richten van 
antigenen naar DC in vivo via DC-SIGN zou een veel directere en minder 
bewerkelijke methode kunnen zijn. Om de mogelijkheid hiervan te testen 
werd een gehumaniseerd DC-SIGN antistof (hD1) chemisch gekoppeld aan 
het model antigeen keyhole limpet hemocyanin (KLH) wat resulteert in de 
chimere antistof-eiwit complex: hD1-KLH. hD1-KLH bond specifiek aan DC 
via DC-SIGN en werd geïnternaliseerd en overgeheveld naar het lysosomale 
compartiment van DC. DC die zo werden beladen met hD1-KLH waren in 
staat om een geheugen T cel reactie tegen KLH te induceren bij een 100-maal 
lagere concentratie dan KLH alleen. Dit suggereert dat het richten van KLH 
naar DC-SIGN zijn immunogeniciteit verhoogt. 
Verder resulteerde het aanbieden van hD1-KLH aan DC in de activering van 
rustende T cellen in de context van de speciale presentatie moleculen MHC I 
en II. Dit betekent dat zowel CD4+ als CD8+ T cellen worden geactiveerd wat 
nodig is voor een effectieve anti-tumor vaccinatie therapie. De presentatie 
van KLH epitopen in MHC I geeft aan dat naast de gebruikelijke route van 
presentatie van oplosbare antigenen via MHC II ook ´cross`-presentatie heeft 
opgetreden. Het beladen van DC met hD1-KLH vier dagen eerder voor het con-
tact met T cellen resulteerde nog steeds in een effectieve anti-KLH T cel reactie. 
Dit is erg belangrijk aangezien na antigeen opname in vivo in de periferie, 
het enige tijd duurt voordat een DC de lymfe knoop bereikt. Daarom is het 
cruciaal dat een DC antigenen kan presenteren over langere periodes om een 
effectieve immuunreactie te starten. Samenvattend laten deze resultaten zien 
dat DC-SIGN een veelbelovend doelwit is voor het aanbieden van antigeen 
aan DC door middel van een antistof. 
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List of Abbreviations
ALL	 Acute	lymphoblastic	leukaemia
APC	 Antigen-presenting	cell
(m)Ab	 (monoclonal)	antibody
BM	 Bone	marrow
BSA	 Bovine	serum	albumin
Ca2+	 Calcium
CD	 Cluster	of	differentiation
CFSE	 Carboxyfluorescein	diacetate	succinimidyl	ester
CLRs	 C-type	lectin	receptors
CLSM	 Confocal	laser	scanning	microscopy
CRD	 Carbohydrate	recognition	domain
DC	 Dendritic	cell(s)
DC-SIGN		 DC-specific	ICAM-3	grabbing	non-integrin
ELISA	 Enzyme-linked	immunosorbent	assay
FACS	 Fluorescence	activated	cell	sorter
FCS	 Fetal	calf	serum
GM-CSF	 Granulocyte/macrophage	colony	stimulating	factor
ICAM	 Intercellular	adhesion	molecule
IFN	 Interferon
Ig	 Immunoglobulin
IL	 Interleukin
KLH	 Keyhole	limpet	hemocyanin
LFA-1	 Leukocyte	functional	antigen-1
LPS	 Lipopolysaccharide
LSEC	 Liver	sinusoidal	endothelial	cells
L-SIGN	 Liver/lymph	node	SIGN
MFI	 Mean	fluorescence	intensity
MHC	 Major	histocompatibility	complex
MLR	 Mixed	lymphocyte	reaction
MR	 Mannose	receptor
NK	 Natural	killer
PAMPs	 Pathogen-associated	molecular	patterns
PB	 Peripheral	blood
PBL	 Peripheral	blood	lymphocytes
PBMC	 Peripheral	blood	mononuclear	cells
PBS	 Phosphate-buffered	saline
PRRs	 Pattern	recognition	receptors
RT	 Room	temperature
TCR	 T	cell	receptor
TEM	 Transmission	electron	microscopy
Th	 T	helper	
TLRs		 Toll	like	receptors
TNF	 Tumor	necrosis	factor
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Dankwoord
Het	zit	er	eindelijk	op;	het	‘boekje’	is	af!	Zonder	hulp	van	anderen	was	dit	
niet	zover	gekomen	en	daarom	wil	ik	graag	op	deze	plaats	een	aantal	mensen	
bedanken.	
Om	te	beginnen	wil	ik	natuurlijk mijn	promotor	Carl	Figdor	en	copromotor	
Ruurd	Torensma	bedanken	voor	jullie	onmisbare	begeleiding.	Jullie	kwamen	
altijd	met	nieuwe	ideeën	en	tips,	maar	lieten	mij	ook	vrij	om	zelf	de	richting	
van	het	onderzoek	te	bepalen.	Beste	Carl,	dankzij	jou	ben	ik	in	de	fasciner-
ende	DC-SIGN	wereld	gerold	en	heb	veel	van	je	geleerd.	Beste	Ruurd,	bij	jou	
kon	ik	altijd	aankloppen	voor	het	(uitgebreid	;-))	bespreken	van	resultaten	
en	nieuwe	experimenten	en	ik	heb	jouw	inzet	en	snelle	corrigeeracties	altijd	
zeer	gewaardeerd!	
Paul	en	Suzanne,	ik	ben	blij	dat	jullie	mij	straks	als	paranimf	willen	bijstaan!	
Beste	Paul,	de	laatste	twee	jaar	van	mijn	promotieonderzoek	deelde	je	samen	
met	mij	een	U-tje	wat	ik	erg	gezellig	vond	en	ook	erg	nuttig	was	omdat	we	
allebei	aan	DC-SIGN	werkten.	Onze	gesprekken	gingen	dus	geregeld	hierover,	
maar	 ook	 over	 niet-wetenschappelijke	 zaken	 zoals	 reizen	 en	 je	was	 altijd	
bereid	om	me	te	helpen.	Bedankt	hiervoor	en	jouw	steun	bij	het	MLR	artikel!	
Lieve	Suuz,	we	zijn	allebei	tegelijk	begonnen	op	het	TIL,	jij	eerst	als	student	
en	toen	ook	als	AIO.	We	zaten	samen	in	meerdere	‘clubjes’	en	ik	ben	je	dank-
baar	voor	al	die	ontelbare	keren	dat	ik	bij	je	mocht	blijven	logeren	na	al	die	
kerstdiners	en	outdoor-borrels.	Dat	was	altijd	erg	gezellig	en	hopelijk	is	dat	
-	nu	ik	niet	meer	werkzaam	ben	op	het	TIL	-	niet	volledig	ten	einde!	
Karin	Broers,	ik	ben	blij	dat	jij	me	hebt	gesteund	als	analist	het	laatste	jaar.	
Het	was	fijn	samenwerken	met	jou.	Ik	wens	jou	heel	veel	succes	met	je	nieuwe	
loopbaan	als	lerares!	
Beste	Gosse,	bedankt	voor	jouw	advies	tijdens	de	humane	DLM	sessies!	
Alessandra,	bedankt	voor	jouw	input	bij	o.a.	het	review	artikel;	dat	plaatje	is	
toch	maar	mooi	op	de	cover	gekomen!
Ben,	bedankt	voor	jouw	hulp	met	de	conjugaat	experimenten.	Dat	was	erg	
leerzaam	en	ook	VET	om	te	doen!	 Inge,	bedankt	voor	de	mooie	TEM	Fig-
uren!	
Friederike,	Aukje,	en	Maaike	L.,	bedankt	voor	jullie	hulp	met	het	maken	van	
de	His-constructen.	Dat	 is	weer	eens	wat	anders	dan	met	celletjes	werken!	
Aukje,	we	hebben	regelmatig	een	kamer	gedeeld	op	congressen,	maar	daar-
buiten	deelden	we	ook	veel	interesses	zoals	broodbakken	en	‘wetenschappelijk	
verantwoorde’	tv-programma’s	zoals	Peking	expres	en	Expeditie	Robinson.	
Die	werden	uitvoerig	besproken	tijdens	de	lunch	wat	ik	altijd	erg	vermakelijk	
vond!
Jolanda	en	‘patienten’-groep,	bedankt	voor	jullie	input	in	het	DC/PBMC	werk.	
En	dat	brengt	me	ook	naar	mijn	‘buddy’	Karin	van	Ginkel	die	me	heeft	in-
gewijd	in	het	DC	werk!	Het	is	alweer	een	paar	jaar	geleden	dat	we	collega’s	
waren,	maar	ik	wil	je	bij	deze	daar	nog	voor	bedanken	en	ook	voor	het	regel-
matig	meeliften	naar	Over(de)ijssel.	
Roger	en	Erik,	bedankt	voor	jullie	FACS-technische	input!
Mihai	 en	 Neeltje,	 bedankt	 voor	 de	 prettige	 samenwerking	 in	 het	 Candida	
onderzoek,	daar	is	toch	mooi	een	artikel	uit	voortgekomen!	
Beste	Reinier,	vanaf	deze	plek	wil	ik	je	graag	bedanken	voor	jouw	bijdrage	
aan	het	ALL	artikel.	Ik	kon	regelmatig	bij	 je	aankloppen	voor	hulp	en	heb	
jouw	inzet	dan	ook	erg	gewaardeerd!
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Gedurende	mijn	promotieonderzoek	kwam	ik	ook	regelmatig	op	het	CHL	en	
wil	graag	Arie,	Gertie,	Rob,	Jeroen,	Elke,	Karel,	Eugenie,	Marij,	Paul,	en	Jan	
Boezeman	bedanken	voor	hun	hulp	bij	dan	wel	de	flow	cytometer,	antilicha-
men,	en/of	ALL	onderzoek.	
I	would	like	to	thank	Alexion	Pharmaceuticals	for	their	input	in	this	research	
project.	I	enjoyed	the	meetings	in	Amsterdam	and	New	York	very	much!
Jeanette	 en	 Louise,	 bedankt	 dat	 jullie	 altijd	 klaar	 staan	 om	 te	 helpen	 bij	
allerlei	regelzaken.
Naast	wetenschap	was	er	natuurlijk	ook	af	en	toe	wat	ontspanning	nodig	dus	
ik	wil	 graag	 de	 volgende	 ‘clubjes’	 bedanken;	 TIL-outdoorborrel-cie	 (Suuz,	
Ben	en	Joost),	BOM-cie	(Suuz	en	Candida)	en	de	Catan-cie	(Suuz,	Ben,	Mar-
tijn	 en	Danielle).	 Voor	 alle	 3	 geldt:	wanneer	 gaan	we	weer?!	 (hoewel	 dat	
misschien	voor	de	BOM-cie	een	beetje	moeilijk	uitvoerbaar	is	met	1	persoon	
‘down	 under’…	maar	 daar	 vinden	we	wel	 iets	 voor,	 desnoods	 gaan	we	 er	
gewoon	heen?)
Verder	wil	ik	alle	‘Tillers’	bedanken	voor	de	fijne	tijd	die	ik	heb	gehad	op	het	
lab.	En	mijn	nieuwe	collega’s	op	het	NVI	voor	de	fijne	tijd	die	ik	tot	dusver	
al	heb	gehad.
Petra,	bedankt	voor	het	lay-outen	van	dit	boekje.	Ziet	er	super	uit!
Als	één	van	de	‘last	but	not	least’	wil	ik	graag	mijn	ouders	bedanken	voor	het	
meeleven	en	vertrouwen	in	mij.	Ook	wil	ik	Jan	en	Manny,	Femke,	rest	van	
familie	en	vrienden	bedanken	voor	hun	interesse,	maar	ook	voor	de	onmis-
bare	afleiding	en	ontspanning!
	
Lieve	Mark,	 jou	ben	 ik	de	meeste	dank	verschuldigd.	 ‘Want	er	 zijn	zoveel	
redenen…	ik	zie	er	duizend	inéén	in	jou	alleen.’
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zij	haar	eindexamen	Atheneum	aan	het	Bernardus	Alfrink	College	te	Schagen	
en	begon	in	datzelfde	jaar	aan	de	studie	Gezondheidswetenschappen	aan	de	
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op	de	afdeling	Farmacologie	en	Toxicologie	bij	Dr.	GR	Haenen,	Dr.	GM	den	
Hartog	en	Dr.	CG	Heijnen	en	deed	onderzoek	naar	flavonoïden.	Als	afslui-
ting	van	de	studie	deed	ze	onderzoek	naar	de	angiogenese	remmer	β-pep25	
(heden	Anginex)	bij	 de	afdeling	Tumor	Angiogenese	Laboratorium	aan	de	
Universiteit	 van	Maastricht	 onder	 begeleiding	van	Prof.	Dr.	AW	Griffioen,	
Dr.	DWJ	van	der	Schaft	en	Dr.	JCA	Bouma-ter	Steege.	Met	de	scriptie	van	dit	
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die	 uitgereikt	werd	 door	 de	Universiteit	 van	Maastricht.	 In	 augustus	 2001	
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Onderzoeker	op	de	afdeling	Tumor	immunologie	van	het	UMC	St.	Radboud	
te	Nijmegen	bij	Prof.	Dr.	CG	Figdor	en	Dr.	R	Torensma.	De	 resultaten	van	
dat	promotieonderzoek	staan	beschreven	in	dit	proefschrift.	Sinds	december	
2006	is	ze	werkzaam	als	postdoc	bij	de	afdeling	Vaccin	Onderzoek	van	het	
Nederlands	Vaccin	Instituut	te	Bilthoven.
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